EXHIBIT A

STATE OF MICHIGAN
IN THE CIRCUIT COURT FOR THE COUNTY OF KENT

GRAND RIVER ASEPTIC MANUFACTURING, INC.,

Plaintiff,

v.

NEXUS PHARMACEUTICALS, INC., SHERRI SCOTT, an individual, and JERROD WEIDENFELLER, an individual,

Defendants.

Case No. 21-00338-CBB

Hon. Terence J. Ackert

MILLER, CANFIELD, PADDOCK and STONE, p.l.c.
Joseph M. Infante (P68719)
Stephen M. Ragatzki (P81952)
Attorneys for Plaintiff/Counter-Defendant
99 Monroe Avenue NW, Suite 1200
Grand Rapids, Michigan 49503
(616) 454-8656
infante@millercanfield.com

Bilal Zaheer (P00283)
LOCKE LORD LLP
Attorneys for Defendant/Counter-Plaintiff Nexus
111 South Wacker Drive, Ste 4100
Chicago, IL 60606
(312) 443-0700
Bilal.zaheer@lockelord.com

VARNUM, LLP
Jon M. Bylsma (P48790)
Attorneys for Defendant/Counter-Plaintiff Nexus
PO Box 352
Grand Rapids, MI 49501-0352
(616) 336-7000
jmbylsma@varnumlaw.com

SILVER & VAN ESSEN PC
Lee T. Silver (P36905)
Attorneys for Defendants Scott and Weidenfeller
300 Ottawa Avenue NW, Suite 620
Grand Rapids, MI 49503
(616) 988-5600
ltsilver@silvervanessen.com

FIRST AMENDED COMPLAINT FOR DAMAGES AND INJUNCTIVE RELIEF

THIS CASE INVOLVES A BUSINESS OR COMMERCIAL DISPUTE AS DEFINED IN MCL 600.8031 AND MEETS THE STATUTORY REQUIREMENTS TO BE ASSIGNED TO THE BUSINESS COURT.

There is no other pending or resolved civil action arising out of the transaction or occurrence alleged in this Complaint.

Plaintiff, Grand River Aseptic Manufacturing, Inc. ("GRAM"), by and through its

attorneys, Miller, Canfield, Paddock and Stone, PLC, for its First Amended Complaint against Defendants Nexus Pharmaceuticals, Inc. ("Nexus"), Sherri Scott, and Jerrod Weidenfeller, states as follows:

1. GRAM is a Delaware corporation with its principal place of business in Grand Rapids, Michigan.

2. Upon information and belief, Nexus is an Illinois corporation with its principal place of business in Lincolnshire, Illinois.

3. Sherri Scott is an individual who, upon information and belief, resides in Gurnee, Illinois.

4. Jerrod Weidenfeller is an individual residing in Kent County, Michigan.

5. Jurisdiction is proper in this Court as GRAM seeks equitable relief and damages in excess of $25,000.

6. Venue is proper in this Court as one of the Defendants resides in Kent County, Michigan and the actions giving rise to this lawsuit arose in Kent County, Michigan.

GENERAL ALLEGATIONS

7. GRAM is a contract pharmaceutical manufacturer engaged in the business of filling, labeling, and packaging pharmaceutical products.

8. GRAM uses current good manufacturing practices ("cGMPs") to perform pharmaceutical manufacturing, analytical testing, and regulatory filling for small molecules, biologics, and controlled substances.

9. GRAM's pharmaceutical manufacturing includes the production of clinical trial materials for the pharmaceutical industry, including, without limitation, aseptic or lyophilized compounds.

10. GRAM is regulated by the United States Food and Drug Administration ("FDA").

11. Because of the specialized nature of the contract pharmaceutical manufacturing business and the stringent FDA regulations governing its practice, there are very few contract pharmaceutical manufacturers with the ability to manufacture aseptic or lyophilized compounds in the United States.

12. Nexus is engaged in the development, bulk production, formulation, sale, and distribution of pharmaceutical products.

13. Upon information and belief, before Nexus engaged GRAM, it did not have the ability to manufacture clinical trial materials for the pharmaceutical industry, including the manufacture of aseptic or lyophilized compounds on a commercial scale.

14. GRAM and Nexus entered into a Commercial Supply Agreement, effective October 11, 2016.

15. The purpose of the Commercial Supply Agreement was for GRAM to fill, package, inspect, label, and test pharmaceutical products for distribution and sale by Nexus.

16. The Commercial Supply Agreement outlined the general relationship between GRAM and Nexus while contemplating that the parties would enter into individual Work Orders and quality agreements for the manufacture of specific products as Nexus' need arose.

17. For example, on or about October 13, 2016, GRAM and Nexus entered into a Work Order for the production of Procainamide Injection, USP.

18. As part of the Commercial Supply Agreement, Nexus agreed that during the term of the agreement and for a period of two years after its expiration or termination, Nexus "shall not, directly or indirectly, on [its] own behalf or on behalf of any other person or entity, whether as an agent, employee, consultant or in any other capacity, recruit or hire or assist in recruiting or hiring, any person who is, or was on (1) year prior to the date of such recruitment or hiring, an employee

(whether temporary or permanent) or independent contractor of [GRAM]." **Exhibit 1** at ¶ 21.1 (the "No-Hire Provision.").

19. Prior to entering into the Commercial Supply Agreement, GRAM and Nexus entered into a Confidentiality Agreement on October 28, 2014. **Exhibit 2**.

20. The Confidentiality Agreement was incorporated into the Commercial Supply Agreement. See **Ex. 1** at ¶ 18.2.

21. Under the Confidentiality Agreement, the parties agreed that Nexus would be provided certain confidential information of GRAM, including "technology and information, whether in readable or in verbal form, relating to the products, services, business, personnel or commercial activities of the Parties, including without limitation: (a) formulas, compilations, programs, devices, concepts, inventions (whether or not patentable), designs, methods, techniques, marketing and commercial strategies, processes, data or specifications, know-how, business or financial information, research and development activities, product and marketing plans, customer and supplier information, and unique combinations of separate items, which individually may or may not be confidential, and which is not generally known to the public; (b) information acquired by a Party, by observation or otherwise, on the other Party's premises; (c) information or other work product developed by a Party in connection with this Agreement; and (d) information that a Party is under an obligation to third parties to maintain as confidential, but for which there is third party permission to share this information between the Parties." **Ex. 2** at ¶ 1.

22. Under the Confidentiality Agreement, "[a]ll Confidential and Proprietary Information supplied by [GRAM] will remain the property of and will be returned to [GRAM] or destroyed upon request. No copies of any Confidential and Proprietary Information may be made without the express prior written permission of [GRAM]." ***Id.*** at ¶ 7.

23. In the event of a breach of the Confidentiality Agreement, GRAM "may be entitled to injunctive relief restraining the act or threatened act that constitutes or would constitute a breach of this Agreement." ***Id.*** at ¶ 13.

24. The "obligations of confidentiality and non-use imposed upon" Nexus by the Confidentiality Agreement and Commercial Supply Agreement are in effect for ten years after the expiration of the Commercial Supply Agreement. However, any confidential information constituting trade secrets were to be kept confidential indefinitely. **Ex. 1** at ¶ 18.7.

GRAM's Employees Work on the Nexus Projects

25. To manage its work for Nexus and other clients, GRAM has its employees work in teams.

26. GRAM hired Scott on or about November 2016.

27. GRAM employed Scott as GRAM's Manager of Microbiology.

28. In her role as a manager/team leader, Scott oversaw a team of GRAM of employees.

29. In her role as Manager of Microbiology, Scott was responsible for management of the QC Microbiologists performing environmental monitoring, water testing and other client-specific microbiology testing in support of aseptic manufacturing operations.

30. Scott's duties included, but were not limited to: oversight of analysts performing complex microbial analysis, review of microbiology test results, assistance with method development and validation work, oversight of contract laboratories performing microbiological analysis on behalf of GRAM, monitoring facility and personnel performance with regards to contamination control, and investigation of out-of-trend/out-of-specification results.

31. Scott managed these responsibilities for Nexus and additionally managed testing for all of their productions and validation testing of their products.

32. Scott managed all microbiology related non-conformance results for Nexus's products.

33. GRAM hired Weidenfeller on or about January 2016.

34. GRAM employed Weidenfeller most recently as a QC Microbiologist II.

35. Weidenfeller worked on Scott's team to support GRAM's work for Nexus.

36. As a necessary requirement of their work, Scott, Weidenfeller, and GRAM's other employees are intimately familiar with GRAM's proprietary and confidential information and processes.

37. To protect its proprietary and confidential information, GRAM makes its employees sign confidentiality agreements.

38. As a condition of his employment with GRAM, on February 15, 2019, Weidenfeller signed a binding and enforceable Confidentiality, Proprietary Rights, and Arbitration Agreement (the "Proprietary Rights Agreement") with GRAM. **Exhibit 3**.

39. As a condition of her employment with GRAM, on March 4, 2019, Scott also signed a binding and enforceable Proprietary Rights Agreement with GRAM. **Exhibit** 4.

40. Weidenfeller and Scott agreed that "During the term of Employee's employment with the Company, and after the termination of such employment for any reason, whatsoever, Employee shall not disclose, divulge, or furnish any Confidential Information" to any person and return any Confidential Information in their possession. **Exhibits 3 and 4**, ¶ 1(a).

41. The Proprietary Rights Agreement defines "Confidential Information" as "any trade secret, confidential or proprietary information of the Company all other information and data that is not generally known to the Company's competitors including, without limitation, any confidential studies, data, calculations, software storage media or other compilation of

information, patent, patent application, copyright, trademark, trade name, service mark, service name, 'know-how,' customer or prospect lists, details of client or customer contract, pricing policies, sales techniques, confidential information relating to suppliers or providers, information relating to the special and particular needs of the Company's customers, operational methods, marketing plans or strategies, products and formulae, product development techniques or plans, business acquisition plans, computer programs (including source of object codes), processes, procedures, research or technical data, improvements or other proprietary or intellectual property of the Company including, without limitation, all Innovations (as hereinafter defined); whether or not in written or tangible form, and whether or not registered, and including all files, records, manuals, books, catalogues, memoranda, notes, summaries, plans, reports, records, documents and other evidence thereof." ***Id.*** at ¶ 1(b).

42. Weidenfeller and Scott further agreed that in addition to other remedies, in the case of breach of the Proprietary Rights Agreement GRAM would be entitled to injunctive relief and to recover its reasonable attorneys' fees incurred. ***Id.*** at ¶ 3.

43. On March 4, 2019, Scott also signed a binding and enforceable Non-Compete, Non-Solicitation, and Arbitration Agreement (the "Restrictive Covenant Agreement") with GRAM. **Exhibit 5**.

44. By signing the Restrictive Covenant Agreement, Scott agreed "that for a period of twelve (12) months from the date on which Employee's employment with Company ends, regardless of the reason, s/he will not directly or indirectly engage in Competition with Company anywhere in the United States of America ('USA') as Company conducts business throughout the USA. 'Competition' means competing with the Company on Employee's own behalf, or having ownership in, operating, managing or working as an agent, employee, representative or consultant,

for a person or entity that produces clinical trial materials for the pharmaceutical industry, including, without limitation, aseptic or lyophilized compounds." ***Id.***, ¶ 2. (the "Non-Compete Clause.")

45. Scott further agreed for a period of twelve months following the end of her employment with GRAM, she would not "directly or indirectly, on Employee's own behalf or on behalf of any other person or entity, solicit, attempt to obtain, divert, take away, do business with any current customer(s) or prospective customer(s) of the Company or interfere in any way with the business relationship between the Company and any of its customers or prospective customers." ***Id.***, ¶ 3. (the "Non-Interference Clause.")

46. Scott further agreed "that for a period of twelve (12) months following the termination of Employee's employment with the Company for any reason, Employee will not directly or indirectly, on Employee's own behalf or on behalf of any other person or entity, solicit, recruit or hire any person who is an employee of Company or who was an employee of Company during the two (2) year period prior to termination of the Employee's employment with the Company, or encourage in any manner any of Company's employees or agents to terminate their employment or agency with Company." ***Id.***, ¶ 4. (the "Non-Solicitation Clause.")

47. Scott further agreed if she breached her obligations, GRAM was entitled to injunctive relief and to recover its reasonable attorneys' fees incurred in enforcing the Restrictive Covenant Agreement. ***Id.***, ¶ 7.

48. On October 8, 2019, Nexus provided notice to GRAM that Nexus would not renew the Commercial Supply Agreement.

49. Based on Nexus' notice, the Commercial Supply Agreement will terminate on October 11, 2021.[1]

50. Upon information and belief, Nexus terminated the Commercial Supply Agreement with GRAM because Nexus has established, or is in the process of establishing, its own facility to compete with GRAM.

51. Upon information and belief, Nexus entered into the Commercial Supply Agreement so that it could obtain GRAM's confidential information and processes so that it could use this information to establish its own competing facility.

52. Upon information and belief, Nexus is utilizing GRAM's confidential information and trade secrets in breach of its confidentiality and non-use restrictions contained within the Commercial Supply Agreement and Confidentiality Agreement.

53. After Nexus provided notice of its intent to terminate the Commercial Supply Agreement, but prior to the termination date, Nexus began soliciting GRAM's employees.

54. This was a violation of the No-Hire Provision.

55. On or about August 12, 2020, Scott resigned from her employment with GRAM.

56. Before she left her employment with GRAM, she plugged a USB drive into her GRAM computer and downloaded 3,072 files to the USB drive. A list of file names is attached as **Exhibit 7** and is referred to as "GRAM's Confidential Information."

57. GRAM's Confidential Information includes, but is not limited to, GRAM's Standard Operating Procedures, testing protocols, training manuals, FDA qualification data and procedures, equipment validation, customer information, customer lists, and pricing information.

[1] Due to Nexus' solicitation of GRAM's employees, discussed below, GRAM is providing separate notice to Nexus of the immediate termination of the Commercial Supply Agreement.

58. After downloading GRAM's Confidential Information, Scott went to work for Nexus.

59. Scott plugged the USB drive into her Nexus computer and uploaded the files she downloaded from GRAM's servers.

60. Hiring Scott was a breach by Nexus of the No-Hire Provision.

61. By going to work for Nexus, Scott breached the Non-Compete Clause.

62. By going to work for Nexus, Scott breached the Non-Interference Clause.

63. On December 28, 2020, GRAM's counsel sent a letter to Scott reminding her of Restrictive Covenant obligations. **Exhibit 6**.

64. On January 4, 2021, Weidenfeller submitted his resignation letter to GRAM.

65. Before he left his employment at GRAM, Weidenfeller downloaded fifty confidential GRAM documents relating to qualifying GRAM's facility with the FDA.

66. Thereafter, Weidenfeller went to work for Nexus.

67. Hiring Weidenfeller is a breach by Nexus of the No-Hire Provision.

68. Upon information and belief, Weidenfeller intends to assist Nexus in establishing its facility to compete with GRAM.

69. Upon information and belief, Weidenfeller is aware of Nexus' no-hire restrictions.

70. Upon information and belief, Weidenfeller is aware of Scott's Non-Compete restrictions.

71. Upon information and belief, Weidenfeller is aware of Scott's Non-Interference restrictions.

72. Upon information and belief, Nexus has hired Weidenfeller to obtain confidential information of GRAM to assist Nexus in establishing its competing facility.

73. Upon information and belief, Scott, in coordination with Nexus, solicited Weidenfeller to leave GRAM and join Nexus.

74. Upon information and belief, Nexus, in coordination with Scott, solicited Weidenfeller to leave GRAM and join Nexus.

75. Upon information and belief, Scott and Weidenfeller, in coordination with Nexus, have solicited at least three other GRAM employees to leave GRAM and join Nexus.

76. Upon information and belief, these GRAM employees currently have offers of employment from Nexus.

77. Upon information and belief, Scott, Weidenfeller, and Nexus solicited these GRAM employees in efforts to develop Nexus' own processes and systems for producing clinical trial materials for the pharmaceutical industry, including, aseptic or lyophilized compounds, to become a direct competitor to GRAM.

78. Upon information and belief, Scott, Weidenfeller, and Nexus have used GRAM's Confidential Information to save time and money in creating Standard Operating Procedures and other documents necessary for Nexus to manufacture pharmaceutical products and gain approval from the FDA.

79. Scott created at least nine documents for Nexus using GRAM's Confidential Information.

80. Upon information and belief, the use of GRAM's Confidential Information has saved Nexus millions of dollars in startup costs.

81. Upon information and belief, the use of GRAM's Confidential Information accelerated the opening of Nexus' new facility months.

82. Upon information and belief, Nexus has used, or will use, GRAM's Confidential Information to produce pharmaceuticals for its own use or third-party use.

83. Shortly before filing this Complaint, GRAM specifically demanded that Nexus rescind the outstanding offers to GRAM employees.

84. Nexus refused to rescind the offers to GRAM employees.

COUNT I – BREACH OF CONTRACT BY SCOTT

85. GRAM incorporates the allegations in paragraphs 1 through 75 as though fully restated herein.

86. The Restrictive Covenant Agreement is a valid and binding contract between Scott and GRAM.

87. In the Non-Compete Clause of the Restrictive Covenant Agreement, Scott agreed "that for a period of twelve (12) months from the date on which Employee's employment with Company ends, regardless of the reason, s/he will not directly or indirectly engage in Competition with Company anywhere in the United States of America ('USA') as Company conducts business throughout the USA."

88. The Non-Compete Clause is reasonable.

89. Nexus meets the definition of "Competition" in the Non-Compete Clause because it produces clinical trial materials for the pharmaceutical industry. **Ex. 5** at ¶ 2.

90. Scott breached the Non-Compete Clause of the Restrictive Covenant Agreement when she began working as an employee at Nexus.

91. In the Non-Solicitation Clause of the Restrictive Covenant Agreement, Scott also agreed "that for a period of twelve (12) months following the termination of Employee's employment with the Company for any reason, Employee will not directly or indirectly, on

Employee's own behalf or on behalf of any other person or entity, solicit, recruit or hire any person who is an employee of Company or who was an employee of Company during the two (2) year period prior to termination of the Employee's employment with the Company, or encourage in any manner any of Company's employees or agents to terminate their employment or agency with Company."

92. The Non-Solicitation Clause is reasonable.

93. Scott breached the Non-Solicitation Clause of the Restrictive Covenant Agreement when she solicited Weidenfeller and at least three other GRAM employees to leave their employment at GRAM and come work for Nexus.

94. In the Proprietary Rights Agreement, Scott agreed that she "shall not disclose, divulge, or furnish any Confidential Information (as hereinafter defined) to any individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof (a 'Person'), other than the Company or upon its written request, or use any Confidential Information directly or indirectly for Employee's own benefit or for the benefit of any other Person other than the Company, as such Confidential Information is strictly confidential and shall at all times remain the property of the Company." **Ex. 4** at ¶ 1(a).

95. This restriction is reasonable.

96. Upon information and belief, Scott disclosed GRAM's Confidential Information to Nexus in an effort for Nexus to develop its own pharmaceutical manufacturing practice to compete with GRAM.

97. Scott breached the Proprietary Rights Agreement when she disclosed GRAM's Confidential Information to Nexus.

98. GRAM has suffered, and continues to suffer, damages resulting from Scott's breaches of the Restrictive Covenant Agreement and Proprietary Rights Agreement.

WHEREFORE GRAM prays that this Court enter judgment in its favor and against Scott in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT II – BREACH OF CONTRACT BY WEIDENFELLER

99. GRAM incorporates the allegations in paragraphs 1 through 89 as though fully restated herein.

100. The Proprietary Rights Agreement is a valid and binding contract between Weidenfeller and GRAM.

101. GRAM has performed all of its obligations under the Proprietary Rights Agreement.

102. In the Proprietary Rights Agreement, Weidenfeller agreed that he "shall not disclose, divulge, or furnish any Confidential Information (as hereinafter defined) to any individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof (a 'Person'), other than the Company or upon its written request, or use any Confidential Information directly or indirectly for Employee's own benefit or for the benefit of any other Person other than the Company, as such Confidential Information is strictly confidential and shall at all times remain the property of the Company." **Ex. 3** at ¶ 1(a).

103. This restriction is reasonable.

104. Upon information and belief, Weidenfeller has disclosed or intends to disclose GRAM's Confidential Information to Nexus in an effort for Nexus to develop its own pharmaceutical manufacturing practice to compete with GRAM.

105. Weidenfeller breached the Proprietary Rights Agreement when he disclosed GRAM's Confidential Information to Nexus.

106. GRAM has suffered and will continue to suffer harm from Weidenfeller's continued breach of the Proprietary Rights Agreement.

107. Weidenfeller agreed that, if he breached the Proprietary Rights Agreement, GRAM may enforce the Proprietary Rights Agreement by "equitable relief, including temporary and permanent injunctive relief (without any requirement to post any bond or other security)" and that Weidenfeller "shall not oppose the granting of such relief." **Ex. 3** at ¶ 3.

108. Weidenfeller also agreed that GRAM "shall be entitled to recover all litigation costs and reasonable attorneys' fees incurred by it in enforcing any provision of this Agreement." ***Id.***

WHEREFORE GRAM prays that this Court enter judgment in its favor and against Weidenfeller in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT III – BREACH OF CONTRACT BY NEXUS

109. GRAM incorporates the allegations in paragraphs 1 through 99 as though fully restated herein.

110. The Commercial Supply Agreement is a valid and enforceable contract between Nexus and GRAM.

111. During the term of the Commercial Supply Agreement and for a period of two years after its expiration or termination, Nexus agreed that it would not directly or indirectly recruit or hire an employee or independent contractor of GRAM or a person who was an employee or independent contract of GRAM within one year of the recruitment or hiring. **Ex. 1** at ¶ 21.1. (the "No-Hire Provision.").

112. The No-Hire Provision is reasonable.

113. Nexus breached the No-Hire Provision by recruiting and hiring Scott.

114. Nexus breached the No-Hire Provision by recruiting and hiring Weidenfeller.

115. Nexus breached the No-Hire Provision by recruiting and making offers to at least three additional GRAM employees.

116. GRAM has been harmed by Nexus's breaches of the No-Hire Provision.

117. GRAM and Nexus are also parties to the Confidentiality Agreement.

118. The Confidentiality Agreement is a valid and enforceable contract.

119. By signing the Confidentiality Agreement, GRAM agreed to disclose its Confidential and Proprietary Information to Nexus on the condition that the Confidential and Proprietary Information would remain GRAM's property. Ex. 2, ¶¶ 1, 7.

120. As the contractual relationship between GRAM and Nexus has dissolved, Nexus was required to return or destroy GRAM's Confidential and Proprietary Information.

121. Upon information and belief, Nexus has misappropriated GRAM's Confidential and Proprietary Information in violation of the Confidentiality Agreement.

122. GRAM has been harmed by Nexus's breach of the Confidentiality Agreement.

WHEREFORE GRAM prays that this Court enter judgment in its favor and against Nexus in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT IV – TORTIOUS INTERFERENCE WITH CONTRACT BY NEXUS

123. GRAM incorporates the allegations in paragraphs 1 through 113 as though fully restated herein.

124. The Non-Compete Agreement is a valid and enforceable contract between Scott and GRAM.

125. The Proprietary Rights Agreement is a valid and enforceable contract between Scott and GRAM.

126. The Proprietary Rights Agreement is a valid and enforceable contract between Weidenfeller and GRAM.

127. Nexus had knowledge that Scott had signed a Non-Compete Agreement and Proprietary Rights Agreement with GRAM.

128. Nexus had knowledge that Weidenfeller had signed a Proprietary Rights Agreement with GRAM.

129. Upon information and belief, Nexus instigated Scott and Weidenfeller to breach their respective contracts with GRAM.

130. Upon information and belief, Nexus instigated Scott and Weidenfeller to breach their respective contracts with GRAM so that Nexus could hire Scott and Weidenfeller and exploit GRAM's Confidential Information.

131. At Nexus' instigation, Scott and Weidenfeller have breached their respective contracts with GRAM.

132. Further, Nexus is aware that other employees of GRAM are subject to similar agreements as Scott and Weidenfeller.

133. Even after GRAM demanded that Nexus rescind offers to these GRAM employees, Nexus refused.

134. Nexus has no legal justification for its instigation.

135. GRAM has suffered, and will continue to suffer, damages due to Nexus' tortious interferences with GRAM's contracts with Scott and Weidenfeller.

WHEREFORE GRAM prays that this Court enter judgment in its favor and against Nexus in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT V – TORTIOUS INTERFERENCE WITH CONTRACT BY SCOTT

136. GRAM incorporates the allegations in paragraphs 1 through 126 as though fully restated herein.

137. The Proprietary Rights Agreement is a valid and enforceable contract between Weidenfeller and GRAM.

138. Scott had knowledge that Weidenfeller had signed a Proprietary Rights Agreement with GRAM.

139. Upon information and belief, Scott instigated Weidenfeller to breach his Proprietary Rights Agreement with GRAM so that Nexus could hire Weidenfeller and exploit GRAM's Confidential Information.

140. At Scott's instigation, Weidenfeller have breached his Proprietary Rights Agreement with GRAM.

141. Scott has no legal justification for its instigation.

142. GRAM has suffered, and will continue to suffer, damages due to Scott's tortious interference with GRAM's contracts with Weidenfeller.

WHEREFORE GRAM prays that this Court enter judgment in its favor and against Scott in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT VI – VIOLATION OF THE MICHIGAN UNIFORM TRADE SECRETS ACT BY ALL DEFENDANTS

143. GRAM incorporates the allegations in paragraphs 1 through 133 as though fully restated herein.

144. GRAM's Confidential Information, as identified in the Confidentiality Agreement and Proprietary Rights Agreements, meets the definition of "trade secret" in the Michigan Uniform Trade Secrets Act, MCL 445.1902(d).

145. GRAM's trade secrets are more than general skills, knowledge, and experience.

146. GRAM has taken reasonable steps to keep its trade secrets confidential by, *inter alia*, requiring its employees to sign Proprietary Rights Agreement and by requiring Nexus to sign a Confidentiality Agreement.

147. Upon information and belief, Nexus obtained confidential information and trade secrets of GRAM as part of the Commercial Supply Agreement and is using or will use that confidential information and trade secrets to set up a facility to compete with GRAM.

148. Upon information and belief, Scott and Weidenfeller have disclosed GRAM's trade secrets to Nexus.

149. Nexus misappropriated GRAM's trade secrets in violation of MCL 445.1901 *et seq.* by hiring Scott and Weidenfeller with the knowledge that Scott and Weidenfeller are subject to

Proprietary Rights Agreements and by using information it obtained as part of the Commercial Supply Agreement.

150. Scott and Weidenfeller misappropriated GRAM's trade secrets in violation of MCL 445.1901 *et seq.* when they disclosed the trade secrets to Nexus despite knowing that they were bound by the Proprietary Rights Agreement.

151. GRAM has not consented to the disclosure of its trade secrets.

152. Upon information and belief, Nexus has used or is planning to use GRAM's trade secrets without authorization.

153. GRAM has been, or will be, harmed by Defendants' misappropriations of GRAM's trade secrets.

154. Under MCL 445.1903, the Court may enjoin Defendants from misappropriating GRAM's trade secrets.

155. Under MCL 445.1904, the Court may award GRAM damages for Defendants' misappropriation of GRAM's trade secrets.

WHEREFORE GRAM prays that this Court enter judgment in its favor and against Defendants in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, enjoin the use of GRAM's confidential information and trade secrets by Defendants and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT VII – INJUNCTIVE RELIEF AGAINST SCOTT

156. GRAM incorporates the allegations in paragraphs 1 through 146 as though fully restated herein.

157. The Non-Compete Agreement is a valid and enforceable contract between Scott and GRAM.

158. The Proprietary Rights Agreement is a valid and enforceable contract between Scott and GRAM.

159. GRAM has performed all of its obligations under the Non-Compete Agreement and Proprietary Rights Agreement.

160. Scott breached the Non-Compete Agreement when she became an employee of Nexus and recruited Weidenfeller to terminate his employment with GRAM and join Nexus.

161. Scott breached their Proprietary Rights Agreement with she disclosed GRAM's Confidential Information to Nexus.

162. Injunctive relief is necessary to enforce Scott's obligations under the Non-Compete Agreement and Proprietary Rights Agreement.

163. Injunctive relief is necessary to prevent Scott from using and misappropriating GRAM's Confidential Information in violation of the Proprietary Rights Agreement and the Michigan Uniform Trade Secrets Act.

164. Scott agreed that, if she breached the Proprietary Rights Agreement, GRAM may enforce the Proprietary Rights Agreement by "equitable relief, including temporary and permanent injunctive relief (without any requirement to post any bond or other security)" and that Scott "shall not oppose the granting of such relief." **Ex. 4** at ¶ 3.

165. Scott also agreed that GRAM "shall be entitled to recover all litigation costs and reasonable attorneys' fees incurred by it in enforcing any provision of this Agreement." ***Id.***

166. Scott has also misappropriated GRAM's trade secrets within the meaning of the Michigan Uniform Trade Secrets Act.

167. The Court should enjoin Scott from misappropriating GRAM's trade secrets pursuant to MCL 445.1903.

WHEREFORE GRAM prays that this Court enjoin Scott from disclosing GRAM's confidential information and trade secrets, enter judgment in its favor and against Scott in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT VIII – INJUNCTIVE RELIEF AGAINST WEIDENFELLER

168. GRAM incorporates the allegations in paragraphs 1 through 158 as though fully restated herein.

169. The Proprietary Rights Agreement is a valid and enforceable contract between Weidenfeller and GRAM.

170. GRAM has performed all of its obligations under the Proprietary Rights Agreement.

171. Weidenfeller breached the Proprietary Rights Agreement with he disclosed GRAM's Confidential Information to Nexus.

172. Injunctive relief is necessary to enforce Weidenfeller's obligations under the Proprietary Rights Agreement.

173. Injunctive relief is necessary to prevent Weidenfeller from using and misappropriating GRAM's Proprietary Rights Agreement in violation of the Confidentiality Agreement and the Michigan Uniform Trade Secrets Act.

174. Weidenfeller agreed that, if he breached the Proprietary Rights Agreement, GRAM may enforce the Proprietary Rights Agreement by "equitable relief, including temporary and permanent injunctive relief (without any requirement to post any bond or other security)" and that Weidenfeller "shall not oppose the granting of such relief." **Ex. 3** at ¶ 3.

175. Weidenfeller also agreed that GRAM "shall be entitled to recover all litigation costs and reasonable attorneys' fees incurred by it in enforcing any provision of this Agreement." ***Id.***

176. Weidenfeller has also misappropriated GRAM's trade secrets within the meaning of the Michigan Uniform Trade Secrets Act.

177. The Court should enjoin Weidenfeller from misappropriating GRAM's trade secrets pursuant to MCL 445.1903.

WHEREFORE GRAM prays that this Court enjoin Weidenfeller from disclosing GRAM's confidential information and trade secrets, enter judgment in its favor and against Weidenfeller in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT IX – INJUNCTIVE RELIEF AGAINST NEXUS

178. GRAM incorporates the allegations in paragraphs 1 through 168 as though fully restated herein.

179. The Commercial Supply Agreement is a valid and enforceable contract between Nexus and GRAM.

180. GRAM has performed all of its obligations under the Commercial Supply Agreement.

181. Nexus breached the No-Hire Provision of the Commercial Supply Agreement when it hired Scott and Weidenfeller and solicited at least three additional GRAM employees.

182. Injunctive relief is necessary to enforce Nexus's obligations under the Commercial Supply Agreement.

183. The Confidentiality Agreement is also a valid and enforceable contract between Nexus and GRAM.

184. GRAM has performed all of its obligations under the Confidentiality Agreement.

185. Nexus breached the Confidentiality Agreement when it retained GRAM's Confidential and Proprietary Information after its relationship with GRAM had terminated.

186. Upon information and belief, Nexus retained GRAM's Confidential and Proprietary Information with the intent to use it to develop a competing business practice to GRAM.

187. Nexus agreed that if it breached or threatened to breach the Confidentiality Agreement, GRAM "may be entitled to injunctive relief restraining the act or threatened act that constitute or would constitute a breach of this Agreement."

188. Nexus has also misappropriated GRAM's trade secrets within the meaning of the Michigan Uniform Trade Secrets Act.

189. The Court should enjoin Nexus from misappropriating GRAM's trade secrets pursuant to MCL 445.1903.

WHEREFORE GRAM prays that this Court enjoin Nexus from any other GRAM employee, using or maintaining GRAM's confidential information and trade secrets, enter judgment in its favor and against Nexus in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT X – UNJUST ENRICHMENT AGAINST NEXUS

190. GRAM incorporates the allegations in paragraphs 1 through 180 as though fully restated herein.

191. This count is brought in the alternative to GRAM's claims for breach of contract and claim under the Michigan Uniform Trade Secrets Act.

192. GRAM provided Nexus with knowledge and expertise in the pharmaceutical manufacturing industry.

193. Nexus has terminated its relationship with GRAM and retained the benefit of GRAM's knowledge and expertise, including several of GRAM's employees and their knowledge of GRAM's systems and processes.

194. It would be inequitable to allow Nexus to retain GRAM's knowledge and expertise, including GRAM's employees and their knowledge of GRAM's systems and processes, without significant payment to GRAM.

WHEREFORE GRAM prays that this Court enter judgment in its favor and against Nexus in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT XI – CIVIL CONSPIRACY AGAINST SCOTT AND NEXUS

195. GRAM incorporates the allegations in paragraphs 1 through 185 as though fully restated herein.

196. Scott and Nexus took a series of concerted steps with one another, including

(a) Scott terminating her employment at GRAM at Nexus's request in violation of her Restrictive Covenant Agreement;

(b) Scott disclosing GRAM's trade secrets and Confidential Information to Nexus, in violation of her Proprietary Rights Agreement with GRAM and the Michigan Uniform Trade Secrets Act;

(c) Jointly encouraging Weidenfeller to terminate his employment with GRAM and recruiting him to accept a job at Nexus;

(d) Hiring Weidenfeller to work at Nexus;

(e) Encouraging Weidenfeller to unlawfully disclose GRAM's trade secrets, in violation of his Proprietary Rights Agreement with GRAM and the Michigan Uniform Trade Secrets Act; and

(f) Recruiting at least three additional GRAM employees to leave their employment with GRAM and join Nexus, in violation of the No-Hire

Provision in the Commercial Supply Agreement and the Non-Solicitation Provision in Scott's Non-Compete Agreement.

197. These actions were either an unlawful purpose or a lawful purpose accomplished by criminal or unlawful means.

198. GRAM has suffered harm resulting from the unlawful purpose and/or unlawful means of the conspiracy.

WHEREFORE GRAM prays that this Court enter judgment in its favor and against Nexus and Scott in an amount to be determined by the finder of fact, plus the statutory interest rate from the date of filing, and that the Court grant GRAM any other relief the Court deems appropriate.

COUNT XII – CIVIL VIOLATION OF THE DEFEND TRADE SECRETS ACT, 18 U.S.C. § 1836, AGAINST NEXUS, SCOTT, AND WEIDENFELLER

199. GRAM incorporates the allegations in paragraphs 1 through 194 as through fully restated herein.

200. GRAM has taken reasonable measures to keep GRAM's Confidential Information secret, including marking its files "CONFIDENTIAL," requiring Nexus to sign the Confidentiality Agreement in **Exhibit 2,** and requiring employees like Scott and Weidenfeller to sign the Proprietary Rights Agreements in **Exhibits 3 and 4**.

201. GRAM's Confidential Information derives independent economic value, both actual and potential, from not being generally know to, and not being readily ascertainable through proper means, by another person or entity like Nexus and Scott who can obtain economic value from the use of GRAM's Confidential Information.

202. GRAM's Confidential Information meets the definition of "trade secret" within 18 U.S.C. § 1839(3).

203. Scott and Weidenfeller knew or should have known that GRAM's Confidential Information was confidential and proprietary.

204. Despite that knowledge, before Scott left her employment with GRAM, Scott downloaded from GRAM's computers/servers onto a USB drive GRAM's Confidential Information.

205. Scott misappropriated GRAM's Confidential Information by downloading it with the intent to carry it away from GRAM, uploading it to onto her new computer at Nexus, and using it to replicate GRAM's practices and procedures for the benefit of Nexus.

206. By transporting GRAM's Confidential Information from GRAM's facility in Grand Rapids, Michigan to Nexus's facilities in Illinois and/or Wisconsin, Scott has transported GRAM's Confidential Information across state lines.

207. Despite his knowledge that GRAM's Confidential Information was confidential and proprietary, Weidenfeller downloaded fifty documents shortly before his employment at GRAM ended.

208. Weidenfeller had no reason to access or download those documents during the course of his job duties for GRAM during the final weeks of his employment.

209. Upon information and belief, Weidenfeller misappropriated GRAM's Confidential Information by downloading these files with the intent to carry them away from GRAM, transporting them to Nexus, across state lines, and using them to replicate GRAM's practices and procedures for the benefit of Nexus.

210. GRAM did not authorize Scott or Weidenfeller to take any of GRAM's Confidential Information.

211. Nexus misappropriated GRAM's Confidential Information by acquiring it from Scott and Weidenfeller and knowing or having reason to know that Scott and Weidenfeller used improper means to acquire it.

212. Scott, Weidenfeller, and Nexus's actions to misappropriate GRAM's Confidential Information were willful and malicious.

213. Nexus received GRAM's Confidential Information and currently possesses it, knowing that Scott and Weidenfeller obtained GRAM's Confidential Information without authorization.

214. Nexus intends to use, and upon information and belief has used, GRAM's Confidential Information to expedite the FDA authorization process to become a contract manufacturing organization at its new facility in Wisconsin.

215. Nexus intends to use GRAM's Confidential Information to manufacture pharmaceutical products for sale and distribution in interstate and/or foreign commerce.

216. Nexus has used GRAM's Confidential Information to secure a contract to manufacture the Moderna COVID-19 vaccine and sell it in interstate and foreign commerce.

WHEREFORE, GRAM prays that this Court grant an injunction to prevent any actual or threatened misappropriation of GRAM's Confidential Information, require an independent digital forensic investigation into Nexus's servers to identify any of GRAM's Confidential Information contained therein, order the destruction of any of any documents or files containing any portion GRAM's Confidential Information, award GRAM a reasonable royalty for Nexus's misappropriation of GRAM's Confidential Information, and enter a money judgment in its favor and against Nexus, Weidenfeller, and Scott in an amount to be determined by the finder of fact, including double damages and attorney fees as authorized by 18 U.S.C. § 1836(b)(3).

COUNT XIII – VIOLATION OF THE MICHIGAN UNIFORM TRADE SECRETS ACT, MCL 445.1901 et seq., AGAINST NEXUS, SCOTT, AND WEIDENFELLER

217. GRAM incorporates the allegations in paragraphs 1 through 212 as through fully restated herein.

218. GRAM's Confidential Information is a "trade secret" within the meaning of MCL 445.1902(d).

219. Scott and Weidenfeller used improper means to misappropriate GRAM's Confidential Information by downloading it from GRAM's servers and delivering it to Nexus.

220. Nexus misappropriated GRAM's Confidential Information by acquiring it from Scott and Weidenfeller when it knew or should have known that Scott and Weidenfeller used improper means to acquire it.

221. Nexus intends to use, and upon information and belief has used, GRAM's Confidential Information to expedite the FDA authorization process to become a contract manufacturing organization at its new facility in Wisconsin.

222. Nexus intends to use GRAM's Confidential Information to manufacture pharmaceutical products for sale and distribution.

223. Nexus has used GRAM's Confidential Information to secure a contract to manufacture the Moderna COVID-19 vaccine and sell it in interstate and foreign commerce.

WHEREFORE, GRAM prays that this Court grant an injunction to prevent any actual or threatened misappropriation of GRAM's Confidential Information, require an independent digital forensic investigation into Nexus's servers to identify any of GRAM's Confidential Information contained therein, order the destruction of any of any documents or files containing any portion GRAM's Confidential Information, award GRAM a reasonable royalty for Nexus's misappropriation of GRAM's Confidential Information, and enter a money judgment in its favor and against Nexus, Weidenfeller, and Scott in an amount to be determined by the finder of fact.

PRAYER FOR RELIEF

WHEREFORE, GRAM prays that this Court:

(a) Enter a temporary restraining order and permanent injunction prohibiting Scott from disclosing any of GRAM's Confidential Information to Nexus;

(b) Enter a temporary restraining order and permanent injunction prohibiting Weidenfeller from disclosing any of GRAM's Confidential Information to Nexus;

(c) Enter a temporary restraining order and permanent injunction prohibiting Nexus from soliciting or hiring any of GRAM's employees in violation of the No-Hire Provision of the Commercial Supply Agreement and requiring Nexus to destroy any of GRAM's Confidential Information in its possession;

(d) Enter a money judgment against Defendants, jointly and severally, in an amount to be determined by the finder of fact;

(e) Award GRAM a reasonable royalty from any revenues made by Nexus that were the result of the misappropriation of GRAM's Confidential Information;

(f) Order Defendants to pay GRAM's fees, costs, and expenses, including attorney fees, incurred in enforcing the terms of the Confidentiality Agreement, Restrictive Covenant Agreement, Proprietary Rights Agreements, and Commercial Supply Agreement; and

(g) Award GRAM any other relief this Court deems appropriate.

Respectfully submitted,

MILLER, CANFIELD, PADDOCK AND STONE, P.L.C.

By: 

Joseph M. Infante (P68719)
Leigh M. Schultz (P71038)
Stephen M. Ragatzki (P81952)
Attorneys for Plaintiff
99 Monroe Avenue NW, Suite 1200
Grand Rapids, Michigan 49503
(616) 454-8656
infante@millercanfield.com
schultzl@millercanfield.com
ragatzki@millercanfield.com

Dated: May 10, 2021

37572289.3/151564.00006

Exhibit 1

COMMERCIAL SUPPLY AGREEMENT

THIS COMMERCIAL SUPPLY AGREEMENT (as amended in accordance with its terms, this "Agreement") is effective as of October 11, 2016 (the "Effective Date"), by and between Nexus Pharmaceuticals, Inc., an Illinois corporation with a place of business at 175 E. Hawthorn Parkway, Suite 155, Vernon Hills, IL 60061 ("CLIENT") and Grand River Aseptic Manufacturing, Inc., a Delaware corporation with a place of business at 140 Front Avenue SW, Suite 3, Grand Rapids, MI 49504 ("GRAM") (each, a "Party" and together, the "Parties").

WHEREAS, CLIENT is engaged in the development, bulk production, formulation, sale and distribution of pharmaceutical products;

WHEREAS, GRAM is engaged in the filling, labeling and packaging of pharmaceutical products;

WHEREAS, CLIENT and GRAM desire to have GRAM fill, package, inspect, label, and test pharmaceutical products for distribution and sale by CLIENT.

NOW, THEREFORE, in consideration of the terms, conditions and mutual covenants set forth in this Agreement and other good and valuable consideration, the Parties, intending to be legally bound, agree as follows:

Article 1. Definitions and Agreements

As used in this Agreement, the following words and phrases shall have the following meanings and grammatical variations thereof and shall have corresponding meanings (the singular shall be interpreted as including the plural and vice versa, unless the context clearly indicates otherwise):

1.1 "Affiliate" of a Party means any entity that controls or is controlled by such Party, or is under common control with such Party. For purposes of this definition, an entity shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the voting equity of another entity.

1.2 "ANDA" means the FDA-required Abbreviated New Drug Application.

1.3 "Annual Forecast" is defined in Section 4.1.

1.4 "Annual Obligation" is defined in Section 4.3.

1.5 "Applicable Legal Requirements" is defined in Section 7.1.

1.6 "Batch" means a specific quantity of a Product comprising a number of Units mutually agreed upon in writing between CLIENT and GRAM, and that (a) is intended to have uniform character and quality within specified limits, and (b) is Produced according to a single manufacturing order during the same cycle of Production.

1.7 "GRAM SOPs" means GRAM's Standard Operating Procedures, a copy of which has been provided to CLIENT, which shall be deemed reviewed and approved by CLIENT prior to entering into each Work Order.

1.8 "Bulk Drug Substance" means the bulk form of the active ingredient used as the raw material in the Production of Product.

1.9 "CLIENT Trademarks" means the proprietary mark(s) for Product owned by CLIENT as stated in a Work Order.

1.10 "Components" means all components used by GRAM in the Production of Product under this Agreement. Components are listed in the Work Order and are identified as Components supplied by CLIENT ("CLIENT Supplied Components") and Components supplied by GRAM ("GRAM Supplied Components").

1.11 "Component Specifications" means the specifications and testing to be performed for the Components, as set forth in the Work Order.

1.12 "Confidential Information" means all confidential or proprietary information and data provided by one Party to the other Party, except any portion of such information and data which:

(i) is known to the recipient as evidenced by its written records before receipt thereof from the disclosing Party;

(ii) is disclosed to the recipient by a third person who has the right to make such disclosure;

(iii) is or becomes part of the public domain through no fault of the recipient; or

(iv) the recipient can reasonably establish is independently developed by recipient without use of the information or data disclosed by the disclosing Party.

1.13 "Contract Requirements" means one hundred percent (100%) of the quantity of a Product sold and/or distributed by CLIENT in the United States and all other parts of the world.

1.14 "Current Good Manufacturing Practices" or "cGMP" means (a) the good manufacturing practices required by the FDA and set forth in the FD&C Act or FDA Regulations (including without limitation 21 CFR 210 and 211), policies or guidelines, in effect at any time during the Term, for the Production and testing of pharmaceutical materials as applied solely to Products, and (b) the corresponding requirements of each applicable Regulatory Authority.

1.15 "Delivery Date" means the date that Product is delivered to a common carrier designated by CLIENT.

1.16 "Effective Date" means the date of this Agreement as set forth above.

1.17 "FDA" means the United States Food and Drug Administration or any successor entity thereto.

1.18 "FD&C Act" means the United States Federal Food, Drug and Cosmetic Act, as may be amended from time to time.

1.19 "Long Range Forecast" is defined in Section 4.1.

1.20 "Master Batch Record" means, with respect to each Presentation of Product to be Produced under this Agreement, a formal set of instructions for the Production of each Presentation of such Product. The Master Batch Record shall be developed and maintained in GRAM's standard format by GRAM, using CLIENT's master formula and technical support.

1.21 "NDA" means the FDA-required New Drug Application.

1.22 "Presentation" means the specific formula and Components for a Product.

1.23 "Produce" or "Production" means the formulation, filling, packaging, inspecting, labeling, and testing of Product by GRAM in accordance with this Agreement, including the Work Order.

1.24 "Product" means formulated Bulk Drug Substance in syringes and/or vials in final packaged and labeled forms as specified in the Work Order and Produced after the first Regulatory Approval therefore.

1.25 "Product Specifications" means, with respect to each Product, the specifications and testing to be performed for the Bulk Drug Substance, the Product, and/or the stability program that are set forth in GRAM's SOPs and the Master Batch Records. The Product Specifications include all tests that GRAM is required to conduct or cause to be conducted as specified in the Work Order. The Product Specifications may be modified from time to time only by a written agreement of CLIENT and GRAM.

1.26 "Purchase Order" means written orders from CLIENT to GRAM which shall specify (a) the quantity of Product ordered, (b) shipping instructions, (c) delivery dates, and (d) delivery destinations.

1.27 "Quality Agreement" is defined in Section 2.1.

1.28 "Regulatory Approval" means all authorizations by the appropriate Regulatory Authority necessary for commercial sale in a jurisdiction, including without limitation, approval of labeling, price, reimbursement and Production.

1.29 "Regulatory Authority" means those agencies or authorities responsible for regulation of the Products in the United States and overseas. GRAM shall have no obligation to Produce Product in compliance with the requirements of a Regulatory Authority not specified in the applicable Work Order.

1.30 "Released Executed Batch Record" means the completed batch record and associated deviation reports, investigation reports, and Certificates of Analysis created for each Batch of Product.

1.31 "Rolling Forecast" is defined in Section 4.1.

1.32 "Testing Standards and Procedures" means, with respect to each Product Produced under this Agreement, the written standards and procedures for evaluating compliance with the applicable Product Specifications, as mutually agreed upon in writing by CLIENT and GRAM, and incorporated in the applicable Work Order.

1.33 "Unit" means an individually packaged dose of a Product, including by way of example only, a vial or prefilled syringe, as specified in the applicable Work Order.

1.34 "Work Order" means the manual containing the parameters for the Production of each Presentation of Product which shall be developed by GRAM and agreed to in writing by CLIENT for each Presentation of Product under this Agreement, which may include, without limitation, the Product, Product Specifications, Components, Component Specifications, Regulatory Authorities, the countries where such Product will be sold, Presentations, Reschedule Fees and pricing for such Product Produced under this Agreement, as set forth in Section 2.2.

Article 2. Quality Agreement and Work Orders

2.1 Quality Agreement. Concurrently with each Work Order, the Parties will execute a mutually acceptable quality agreement ("Quality Agreement"), which will allocate the roles and responsibilities to each Party with respect to quality control and regulatory compliance as they apply to the services provided by GRAM to CLIENT under the Work Order. In the event of a conflict between this Agreement, a Work Order and/or a Quality Agreement, the Quality Agreement shall prevail as it relates to quality control and regulatory compliance, and, without limitation, this Agreement shall prevail as it relates to limitations of damages or liabilities.

2.2 Work Order. For each Presentation of Product to be Produced under this Agreement, the Parties shall agree in writing upon a Work Order. GRAM shall deliver two (2) copies of each Work Order to CLIENT at least two (2) calendar weeks prior to the date of initial Production of the applicable Presentation of Product. CLIENT shall either sign such Work Order and return one (1) copy to GRAM or shall return an amended Work Order acceptable to CLIENT, in each case within five (5) business days of receipt of such Work Order from GRAM. If such amended Work Order is not acceptable to GRAM, then GRAM shall so notify CLIENT within five (5) business days of GRAM's receipt of such amended Work Order, and the Parties shall promptly meet in order to resolve in good faith any outstanding disagreements with respect to such amended Work Order. In no event shall GRAM be required to schedule or commence the Production of the Presentation of the applicable Product until a Work Order for such Presentation of Product has been approved in writing by both GRAM and CLIENT.

2.3 Amendment of Plans. Each Work Order may be amended from time to time, as the Parties experience with the development, Production, testing and use of the applicable Product warrants, only upon the mutual written agreement of CLIENT and GRAM.

2.4 No Amendment of Agreement. In the event that the terms of any Work Order are inconsistent with the terms of this Agreement, this Agreement shall control, unless otherwise explicitly agreed to in writing by the Parties. No Work Order shall be deemed to amend this Agreement. Upon execution of any Work Order, such plan shall be deemed to be incorporated herein and by reference and made a part of this Agreement.

2.5 Effect of Failure to Execute Plans or Addendum. No failure to execute a Work Order with respect to a particular Product will relieve either Party of any obligation accruing with respect to such Product prior to such failure to execute. CLIENT shall reimburse GRAM for all non-cancelable costs incurred by GRAM for work performed with respect to such Product.

Article 3. Purchase and Supply of Product

3.1 Agreement to Purchase and Supply; Exclusively. Pursuant to the terms and conditions of this Agreement, CLIENT shall purchase from GRAM the Contract Requirements of Product, and GRAM shall use good faith efforts to Produce and deliver to CLIENT the Contract Requirements of Product in accordance with Article 4 of this Agreement. During the Term, CLIENT shall not: purchase or otherwise obtain from any person or entity other than GRAM, any Product, or otherwise Produce any Product itself or through any Affiliate. With regard to the Production of Procainamide, GRAM will Produce Procainamide exclusively for CLIENT during the Term with regard to any indication (as determined by the FDA) of Procainamide.

3.2 Bulk Drug Substance and Components Delivery. CLIENT, at its expense, shall deliver or cause to be delivered, in a timely manner, (a) all Bulk Drug Substance required to satisfy the terms of this Agreement and applicable certificate of analysis therefore and (b) all other CLIENT Supplied Components, all to be delivered to GRAM at least sixty (60) days in advance of the date set forth in the applicable Work Order for Production of such Product. Except as may specifically be set forth in the Work Order, on receipt of the Bulk Drug Substance and CLIENT Supplied Components as set forth above, GRAM will develop material specifications, which require approval by CLIENT. GRAM is responsible for all release testing and release of the drug substance for Production.

3.3 Bulk Drug Substance and Component Delivery Delays. GRAM shall have no responsibility for delays in delivery of Product caused by delays in receipt of Bulk Drug Substance or Components, including those Components supplied by both GRAM and CLIENT. Notwithstanding anything in this Agreement to the contrary, in the event that GRAM receives the Bulk Drug Substance for development or Production of Product from CLIENT with less time than requested in the applicable Work Order prior to the scheduled date of development or Production of such Product, but within sufficient time to develop or Produce such Product on such scheduled date as determined by GRAM in its sole discretion, GRAM shall charge CLIENT an additional fee of Five Thousand and no/100 Dollars ($5,000.00), which shall be paid promptly to GRAM prior to development or Production and GRAM shall develop or Produce such Product as per the original schedule. Notwithstanding anything in this Agreement to the contrary, in the event that GRAM receives the Bulk Drug Substance for development or Production of Product from CLIENT with less time than requested in the applicable Work Order prior to the scheduled date of development or Production of such Product, and without sufficient time to develop or Produce such Product on the scheduled date as determined by GRAM in its sole discretion, GRAM shall reschedule development or Production of such Product and shall charge CLIENT the applicable Reschedule Fee as specified in the Work Order.

3.4 Material Safety Data Sheet. CLIENT shall provide GRAM a Material Safety Data Sheet for Bulk Drug Substance, excipients and for each Product. GRAM shall immediately notify CLIENT of any unusual health or environmental occurrence known to GRAM relating to the Product, including, but not limited to, any claim or complaint by any employee of GRAM or any of its Affiliates or third parties that the operations of GRAM pursuant to this Agreement have resulted in any adverse health or safety effect on an employee or third party. GRAM agrees to advise CLIENT immediately of any safety or toxicity problems of which it becomes aware regarding the Product.

3.5 Vendor and Supplier Audit and Certification. CLIENT shall certify and audit all Product-related vendors and suppliers. GRAM will accept CLIENT vendors, suppliers and audit qualifications only

if GRAM is allowed to review CLIENT qualification documentation and agrees that the vendor or supplier can be added to GRAM's program.

3.6 Purchase of Materials. As specified in the Work Order, GRAM shall purchase, at CLIENT's expense, all packaging materials, primary container Components and secondary packaging materials required to Produce the Product. CLIENT shall reimburse GRAM for its actual costs for such materials and Components within thirty (30) days after delivery of an invoice therefore to CLIENT. GRAM shall control packaging materials listed in the Work Order and shall assist CLIENT with evaluation and purchase of modified materials in the event that CLIENT requests a change in Presentation. GRAM shall not initiate any changes to materials without written approval from CLIENT.

3.7 GRAM Supplied Components. GRAM will purchase the GRAM Supplied Components in quantities sufficient to meet CLIENT's Purchase Orders for Product consistent with Article 4. CLIENT shall reimburse GRAM for its actual costs for the GRAM Supplied Components within thirty (30) days after delivery of an invoice therefore to CLIENT.

3.8 Importer of Record. In the event any material or equipment to be supplied by CLIENT, including without limitation CLIENT Supplied Components and Bulk Drug Substance, is imported into the United States for delivery to GRAM ("Imported Goods"), such Imported Goods shall be imported DDP GRAM's facility in Grand Rapids, Michigan (Incoterms 2010). CLIENT shall be the "Importer of Record" of such Imported Goods. As the Importer of Record, CLIENT shall be responsible for all aspects of the Imported Goods including, without limitation (a) customs and other regulatory clearance of Imported Goods, (b) payment of all tariffs, duties, customs, fees, expenses and charges payable in connection with the importation and delivery of the Imported Goods, and (c) keeping all records, documents, correspondence and tracking information required by applicable laws, rules and regulations arising out of or in connection with the importation or delivery of the Imported Goods.

3.9 Storage.

3.10.1 *Product Storage.* If GRAM has adequate space in its current facility in Grand Rapids, Michigan, as determined in GRAM's sole discretion, GRAM will store Product for CLIENT after the Product release, and with regard to any such storage, CLIENT shall pay to GRAM those storage fees set forth in the applicable Work Order, pursuant to the terms of the applicable Work Order.

3.10.2 *Bulk Drug Substance and Component Storage.* If GRAM has adequate space in its current facility in Grand Rapids, Michigan, as determined in GRAM's sole discretion, GRAM will store Bulk Drug Substance and Components for CLIENT, and with regard to any such storage, CLIENT shall pay to GRAM those storage fees set forth in the applicable Work Order.

3.10.3 *Third Party Storage.* GRAM shall be permitted to store Product, Bulk Drug Substance and Components in third party storage facilities with the prior written consent of CLIENT, which consent shall not be unreasonably withhold, conditioned or delayed. GRAM shall have no liability for, and CLIENT releases all claims against GRAM arising out of, any damage or loss to Product, Bulk Drug Substance or Components arising out of, or in connection with, the storage in such third-party facilities.

Article 4. Forecasts, Orders, and Capacity

4.1 Forecasts and Order Limits.

4.1.1 Commencing on the Effective Date, and prior to July 1 of each year thereafter, CLIENT will provide to GRAM in writing a non-binding annual forecast for each calendar year during the remainder of the Term of CLIENT's estimated Contract Requirements for each Product (the "Long Range Forecast"). Commencing on the Effective Date, and prior to the tenth (10th) calendar day of each month thereafter, CLIENT will provide GRAM in writing a twelve (12) month rolling forecast of CLIENT's estimated Contract Requirements for each Product (the "Rolling Forecast"). GRAM specifically agrees that such Long Range Forecasts and Rolling Forecasts submitted by CLIENT will be for general planning purposes only, and shall not be binding on CLIENT or GRAM. Commencing on the Effective Date, and prior to July 1 of each calendar year thereafter, CLIENT will provide to GRAM in writing a non-binding monthly forecast of CLIENT's Contract Requirements for each Product for the next succeeding calendar year (the "Annual Forecast").

4.1.2 During each calendar quarter, GRAM shall supply CLIENT with the quantity of Product ordered by CLIENT, unless the quantity for any calendar quarter exceeds one hundred twenty (120%) of the Annual Forecast for such calendar quarter, in which event GRAM shall use good faith efforts to supply quantities in excess of one hundred twenty percent (120%) of the Annual Forecast for such calendar quarter.

4.2 Purchase Orders. Prior to or on the tenth (10th) calendar day of each month, CLIENT shall submit Purchase Orders to GRAM covering CLIENT's purchases of Product pursuant to this Agreement. CLIENT shall not, without the written consent of GRAM, designate a delivery date in a Purchase Order earlier than ninety (90) calendar days from the date CLIENT submits the Purchase Order. GRAM shall provide a confirmation of receipt of each Purchase Order setting forth the delivery date that GRAM will meet and setting forth GRAM's filling date for such order. Upon CLIENT's receipt of the confirmation, such Purchase Order shall become a "Firm Purchase Order." If GRAM is unable to meet the specified delivery date, except when caused by CLIENT's delay in delivery of Bulk Drug Substance, GRAM shall so notify CLIENT and provide to CLIENT an alternative delivery date which shall not be more than thirty (30) calendar days later than the initial delivery date designated by CLIENT in its Purchase Order. In the event that CLIENT cancels a Firm Purchase Order, CLIENT shall pay, as liquidated damages and not as a penalty, the Purchase Price of the Product in the Firm Purchase Order. In the event that CLIENT modifies a Firm Purchase Order, CLIENT shall pay, as liquidated damages and not as a penalty, the applicable Reschedule Fee as specified in the Work Order. To the extent of any conflict between Purchase Orders submitted by CLIENT and this Agreement, this Agreement shall control.

4.3 Annual Obligation. CLIENT shall be obligated to purchase from GRAM at least the following minimum Batches of Procainamide in each calendar year during the Term of this Agreement (the "Annual Obligation"), which Annual Obligation shall be pro-rated for any partial calendar year: 150,000 Units of 2mL Procainamide (total value of $590,000) and 100,000 Units of 10mL Procainamide (total value of $667,500). Within thirty (30) days after the end of each calendar year, CLIENT shall pay to GRAM the difference between the Purchase Price of Product actually purchased pursuant to Sections 4.1 and 4.2 by CLIENT and the Purchase Price of the Annual Obligation of Product.

4.4 Annual Order Increases. In any calendar year during the Term of this Agreement, in no event shall GRAM be obligated to Produce more than one-hundred twenty percent (120%) of the quantity of Product Produced by GRAM in the preceding calendar year; provided, however, GRAM will use good faith efforts to meet such increased demand.

Article 5. Price; GDUFA Fee

5.1 Product Purchase Price. The price to be paid by CLIENT for Product ("Purchase Price") shall be set forth in the Work Order.

5.2 Purchase Price Adjustment. Upon the first anniversary of the date of this Agreement and on each anniversary thereafter, the Purchase Price of such Product may be adjusted as mutually agreed by the Parties to reflect changes in the cost of materials provided by GRAM and labor costs paid by GRAM in connection with the Production of such Product. If no agreement is reached on an adjustment, GRAM may increase the Purchase Price by a percentage which may not exceed the percentage change in the U.S. PPI (Producer Price Index) for the previous 12 months. GRAM shall provide CLIENT with written notice not less than thirty (30) days prior to any Purchase Price increase, which notice shall set forth the amount of such Purchase Price increase.

5.3 GDUFA Fee. Each calendar year GRAM must pay a GDUFA (Generic Drug User Fee Amendments of 2012, as amended, or any successor law) manufacturing site fee for GRAM's facility located at 140 Front Avenue SW, Ste. 3, Grand Rapids, MI 49504 (the "Site Fee"). To partially reimburse GRAM for the Site Fee, (i) upon the execution of this Agreement, CLIENT shall pay to GRAM Twenty-Five Thousand Dollars ($25,000), and (ii) by September 1 of each subsequent year (beginning September 1, 2017) during the Term, CLIENT shall pay to GRAM ten percent (10%) of the Site Fee due by GRAM during such year (the "Site Fee Payment"). Upon the expiration or termination of this Agreement, CLIENT shall pay to GRAM a prorated portion of the Site Fee Payment.

Article 6. Shipment and Invoicing

6.1 Delivery Terms. GRAM shall deliver all Product to CLIENT or to a location designated by CLIENT in the Purchase Order. All shipments shall be delivered EXW GRAM's facility in Grand Rapids, Michigan (Incoterms 2010), freight collect, by a common carrier designated by CLIENT in the Purchase Order, at CLIENT's expense; provided, however, GRAM shall be responsible for the loading of Product on departure and shall bear all costs of such loading. CLIENT shall procure, at its cost, insurance covering damage or loss of Product during shipping. All shipping instructions of CLIENT shall be accompanied by the name and address of the recipient and the shipping date.

6.2 Exporter of Record. CLIENT shall be the exporter of record for any Product shipped out of the United States, as CLIENT remains the owner of Product. CLIENT warrants that all shipments of Product exported from the United States will be made in compliance with all applicable United States export laws and regulations and all applicable import laws and regulations into the country of importation. CLIENT shall be responsible for obtaining and paying for any licenses or other governmental authorization(s) necessary for the exportation from the United States. CLIENT shall select and pay the freight forwarder who shall solely be CLIENT's agent. CLIENT and its freight forwarder shall be solely responsible for preparing and filing the Shipper's Export Declaration and any other documentation required for the export.

6.3 Foreign Corrupt Practices Act. CLIENT acknowledges that it is not the agent of GRAM and represents and warrants that CLIENT has not, and covenants that it and its Affiliates and agents will not, pay anything of value to any government employee in connection with the resale of Product or otherwise violate the Foreign Corrupt Practices Act, as amended.

6.4 Payment Terms. CLIENT shall pay all invoices within thirty (30) days of the invoice date, subject, as applicable, to the terms of each applicable Work Order. Product will be invoiced by GRAM upon the quality assurance release of the finished Product. Payments shall be made in U.S. dollars by check delivered to GRAM by overnight delivery with a reputable overnight delivery service or by wire transfer as directed by GRAM. Each invoice shall be payable by CLIENT in accordance with the terms noted above. Any payment due under this Agreement not received within the times noted above shall bear interest at the lesser of (a) the maximum rate permitted by law, or (b) 1.5% per month on the outstanding balance compounded monthly.

6.5 Default in Payment Obligations. In addition to all other remedies available to GRAM in the event of a CLIENT default, if CLIENT fails to make payments as required under this Agreement, GRAM may refuse all further Purchase Orders, refuse to develop or Produce any Product or provide any other services until CLIENT's account is paid in full, modify the foregoing terms of payment, place the account on a letter of credit basis, require full or partial payment in advance, suspend deliveries of Product until CLIENT provides assurance of performance reasonably satisfactory to GRAM, and/or take other reasonable means as GRAM may determine.

Article 7. Acceptance of Product

7.1 Product Conformity. GRAM shall Produce Product in accordance with cGMP and any other applicable federal laws or regulations as set forth in the Work Order ("Applicable Legal Requirements"). Production deviations and investigations which occur during Production of Product and which do not cause the Production to be non-compliant with cGMP shall not be deemed to cause such Product to be non-conforming under this Article 7. Within fifteen (15) calendar days from the date of shipment of both Product and the Released Executed Batch Record to CLIENT, CLIENT shall determine whether the Product conforms to Applicable Legal Requirements, the Quality Agreement, GRAM's Product Specifications, Master Batch Record, GRAM SOPs and the Work Order (collectively the "Product Requirements").

7.1.1 If (a) any Batch of Product conforms to the Product Requirements, or (b) CLIENT fails to notify GRAM within the applicable time period that any Batch of Product does not conform to the Product Requirements, then CLIENT shall be deemed to have accepted Product and waived its right to revoke acceptance or make any claim that such Product does not conform to the Product Requirements.

7.1.2 If CLIENT believes any Batch of Product does not conform to the Product Requirements, it shall notify GRAM immediately by telephone including a detailed explanation of the non-conformity and shall confirm such notice in writing via overnight delivery to GRAM. Upon receipt of such notice, GRAM will investigate such alleged non-conformity, and (i) if GRAM agrees such Product is non-conforming, deliver to CLIENT a corrective action plan within thirty (30) calendar days after receipt of CLIENT's written notice of non-conformity, or such additional time as is reasonably required if such investigation or plan requires data from sources other than CLIENT or GRAM, or (ii) if GRAM disagrees with CLIENT's determination that the Batch of

Product is non-conforming, GRAM shall so notify CLIENT by telephone within the thirty (30) calendar day period and confirm such notice in writing by overnight delivery.

7.1.3 If the Parties dispute whether a Batch of Product is conforming or non-conforming, samples of the Batch of Product will be submitted to a mutually acceptable laboratory or consultant for resolution, whose determination of conformity or non-conformity, and the cause thereof if non-conforming, shall be binding upon the Parties absent manifest error. CLIENT shall bear the costs of such laboratory or consultant, except as set forth in Section 7.2.3.

7.2 Remedies for Non-Conforming Product.

7.2.1 In the event GRAM agrees that a Batch of Product is non-conforming or the laboratory determines that the shipment of Product is non-conforming, GRAM shall replace such non-conforming Product within the latter of (i) sixty (60) calendar days from receipt of replacement Bulk Drug Substance from CLIENT or (ii) sixty (60) calendar days from the date of determination by the third party of non-conformity or agreement by GRAM of such non-conformity.

7.2.2 CLIENT shall pay for all Product, including replacement Product and the cost of Bulk Drug Substance therefore, except as specifically set forth in Section 7.2.3.

7.2.3 In the event GRAM agrees, or the laboratory or consultant determines, that Product is non-conforming solely as a result of the negligence or willful misconduct of GRAM, GRAM shall incur the cost of Production of the replacement Product, shall reimburse CLIENT for its actual cost of the Bulk Drug Substance for its replacement Product, which cost shall not exceed the Purchase Price of Product, and shall bear the costs of such laboratory or consultant.

7.3 Non-Conforming Bulk Drug Substance. If Product is rejected by CLIENT, and such Product's failure to meet the Product Requirements is the result of non-conforming Bulk Drug Substance or any other components or materials supplied by CLIENT, then such non-conformity shall be deemed not to be non-conforming for purposes of this Article 7 or otherwise.

Article 8. Term and Termination

8.1 Initial Term. This Agreement shall be effective on the Effective Date and shall continue for sixty (60) months thereafter (the "Initial Term"), unless earlier terminated in accordance with the terms of this Agreement. This Agreement will be renewed automatically for two (2) additional twenty-four (24) month periods commencing at the expiration of the Initial Term and any extensions thereof unless either the CLIENT or GRAM terminates this Agreement by giving the other Party written notice of intent to terminate at least twenty-four (24) months prior to the expiration of the Initial Term or any extension thereof. The Initial Term as may be extended is referred to in this Agreement as the "Term."

8.2 Termination for Breach. Either Party may terminate this Agreement upon the material breach of any provision of this Agreement by the other Party if such breach is not cured by the breaching Party within ten (10) calendar days for monetary defaults and thirty (30) calendar days for non-monetary defaults (or such additional time reasonably necessary to cure such non-monetary default provided the breaching Party has commenced a cure within the thirty (30) day period and is diligently pursuing completion of such cure) after receipt by the breaching Party of written notice of such default. At the

option of the non-breaching Party, such termination may be with respect to the entire Agreement, or only with respect to Product that is subject to the breach.

8.3 Termination for Financial Matters. This Agreement may be terminated immediately by either Party by giving the other Party written notice thereof in the event such other Party makes a general assignment for the benefit of its creditors, or proceedings of a case are commenced in any court of competent jurisdiction by or against such Party seeking (a) such Party's reorganization, liquidation, dissolution, arrangement or winding up, or the composition or readjustment of its debts, (b) the appointment of a receiver or trustee for or over such Party's property, or (c) similar relief in respect of such Party under any law relating to bankruptcy, insolvency, reorganization, winding up or composition or adjustment of debt; and such proceedings shall continue undismissed, or an order with respect to the foregoing shall be entered and continue unstated, for a period of more than sixty (60) days.

8.4 Termination Without Cause. Either Party may terminate this Agreement at any time with at least two (2) years prior written notice to the other Party, in a writing that clearly states that such Party wishes to terminate this Agreement and which states the effective date of such termination (which date shall be at least two (2) years after the written notice).

8.5 Non-Cancelable Costs and Expenses. In the event of the termination or cancellation of this Agreement, except by CLIENT as a result of a breach by GRAM under Section 8.2 or 8.3, CLIENT shall (a) reimburse GRAM for all Components ordered prior to termination and not cancelable at no cost to GRAM, and (b) pay GRAM for all outstanding Firm Orders (which GRAM shall fill and deliver to CLIENT). In addition, in the event of termination or cancellation for any reason, CLIENT shall pay prices described in Article 5 for (i) all work-in-process commenced by GRAM and (ii) all finished goods of GRAM (which finished goods shall be delivered to CLIENT unless otherwise directed by CLIENT). GRAM shall ship such materials and finished goods to CLIENT pursuant to Section 6.1. CLIENT shall make payment for all expenses described in this Section 8.5 thirty (30) days from the invoice date.

8.6 Termination Damages. In addition to the costs and expenses payable in Section 8.5, in the event of termination or cancellation of this Agreement, except by CLIENT as a result of a breach by GRAM under Section 8.2 or 8.3, CLIENT shall pay GRAM, as liquidated damages and not as a penalty, (i) eighty percent (80%) of the Annual Obligation, as defined in Section 4.3, for the next succeeding calendar year after the calendar year in which termination or cancellation occurs, (ii) sixty percent (60%) of the Annual Obligation for the second succeeding calendar year after the calendar year in which termination or cancellation occurs, and (iii) fifty (50%) of the Annual Obligation of any subsequent calendar year during the Term. Notwithstanding the foregoing in this Section 8.6, if this Agreement is terminated by either Party pursuant to Section 8.4, CLIENT shall pay GRAM any Annual Obligation during the Term (for example, during the two (2) year period prior to the termination of this Agreement but after the notice of termination under Section 8.4) but CLIENT shall not otherwise be obligated to pay GRAM any amounts under this Section 8.6 for periods after the termination of this Agreement.

8.7 Survival. Termination, expiration, cancellation or abandonment of this Agreement through any means or for any reason, except as set forth in Section 13.1, shall be without prejudice to the rights and remedies of either Party with respect to any antecedent breach of any of the provisions of this Agreement. Any expiration or termination of this Agreement shall not relieve either Party from obligations that are expressly indicated, or that by their nature are contemplated, to survive such expiration or termination.

Article 9. Production of Product

9.1 Presence of CLIENT. Subject to compliance with reasonable rules and regulations of GRAM, CLIENT shall have the right to be present during Production of Product.

9.2 Audits. CLIENT shall have the right to audit GRAM's facilities to determine compliance with (i) cGMP and (ii) applicable federal, state, and local laws, regulations and rules as set forth in the Work Order. Such audits shall be scheduled at mutually agreeable times upon reasonable advance written notice to GRAM, shall be at CLIENT's expense, and shall not occur more than one (1) time per calendar year unless required by GRAM's compliance status or CLIENT's obligations as a license holder or by CLIENT's customs. If CLIENT requests additional audits which are not due to GRAM's compliance status and GRAM agrees to such audits, CLIENT will incur fees as reasonably determined by GRAM. Such fees shall be paid promptly upon completion of such audits. In connection with performing such audits, CLIENT shall comply with all reasonable rules and regulations promulgated by GRAM. All information disclosed or reviewed in such inspections shall be deemed to be the property of GRAM and GRAM's Confidential Information.

9.3 Testing. GRAM shall test, or cause to be tested by third party testing facilities audited by GRAM, in accordance with the Product Specifications, each Batch of Product Produced pursuant to this Agreement before delivery to CLIENT. A certificate of analysis for each Batch of Product delivered to CLIENT shall set forth the items tested by GRAM, specifications, and test results. GRAM shall send, or cause to be sent, such certificates along with one (1) copy of the Released Executed Batch Record and certificate of product release to CLIENT prior to or at the same time of shipment of Product to CLIENT. As required by the FDA, CLIENT shall assume full responsibility for final release of each lot of the Product.

9.4 Stability Testing. At CLIENT's cost and expense, CLIENT or a Party selected by CLIENT shall perform all stability testing required to be performed on clinical, development, and/or Production Batches of Product. If performed by GRAM, such testing shall be performed in accordance with the procedures set out in the Product-specific GRAM SOPs for the stability protocol and the Work Order.

9.5 Permits and Licenses. CLIENT shall have sole responsibility, at its expense, for obtaining all permits and licenses necessary or required for the sale, marketing and commercialization of each Product Produced by GRAM under this Agreement. GRAM shall be responsible, at its expense, to obtain and maintain all permits and licenses required for it to carry out its development and Production obligations under this Agreement.

9.6 Regulatory Requirements. Each Party promptly shall notify the other of new regulatory requirements of which it becomes aware which are relevant to the Production of a Product under this Agreement and which are required by the FDA, any other applicable Regulatory Authority or other applicable laws or governmental regulations, and shall confer with each other with respect to the best means to comply with such requirements.

9.7 Drug Master File. GRAM shall file and maintain the appropriate Type V Drug Master File ("DMF") and related reference applications (e.g. Site Master File) for its Production of each Product under this Agreement in accordance with 21 CFR 314.420, as may be amended from time to time, at GRAM's expense.

9.8 Quality Review. At CLIENT's cost and expense and as set forth in the applicable Work Order, GRAM shall be responsible for evaluating the quality of the Product to determine the need for changes in the Specifications, manufacturing processes and/or controlled documents. GRAM shall provide CLIENT a copy of the examination results and recommendations, if any.

9.9 Customer Complaints and Adverse Events. CLIENT, as required by cGMP, shall maintain all customer complaint and adverse event files. Any such complaints received by GRAM shall be forwarded to CLIENT. CLIENT shall be responsible for the review of the complaint or adverse event to determine the need for an investigation or the need to report to the FDA as required by cGMP. CLIENT shall send to GRAM all Product performance or manufacturing-related complaints which require investigation and shall provide to GRAM all Product which is the subject of such complaints. GRAM shall conduct an investigation for each Product performance or manufacturing-related complaint and shall report findings and follow-up of each investigation to CLIENT. CLIENT shall make these complaint files available to GRAM in the event they are required during an FDA inspection.

9.10 Changes in Manufacturing.

9.10.1 *Changes to Master Batch Records and Product Specifications.* GRAM agrees to inform CLIENT within fifteen (15) days of the result of any regulatory development or changes to Product-specific GRAM SOPs that materially affect the Production of Product. GRAM shall notify CLIENT of and require written approval from CLIENT for changes to Master Batch Records and Product Specifications prior to Production of subsequent Batches of Product. CLIENT shall approve or deny GRAM's suggested changes within thirty (30) days of GRAM's request for written approval.

9.10.2 *Product-Specific Changes.* If facility, equipment, process or system changes are required of GRAM as a result of requirements set forth by the FDA or any other Regulatory Authority, and such regulatory changes apply primarily to the development or Production and supply of one or more Products, then CLIENT and GRAM will review such requirements and agree in good faith and in writing to such regulatory changes, and CLIENT shall bear 100% of the reasonable costs thereof.

9.10.3 *General Changes.* If such regulatory changes apply generally to one or more Products as well as to other products produced by GRAM for itself or for third parties, then CLIENT shall pay a pro rata amount, as reasonably determined by GRAM, of the reasonable cost of such regulatory changes based upon the proportion of time that such facility is dedicated to the Production of Products relative to the production of such other products.

9.11 Equipment Expenses. If GRAM is required to obtain specialized equipment in order to Produce Product for CLIENT, the costs of such equipment shall be paid by CLIENT. GRAM shall advise CLIENT of the specialized equipment required and the estimated costs associated with the purchase and installation of such equipment. If CLIENT, in its sole discretion, determines that it does not desire to pay the costs for such equipment, then CLIENT shall have the right to terminate this Agreement with respect to such Product for which such equipment is required only, on ninety (90) days prior written notice to GRAM. CLIENT shall be invoiced for all approved costs after installation and acceptance of such equipment by GRAM, and CLIENT shall make payments promptly thereafter.

9.12 Ownership of Equipment. Upon termination or expiration of this Agreement, GRAM, at its option, shall either (i) transfer ownership of the specialized equipment paid for by CLIENT to CLIENT, or (ii) purchase such equipment by paying CLIENT the then current book value of such equipment. Depreciation of such equipment shall be calculated in accordance with general accepted accounting principles.

Article 10. Regulatory

10.1 Regulatory Approvals. CLIENT will diligently pursue Regulatory Approval of marketing licenses for each Product Produced by GRAM under this Agreement. CLIENT will advise GRAM of document requirements in support of NDA and/or ANDA and similar applications required of foreign governments and agencies including amendments, license applications, supplements and maintenance of such. GRAM will provide documents and assist CLIENT in preparation of submissions to Regulatory Authorities (both U.S and foreign) designated by CLIENT in support of CLIENT's NDAs, ANDAs, similar applications required of foreign governments and licenses. Prior to submission to the Regulatory Authority, CLIENT will provide GRAM with a copy of the CMC section for review and comment. A final copy of the CMC section will be provided by CLIENT to GRAM upon submission to the Regulatory Authority. Upon Regulatory Approval, CLIENT will notify GRAM within two (2) days of such approval and the anticipated date of Product launch to the market.

10.2 Regulatory Authority Inspections. At CLIENT's request, GRAM will authorize Regulatory Authorities to review related applications on CLIENT's behalf. GRAM will notify CLIENT within five (5) calendar days of all contacts with Regulatory Authorities (both written and verbal) related to each Product. GRAM shall inform CLIENT of the result of any regulatory inspection which directly affects the Production of a Product, including any notice of inspection, notice of violation or other similar notice received by GRAM affecting Production, facility, testing, storage or handling of a Product. In the event of an FDA inspection which directly involves a Product, CLIENT shall be immediately informed of the issuance of the Notice of Inspection (FDA Form 482). In the event that there are Inspectional Observations (FDA Form 483), CLIENT shall be informed immediately and shall have the opportunity to review and provide GRAM with comments to GRAM's response. CLIENT shall provide its comments to the response of these observations within five (5) calendar days. The contents of GRAM's response shall be determined by GRAM in its sole discretion.

Article 11. Trademarks

11.1 CLIENT grants to GRAM a non-exclusive, royalty free license to use the CLIENT Trademarks for the sole purpose of allowing GRAM to fulfill its responsibilities under this Agreement. Such license shall not be transferable in whole or in part.

11.2 CLIENT shall be solely responsible for selecting, registering and enforcing the CLIENT Trademarks used to identify the Product and, except as set forth in Section 11.1, shall have sole and exclusive rights in such CLIENT Trademarks.

Article 12. Representations and Warranties

12.1 Mutual Representations and Warranties. Each Party represents and warrants to the other Party that (i) the person executing this Agreement is authorized to execute this Agreement, (ii) this Agreement is legal and valid and the obligations binding upon such Party are enforceable in accordance

with their terms, and (iii) the execution, delivery and performance of this Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which such Party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.

12.2 GRAM Representations and Warranties. GRAM represents and warrants that Product shall be Produced in accordance with cGMP. GRAM represents and warrants that it has obtained (or will obtain prior to Producing Product), and will remain in compliance with during the Term, all permits, licenses and other authorizations ("Permits") which are required under U.S. federal, state and local laws, rules and regulations applicable to the Production only of Product as specified in the Work Order; provided, however, GRAM shall have no obligation to obtain Permits relating to the sale, marketing, distribution or use of Bulk Drug Substance or Product or with respect to the labeling of Product. GRAM makes no representation or warranty with respect to, and shall have no responsibility for, the sale, marketing, distribution or use of the Bulk Drug Substance or Product or any other components or materials supplied by CLIENT, the content of the labeling or as to printed materials specified by CLIENT or its consignee.

12.3 Disclaimer of Representations and Warranties. Except for those representations and warranties set forth in Sections 12.1 and 12.2 of this Agreement, GRAM makes no representations or warranties, written, oral, express or implied, with respect to Product or the development or Production of Product or the services provided to CLIENT under this Agreement. IN PARTICULAR, ALL WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT, ARE HEREBY DISCLAIMED BY GRAM. NO WARRANTIES OF GRAM MAY BE CHANGED BY ANY REPRESENTATIVES OF GRAM. CLIENT accepts Product subject to the terms hereof.

12.4 CLIENT Representations and Warranties. CLIENT represents and warrants that (a) it has the right to give GRAM any information provided by CLIENT under this Agreement, and that GRAM has the right to use such information for the development and Production of Product, and (b) CLIENT has no knowledge of any (i) patents or other intellectual property rights that would be infringed by GRAM's development or Production of Product under this Agreement, or (ii) proprietary rights of third parties that would be violated by GRAM's performance under this Agreement. CLIENT further represents and warrants that the Bulk Drug Substance provided to GRAM under this Agreement (1) conforms to the Bulk Drug Substance Specifications and (2) is not adulterated or misbranded within the meaning of the FD&C Act.

Article 13. Limitation of Liability and Waiver of Subrogation

13.1 Limitation of Liability. Except as expressly set forth in Article 14, each Party acknowledges and agrees that GRAM's sole liability on any claim of any kind, including without limitation negligence, strict or product liability, statutory violations, or breach of warranty or contract, for any loss or damage arising out of or connected with this Agreement, a Work Order or a Quality Agreement, or the performance or breach thereof by GRAM, or the development or Production of Product, and CLIENT's sole and exclusive remedy, is limited to those remedies set forth in Section 7.2 (and with regard to Product recalls, Section 16.1) and in GRAM's sole discretion, to either replace the non-conforming Product or reimburse CLIENT for the Purchase Price for the non-conforming Product. Notwithstanding anything to the contrary in this Agreement, a Work Order or a Quality Agreement, UNDER NO CIRCUMSTANCES SHALL GRAM BE LIABLE TO CLIENT OR ANY THIRD PARTY FOR ANY INDIRECT, SPECIAL,

INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS AND SALES, OF ANY KIND OR NATURE IN CONNECTION WITH PRODUCT, THIS AGREEMENT, A WORK ORDER OR A QUALITY AGREEMENT OR ANY SERVICES PROVIDED TO CLIENT UNDER THIS AGREEMENT, A WORK ORDER OR A QUALITY AGREEMENT, including but not limited to, the cost of cover or the cost of a recall in connection with, or by reason of the development or Production and delivery of, Product, whether such claims are founded in tort, contract or otherwise. Except as expressly set forth in Article 14, the foregoing constitutes the sole and exclusive remedy of CLIENT and the sole and exclusive liability of GRAM for breach of this Agreement, a Work Order or a Quality Agreement by GRAM or otherwise. CLIENT shall not be entitled to any other rights or remedies against GRAM (under this Agreement, a Work Order, a Quality Agreement, at law, in equity or otherwise). All claims by CLIENT for breach of or otherwise related to this Agreement, a Work Order or a Quality Agreement shall be brought within one (1) year after the cause of action accrued or shall be deemed waived.

13.2 Waiver of Subrogation. All GRAM Supplied Components and equipment used by GRAM in the Production of Product (collectively, "GRAM Property") shall at all times remain the property of GRAM and GRAM assumes risk of loss for such property until delivery of Product to a common carrier as specified under Section 6.1. GRAM hereby waives any and all rights of recovery against CLIENT and its Affiliates, and against any of their respective directors, officers, employees, agents or representatives, for any loss or damage to GRAM Property to the extent the loss of damage is covered or could be covered by insurance (whether or not such insurance is described in this Agreement). CLIENT assumes all risk of loss for all CLIENT Supplied Components, all Bulk Drug Substance supplied by CLIENT, and all Product (collectively, "CLIENT Property"). CLIENT hereby waives any and all rights of recovery against GRAM and its Affiliates, and against any of their respective directors, officers, employees, agents or representatives, for any loss or damage to the CLIENT Property to the extent the loss of damage is covered or could be covered by insurance (whether or not such insurance is described in this Agreement).

13.3 Waiver of Claims. GRAM makes no representation or warranty, and CLIENT expressly waives all claims against GRAM and its Affiliates, and any of their respective agents or employees, arising out of or in connection with any claims relating to the stability, efficacy, safety, or toxicity of Product developed, formulated, packaged, manufactured or Produced in accordance with the applicable Work Order.

Article 14. Indemnification

14.1 CLIENT Indemnification. CLIENT shall pay, reimburse, indemnify, defend and hold harmless GRAM and its Affiliates and any of their respective directors, officers, employees, subcontractors, agents and representatives (collectively the "Indemnified Parties") from and against any and all liabilities, obligations, penalties, claims, judgments, demands, actions, disbursements of any kind and nature, suits, losses, damages, costs and expenses (including, without limitation, reasonable attorney's fees) (collectively, "Damages"), including without limitation property damage, personal injury and Damages allegedly resulting in whole or in part by the negligent acts or omission of the Indemnified Parties or for acts or omissions for which the Indemnified Parties otherwise would be strictly liable, arising out of or in connection with (a) the storage, promotion, labeling, marketing, distribution, use or sale of Bulk Drug Substance or Product, (b) CLIENT's negligence or willful misconduct, (c) CLIENT's breach of this Agreement, or (d) any claim that the use, sale, Production, development, marketing or distribution of Bulk Drug Substance or Product by GRAM or CLIENT violates any patent, trademark, copyright or other proprietary rights of any third party; except to the extent any of the foregoing is caused primarily by the

negligence or willful misconduct of GRAM or primarily by the breach by GRAM of its obligations under this Agreement.

14.2 GRAM Indemnification. GRAM shall pay, reimburse, indemnify, defend and hold harmless CLIENT and its Affiliates and any of their respective directors, officers, employees, subcontractors, agents and representatives from and against any and all Damages to the extent (a) resulting primarily from GRAM's negligence or willful misconduct, or (b) arising out of or in connection with GRAM's breach of this Agreement; except to the extent any of the foregoing is caused primarily by the negligence or willful misconduct of CLIENT or primarily by the breach by CLIENT of its obligations under this Agreement.

14.3 Indemnitee Obligations. A Party (the "Indemnitee") which intends to claim indemnification under this Article 14 shall promptly notify the other Party (the "Indemnitor") in writing of any action, claim or other matter in respect of which the Indemnitee or any of its Affiliates, or any of their respective directors, officers, employees, subcontractors, agents or representatives, intend to claim such indemnification; provided, however, that failure to provide such notice within a reasonable period of time shall not relieve the Indemnitor of any of its obligations under this Article 14 except to the extent the Indemnitor is actually prejudiced by such failure. The Indemnitee shall permit, and shall cause its Affiliates, and their respective directors, officers, employees, subcontractors, agents and representatives to permit, the Indemnitor, at its discretion, to settle any such action, claim or other matter, and the Indemnitee agrees to the complete control of such defense or settlement by the Indemnitor. Notwithstanding the foregoing, the Indemnitor shall not enter into any settlement that would adversely affect the Indemnitee's rights under this Article 14, or impose any obligations on the Indemnitee in addition to those set forth herein, in order for it to exercise such rights, without Indemnitee's prior written consent, which shall not be unreasonably withheld, conditioned or delayed. No such action, claim or other matter shall be settled without the prior written consent of the Indemnitor, which shall not be unreasonably withheld, conditioned or delayed. The Indemnitee, its Affiliates, and their respective directors, officers, employees, subcontractors, agents and representatives shall fully cooperate with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or other matter covered by the indemnification obligations of this Article 14. The Indemnitee shall have the right, but not the obligation, to be represented in such defense by counsel of its own selection and at its own expense.

14.4 Injunction. In the event that the development, Production or sale of a Product is enjoined due to alleged infringement by either Party of the proprietary rights of a third party, such action shall be deemed a material breach of this Agreement by CLIENT.

14.5 Limitation. Notwithstanding anything to the contrary set forth in this Agreement, a Work Order or a Quality Agreement, GRAM's sole liability under this Article 14 for any Damages (or otherwise for any claims, actions, losses, damages, injuries, defects, costs, expenses or other liabilities arising out of or connected with this Agreement, a Work Order or a Quality Agreement, or the performance or breach of this Agreement, a Work Order or a Quality Agreement, or the Production, sale or use of Product) on any claim of any kind (or series of related claims, including without limitation claims arising from a common source or issue), including negligence, strict or product liability, statutory violations, or breach of warranty or contract, shall in no case exceed the greater of $100,000 (which would include any insurance proceeds used to satisfy GRAM's liability) or an amount equal to the insurance proceeds actually received by GRAM (and not used by GRAM for its own or third party damages or expenses) in relation to the applicable claim (or series of related claims, including without limitation claims arising from a common source or issue).

Article 15. Insurance.

15.1 CLIENT Insurance. CLIENT shall procure and maintain, during the Term and for a period of one (1) year beyond the expiration date of Product, Commercial General Liability Insurance, including without limitation, Product Liability and Contractual Liability coverage (the "CLIENT Insurance"). The CLIENT Insurance shall cover amounts not less than ten million dollars ($10,000,000) combined single limit and shall be with an insurance carrier reasonably acceptable to GRAM. GRAM shall be named as an additional insured on the CLIENT Insurance and CLIENT promptly shall deliver a certificate of CLIENT Insurance and endorsement of additional insured to GRAM evidencing such coverage. If CLIENT fails to furnish such certificates or endorsements, or if at any time during the Term GRAM is notified of the cancellation or lapse of the CLIENT Insurance, and CLIENT fails to rectify the same within ten (10) calendar days after notice from GRAM, in addition to all other remedies available to GRAM under this Agreement, GRAM, at its option, may obtain the CLIENT Insurance and CLIENT promptly shall reimburse GRAM for the cost of the same. Any deductible and/or self-insurance retention shall be the sole responsibility of CLIENT.

15.2 GRAM Insurance. GRAM is, and shall during the Term remain, insured as follows: worker's compensation as required by Applicable Law; employer's liability insurance not less than $1,000,000; bodily injury and property damage insurance not less than $2,000,000 (combined single limit, per occurrence); and product liability insurance not less than $10,000,000 (combined single limit, per occurrence).

Article 16. Recall of Product

16.1 In the event CLIENT shall be required to recall any Product because such Product may violate local, state or federal laws or regulations, the laws or regulations of any applicable foreign government or agency or the Product Specifications, or in the event that CLIENT elects to institute a voluntary recall, CLIENT shall be responsible for coordinating such recall. CLIENT promptly shall notify GRAM if any Product is the subject of a recall and provide GRAM with a copy of all documents relating to such recall. GRAM shall cooperate with CLIENT in connection with any recall, at CLIENT's expense. In the event a recall is necessary because both (i) GRAM has delivered a non-conforming Product to CLIENT, and (ii) such non-conformity is primarily due to the negligence of GRAM, GRAM will bear all reasonable costs associated with such recall (including but not limited to costs associated with receiving and administering the recalled Product and notification of the recall to those persons whom CLIENT deems appropriate); notwithstanding the foregoing, in no event shall GRAM's liability for costs associated with such recall exceed the purchase price paid to GRAM by CLIENT for the Product which is the subject of such recall. In all other cases CLIENT shall be responsible for all of the costs and expenses of any recall of Product.

Article 17. Intellectual Property and Inventions.

17.1 Existing Intellectual Property. Except as the Parties may otherwise expressly agree in writing, each Party shall continue to own its existing patents, trademarks, copyrights, trade secrets and other intellectual property, without conferring any interests therein to the other Party. Without limiting the generality of the preceding sentence, CLIENT shall retain all right, title and interest arising under the U.S. Patent Act, U.S. Trademark Act, U.S. Copyright Act and all other applicable laws, rules and regulations in and to all Products, Bulk Drug Substance, labeling and trademarks associated therewith (collectively, "CLIENT's Intellectual Property"). Neither GRAM nor any third party shall acquire any right, title or

interest in CLIENT's Intellectual Property by virtue of this Agreement or otherwise, except to the extent expressly provided herein or as necessary for GRAM to perform its obligations under this Agreement.

17.2 Individually Owned Inventions. Except as the Parties may otherwise agree in writing, all Inventions (as defined herein) which are conceived, reduced to practice, or created by a Party in the course of performing its obligations under this Agreement shall be solely owned and subject to use and exploitation by the inventing Party without a duty to account to the other Party. For purposes of this Agreement, "Invention" means information relating to any innovation, improvement, development, discovery, computer program, device, trade secret, method, know-how, process, technique or the like, whether or not written or otherwise, fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable.

17.3 Jointly Owned Inventions. All Inventions which are conceived, reduced to practice, or created jointly by the Parties and/or their respective agents (i.e., employees or agents who would be or are properly named as co-inventors under the laws of the United States on any patent application claiming such inventions) in the course of the performance of this Agreement shall be owned jointly by the Parties. Each Party shall have full rights to exploit such Inventions for its own commercial purposes without any obligation to the other. The Parties shall share equally in the cost of mutually agreed patent filings with respect to all such jointly owned Inventions. The decision to file for patent coverage on jointly owned Inventions shall be mutually agreed upon, and the Parties shall select a mutually acceptable patent counsel to file and prosecute patent applications based on such joint Inventions.

17.4 Disclaimer. Except as otherwise expressly provided in this Agreement or as necessary for GRAM to perform its obligations under this Agreement, nothing contained in this Agreement shall be construed or interpreted, either expressly or by implication, estoppel or otherwise, as: (i) a grant, transfer or other conveyance by either Party to the other of any right, title, license or other interest of any kind in any of its Inventions or other intellectual property, (ii) creating an obligation on the part of either Party to make any such grant, transfer or other conveyance, or (iii) requiring either Party to participate with the other Party in any cooperative development program or project of any kind or to continue with any such program or project.

17.5 Rights in Intellectual Property. The Party owning any intellectual property shall have the world wide right to control the drafting, filing, prosecution and maintenance of patents covering the Inventions relating to such intellectual property, including decisions about the countries in which to file patent applications. Patent costs associated with the patent activities described in this Section shall be borne by the sole owner. Each Party will cooperate with the other Party in the filing and prosecution of patent applications. Such cooperation will include, but not be limited to, furnishing supporting data and affidavits for the prosecution of patent applications and completing and signing forms needed for the prosecution, assignment and maintenance of patent applications.

17.6 Confidentiality of Intellectual Property. Intellectual property shall be deemed to be the Confidential Information of the Party owning such intellectual property. The protection of each Party's Confidential Information is described in Article 18. Any disclosure of information by one Party to the other under the provisions of this Article 17 shall be treated as the disclosing Party's Confidential Information under this Agreement. It shall be the responsibility of the Party preparing a patent application to obtain the written permission of the other Party to use or disclose the other Party's Confidential Information in the patent application before the application is filed and for other disclosures made during the prosecution of the patent application.

Article 18. Confidential Information, Nondisclosure and Publicity

18.1 Confidentiality. In the course of the performance of this Agreement each Party may, from time to time, disclose Confidential Information to the other Party. Except as otherwise provided in this Article 18, each Party shall not disclose Confidential Information of the other Party to any third parties, and each Party shall take all reasonable steps to prevent the disclosure of Confidential Information of the other Party to third parties. However, no provision of this Agreement shall be construed so as to preclude disclosure of Confidential Information as may be reasonably necessary to secure from any governmental agency necessary approvals or licenses.

18.2 Prior Confidentiality Agreement. This Agreement, by reference, incorporates the Confidentiality Agreement signed by CLIENT and GRAM on October 28, 2014, which is made a part hereof as though fully set forth herein.

18.3 Third Party Disclosure. GRAM shall be permitted to disclose Product information to third party developmental and analytical services providers in connection with the performance of its obligations under this Agreement provided such providers shall be subject to confidentiality agreements. Either Party may disclose Confidential Information of the disclosing Party to those Affiliates, agents and consultants who need to know such information to accomplish the purposes of this Agreement (collectively, "Permitted Recipients"); provided such Permitted Recipients are bound to maintain such Confidential Information in confidence.

18.4 Litigation and Governmental Disclosure. Each Party may disclose Confidential Information under this Agreement to the extent such disclosure is reasonably necessary for prosecuting or defending litigation, complying with applicable governmental regulations or conducting pre-clinical or clinical trials, provided that if a Party is required by law or regulation to make any such disclosure of the other Party's Confidential Information it will, except where impractical for necessary disclosures (for example in the event of a medical emergency), give reasonable advance notice to the other Party of such disclosure requirement and will use good faith efforts to assist such other Party to secure a protective order or confidential treatment of such Confidential Information required to be disclosed.

18.5 Limitation of Disclosure. The Parties agree that, except as otherwise may be required by applicable laws, regulations, rules or orders, including without limitation the rules and regulations promulgated by the United States Securities and Exchange Commission, and except as may be authorized in this Article 18, no information concerning this Agreement and the transactions contemplated herein shall be made public by either Party without the prior written consent of the other Party.

18.6 Publicity and SEC Filings. The Parties agree that the public announcement of the execution of this Agreement shall only be by one or more press releases mutually agreed to by the Parties. The failure of a Party to return a draft of a press release with its proposed amendments or modifications to such press release to the other Party within five (5) days of such Party's receipt of such press release shall be deemed as such Party's approval of such press release as received by such Party. Each Party agrees that it shall cooperate fully and in a timely manner with the other with respect to all disclosures to the Securities and Exchange Commission and any other governmental or regulatory agencies, including requests for confidential treatment of Confidential Information of either Party included in any such disclosure.

18.7 Duration of Confidentiality. All obligations of confidentiality and non-use imposed upon the Parties under this Agreement shall expire ten (10) years after the expiration or earlier termination of this Agreement; provided, however, that Confidential Information that constitutes trade secrets of a Party shall be kept confidential indefinitely, subject to this Article 18.

Article 19. Force Majeure

19.1 Any delay in the performance of any of the duties or obligations of either Party (except the payment of money) caused by an event outside the affected Party's reasonable control shall not be considered a breach of this Agreement, and unless provided to the contrary herein, the time required for performance shall be extended for a period equal to the period of such delay. Such events shall include without limitation, acts of God; acts of public enemies; insurrections; riots; injunctions; embargoes; fires; explosions; floods; shortages of material or energy; delays in the delivery of raw materials; acts or orders of any government or agency thereof or other causes beyond the reasonable control of the Party so affected, whether or not foreseeable. The Party so affected shall give prompt notice to the other Party of such cause and a good faith estimate of the continuing effect of the force majeure condition and duration of the affected Party's nonperformance, and shall take whatever reasonable steps are appropriate to relieve the effect of such causes.

Article 20. Notices

20.1 All notices under this Agreement shall be delivered by facsimile (confirmed by overnight delivery), or by overnight delivery with a reputable overnight delivery service, to the following address of the respective Parties:

If to CLIENT:

Nexus Pharmaceuticals, Inc.
175 E. Hawthorn Parkway, Suite 155
Vernon Hills, IL 60061
Facsimile: (888) 806-4617

With a copy to:

Kristian A. Werling
McDermott Will & Emery
225 W. Monroe Street
Suite 5500
Chicago, IL 60606

If to GRAM:

Grand River Aseptic Manufacturing, Inc.
140 Front Avenue SW, Suite 3
Grand Rapids, MI 49504
Attn: Tom J. Ross, President and CEO
Facsimile: (616) 776-5584

With a copy to:

Miller, Canfield, Paddock and Stone, P.L.C.
Attn: Thomas G. Appleman
840 W. Long Lake Road, Suite 200
Troy, MI 48098
Facsimile No.: 248-879-2001

Notices shall be effective on the day following the date of transmission if sent by facsimile, and on the second business day following the date of delivery to the overnight delivery service if sent by overnight delivery. A Party may change its address listed above by notice to the other Party given in accordance with this Article.

Article 21. General Provisions

21.1 Non-Solicitation. During the Term and for a period of two (2) years after the expiration or termination of this Agreement for whatever reason, each Party shall not, directly or indirectly, on such Party's own behalf or on behalf of any person or entity, whether as an agent, employee, consultant or in any other capacity, recruit or hire or assist others in recruiting or hiring, any person who is, or was one (1) year prior to the date of such recruitment or hiring, an employee (whether temporary or permanent) or independent contractor of the other Party. The Parties agree that the terms contained in this Section are reasonable in all respects. In the event a court determines that any part of this Section is unreasonable, the court may limit the application of such part, or modify such part, and proceed to enforce this Section as so limited or modified.

21.2 Governing Law. This Agreement is being delivered and executed in the State of Michigan. In any action brought regarding the validity, construction and enforcement of this Agreement, it shall be governed in all respects by the laws of the State of Delaware, without regard to any conflicts of laws or principles thereof and excluding the United Nations Convention on the International Sale of Goods. EACH PARTY HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY RELATED INSTRUMENT.

21.3 Assignment. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns, and may not be assigned by either Party without the prior written consent of the other, which consent shall not be unreasonably withheld, conditioned or delayed, except that no consent shall be required in the case of a transaction involving the merger, consolidation or sale of substantially all of the assets of the Party seeking such assignment and such transaction relates to the business covered by this Agreement and the resulting entity assumes all the obligations under this Agreement. GRAM may, without such consent, assign this Agreement to an Affiliate of GRAM, provided that the assignee assumes all obligations of GRAM under this Agreement. This Agreement is not intended and shall not be construed to create any rights in any parties other than CLIENT and GRAM and no other person or entity shall have or assert any rights as a third party beneficiary under this Agreement.

21.4 Alliances. GRAM agrees that CLIENT shall have the right to enter into alliances with third parties who may engage in joint (with CLIENT) or unilateral marketing and promoting of the Product or any combination of products that includes the Product.

21.5 Obligations to Third Parties. Each Party represents and warrants that this Agreement is not inconsistent with any contractual obligations of such Party, expressed or implied, undertaken with any third party.

21.6 Taxes. CLIENT shall pay all federal, state, municipal, foreign or other sales, use, excise, import, property, value added, or other similar taxes, assessments or tariffs assessed upon or levied against the sale of Product to CLIENT pursuant to this Agreement or the sale or distribution of Product by CLIENT (or at CLIENT's sole expense, defend against the imposition of such taxes and expenses). GRAM shall notify CLIENT of any such taxes that any governmental authority is seeking to collect from GRAM, and CLIENT may assume the defense thereof in GRAM's name, if necessary, and GRAM agrees to reasonably cooperate in such defense to the extent of the capacity of GRAM, at CLIENT's expense. GRAM shall pay

all federal, state, municipal or other taxes on the income resulting from the sale by GRAM of Product to CLIENT under this Agreement, including but not limited to, gross income, adjusted gross income, supplemental net income, gross receipts, excess profit taxes, or other similar taxes.

21.7 Entire Agreement. This Agreement constitutes the entire agreement between the Parties concerning the subject matter hereof and supersedes all written or oral prior representations, warranties, agreements or understandings with respect to the subject matter hereof.

21.8 Severability. In the event that any term or provision of this Agreement shall violate any applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or otherwise be unenforceable, such provision shall be ineffective to the extent of such violation without invalidating any other provision of this Agreement.

21.9 Waiver and Modification of Agreement. No waiver or modification of any of the terms of this Agreement shall be valid unless in writing and signed by authorized representatives of both Parties. The failure by either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights nor shall a waiver by either Party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances. No course of dealing or usage of trade shall be used to modify the terms and conditions of this Agreement.

21.10 Independent Contractor. GRAM shall act as an independent contractor for CLIENT in providing the services required under this Agreement and shall not be considered an agent of, or joint venturer with, CLIENT. Unless otherwise provided herein to the contrary, GRAM shall furnish all expertise, labor, supervision, machining and equipment necessary for performance under this Agreement and shall obtain and maintain all building and other permits and licenses required under applicable law.

21.11 Attorney's Fees. The successful Party in any litigation or other dispute resolution proceeding to enforce the terms and conditions of this Agreement shall be entitled to recover from the other Party reasonable attorney's fees and related costs involved in connection with such litigation or dispute resolution proceeding.

21.12 Headings. The headings used in this Agreement are for convenience only and are not part of this Agreement.

IN WITNESS WHEREOF, the Parties have each caused this Agreement to be executed by their duly-authorized representatives as of the Effective Date.

NEXUS PHARMACEUTICALS, INC.		GRAND RIVER ASEPTIC MANUFACTURING, INC.	
By:	Usman Ahmed	By:	Thomas J Ross
Name:		Name:	Thomas J. Ross
Title:	CFO	Title:	President and CEO

27535625.4\151564-00001

Exhibit 2

GRAND RIVER
ASEPTIC MANUFACTURING

MUTUAL CONFIDENTIALITY AND NONDISCLOSURE AGREEMENT

This Mutual Confidentiality and Nondisclosure Agreement (the "Agreement"), made and entered into as of this 28th day of October, 2014, by and between GRAND RIVER ASEPTIC MANUFACTURING, INC., a corporation organized under the laws of the State of Delaware having an address of 140 Front Avenue SW, Suite 3, Grand Rapids, MI 49504 ("Grand River"), and Nexus Pharmaceuticals, a corporation organized under the laws of the State of Illinois having an address of 175 E Hawthorn Pkwy Vernon Hills, IL 60061 (each referred to as "Party" and both collectively referred to as "the Parties").

BACKGROUND

WHEREAS, the parties hereto desire to explore and discuss a possible transaction relating to the formulation development and aseptic fill of an injectable drug product (the "Transaction");

WHEREAS, in connection with the Transaction, the parties will be given access to Confidential Information (as defined below) relating to each other's businesses and affairs; and

WHEREAS, the parties hereto wish to set forth their understanding with respect to the provision, retention and return of such Confidential Information during and after the discussions relating to the Transaction.

NOW, THEREFORE, in consideration of the premises and the mutual covenants and obligations hereinafter set forth, the sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows.

1. For purposes of this Agreement, "Confidential and Proprietary Information" means technology and information, whether in readable or in verbal form, relating to the products, services, business, personnel or commercial activities of the Parties, including, without limitation: (a) formulas, compilations, programs, devices, concepts, inventions (whether or not patentable), designs, methods, techniques, marketing and commercial strategies, processes, data or specifications, know-how, business or financial information, research and development activities, product and marketing plans, customer and supplier information, and unique combinations of separate items, which individually may or may not be confidential, and which is not generally known to the public; (b) information acquired by a Party, by observation or otherwise, on the other Party's premises; (c) information or other work product developed by a Party in connection with this Agreement; and (d) information that a Party is under an obligation to third parties to maintain as confidential, but for which there is third party permission to share this information between the Parties.

2. Notwithstanding the definition of "Confidential and Proprietary Information" or any other provision of this Agreement, a receiving Party will not be required to treat any information received from the other Party as Confidential and Proprietary Information if and to the extent a receiving Party can establish by a preponderance of the evidence that:

(a) such information is or becomes generally known or available, by publication, commercial use or otherwise, without breach or violation of any confidentiality or other obligation; (b) such information was known by the receiving Party at the time of disclosure by the other Party and was not subject to any obligation of confidentiality; (c) such information was rightfully communicated to the receiving Party by a third party free of any obligation of confidentiality; or (d) such information was developed by employees or agents of the receiving Party independent of and without reference to Confidential and Proprietary Information of the other Party.

3. A Party receiving Confidential and Proprietary Information will use reasonable care not to disclose such information to any third party, except as provided herein. "Reasonable care" will be the same degree of care which the receiving party normally accords its own proprietary and confidential information. A Party receiving Confidential and Proprietary Information will limit disclosure of the other Party's Confidential and Proprietary Information to employees and agents on a need-to-know basis in performance of activities directly related to this Agreement and who have signed confidentiality agreements prohibiting disclosure of any Confidential and Proprietary Information. Neither Party will publish or announce, publicly or privately, any potential or actual business relationship or transaction with the other Party without the other Party's prior written consent. If a Party becomes legally compelled by law, process or order of any court or governmental agency to disclose any Confidential and Proprietary Information that Party will promptly notify the disclosing Party so that a protective order or other appropriate action may be immediately taken to protect such information to the extent possible. This Agreement will not preclude a Party from working with others in any connection, provided that the obligations of this Agreement are respected.

4. No right, license, title or interest, either express or implied, under any patent, copyright, trade secret, trademark or other property right is granted hereunder. The relationship of the Parties will be that of independent contractors, and nothing contained in this Agreement will be deemed to create any relationship of agency, joint venture or partnership. Neither Party will have any power to commit, contract for or otherwise obligate the other Party. None of the Confidential and Proprietary Information that may be disclosed or exchanged by the Parties under this Agreement will constitute any representation, warranty, assurance, guarantee or inducement of any kind by either Party to the other Party. Neither Party will have any liability or responsibility to the other Party for errors or omissions in any decisions made in reliance upon any Confidential and Proprietary Information disclosed under this Agreement.

5. Neither Party will assign or transfer any rights or obligations under this Agreement without the prior written consent of the other Party, except to a successor in ownership of substantially all of the assets of that Party, which successor in ownership will expressly assume in writing the performance of the terms and conditions of this Agreement.

6. The Parties do not make any representations or warranties, express or implied, regarding the value or suitability for any purpose of the Confidential and Proprietary Information.

7. All Confidential and Proprietary Information supplied by a Party will remain the property of and will be returned to the disclosing Party or destroyed upon request. No copies of any Confidential and Proprietary Information may be made without the express prior written permission of the disclosing Party.

8. In executing this Agreement, each Party warrants and represents that it has a right to enter into this Agreement and that the Agreement does not violate policies, if any, of institutions with which the Party is affiliated or any other contract or relationship of the Party.

9. If any term or provision of this Agreement is, to any extent, ruled invalid or unenforceable, the remainder of this Agreement will not be affected, and each other term and provision of this Agreement will be valid and will be enforced to the fullest extent permitted by law.

10. This Agreement is in addition to and does not supersede any prior agreements of confidentiality or nondisclosure between the Parties. This Agreement is not, and will not be construed to be, an obligation to enter into any other agreement or contract or to result in any claim whatsoever by either Party against the other Party for reimbursement of costs for any effort expended.

11. The Parties agree to comply with all relevant and applicable state and federal laws and regulations pertaining to the confidentiality of the Confidential and Proprietary Information and to execute such confidentiality agreements as may be required by such laws and/or regulations.

12. This Agreement and the rights and obligations of the Parties, including all matters of construction, validity and performance, will, in all respects, be governed by the laws of the State of Michigan.

13. In the event that a breach of this Agreement by either Party occurs or is threatened, the other Party may be entitled to injunctive relief restraining the act or threatened act that constitutes or would constitute a breach of this Agreement. In addition, the aggrieved Party will be entitled to receive damages to the extent allowable under the laws of the State of Michigan, or other available relief for any breach.

14. This Agreement is effective as of the date first written above and will apply to all Confidential and Proprietary Information provided by either Party to the other Party under this Agreement. This Agreement will terminate upon written notice from either Party to the other Party with respect to any disclosures after the date of notice, but the confidentiality obligations of this Agreement shall continue in effect after the termination date indefinitely as to Confidential and Proprietary Information disclosed prior to the termination date, unless both Parties otherwise consent in writing. All obligations created by this Agreement will survive change or termination of the Parties' business relationship.

15. Thomas J. Ross shall be the Official Correspondent for Grand River. In addition, in the event that correspondence with other personnel of Grand River becomes necessary, copies of such correspondence should be sent to Mr. Ross electronically at tross@grandriverasepticmfg.com or by hardcopy to Grand River Aseptic Manufacturing, Inc. at 140 Front Avenue SW, Suite 3, Grand Rapids, MI 49504 so that he may keep a complete file on our interaction. In a similar manner, Omair Ahmed shall be the official correspondent for Company.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered by their respective appropriate officers, thereunto duly authorized, as of the date first written above.

GRAND RIVER ASEPTIC MANUFACTURING, INC.

By: Thomas J Ross
Name: Thomas J. Ross
Title: President

COMPANY NAME

By:
Name: Omair Ahmed
Title: VP Business Development

Exhibit 3

CONFIDENTIALITY, PROPRIETARY RIGHTS, AND ARBITRATION AGREEMENT

This CONFIDENTIALITY, PROPRIETARY RIGHTS, AND ARBITRATION AGREEMENT (this "Agreement"), dated March 1, 2019, between Grand River Aseptic Manufacturing, Inc., a Delaware corporation (the "Company"), and Jerrod Weidenfeller (the "Employee").

RECITALS

A. The Company has employed Employee and desires reasonable protection of its confidential information and proprietary rights and innovations which it has developed and will develop at substantial expense.

B. The execution and delivery of this Agreement is a condition to the Company's willingness to employ or continue to Employee, and Employee desires to make his or her agreements set forth herein.

AGREEMENT

NOW, THEREFORE, in consideration of Employee's employment or continued employment with the Company, the parties hereto hereby agree as follows:

1. Confidential Information.

(a) During the term of Employee's employment with the Company, and after the termination of such employment for any reason whatsoever, Employee shall not disclose, divulge or furnish any Confidential Information (as hereinafter defined) to any individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof (a "Person"), other than the Company or upon its written request, or use any Confidential Information directly or indirectly for Employee's own benefit or for the benefit of any other Person other than the Company, as such Confidential Information is strictly confidential and shall at all times remain the property of the Company. Upon the termination of Employee's employment for any reason whatsoever, Employee shall promptly turn over to the Company all business correspondence, letters, papers, reports, customer lists, financial statements, credit reports or Confidential Information or other documents or property of the Company in the possession or control of Employee, all of which are and shall continue to be the sole and exclusive property of the Company.

(b) For purposes of this Agreement, the term "Confidential Information" means any trade secret, confidential or proprietary information of the Company all other information and data that is not generally known to the Company's competitors including, without limitation, any confidential studies, data, calculations, software storage media or other compilation of information, patent, patent application, copyright, trademark, trade name, service mark, service name, "know-how," customer or prospect lists, details of client or customer contracts, pricing policies, sales techniques, confidential information relating to suppliers or providers, information relating to the special and particular needs of the Company's customers, operational methods, marketing plans or strategies, products and formulae, product development techniques or plans, business acquisition plans, computer programs (including source of object codes), processes,

procedures, research or technical data, improvements or other proprietary or intellectual property of the Company including, without limitation, all Innovations (as hereinafter defined); whether or not in written or tangible form, and whether or not registered, and including all files, records, manuals, books, catalogues, memoranda, notes, summaries, plans, reports, records, documents and other evidence thereof.

2. Innovations and Inventions.

(a) For purposes of this Agreement, the term "Innovations" means all processes, machines, manufactures, compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), mask works, trademarks, trade names, trade dress, trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and all other subject matter protectable under patent, copyright, moral rights, mask work, trademark, trade secret or other laws, and includes without limitation all new or useful art, combinations, discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software, and designs. "Innovations" includes "Inventions," which is defined to mean any inventions protectable under patent laws. It is also understood that Innovations subject to copyright shall be works made for hire.

(b) Employee represents that Employee has neither conceived, reduced to practice, created, derived, developed nor made any Innovations applicable to the business of the Company or relating in any way to its demonstrably anticipated research and development prior to the date of this Agreement (collectively, the "Prior Innovations") to which Employee has any rights.

(c) In addition, Employee hereby agrees promptly to disclose and describe to the Company, and hereby does and will assign to the Company or the Company's designee, Employee's entire right, title, and interest in and to, each of the Innovations, and any associated intellectual property rights, which Employee may solely or jointly conceive, reduce to practice, create, derive, develop or make during the period of his employment with the Company, which either (i) relate, at the time of conception, reduction to practice, creation, derivation, development, or making of such Innovation, to the Company's business or actual or demonstrably anticipated research or development, or (ii) were developed on any amount of the Company's time or with the use of any of the Company's equipment, supplies, facilities or trade secret information, or (iii) resulted from any work performed by Employee for the Company. Employee will execute such applications, assignments or other documents as may be necessary or convenient to vest in the Company full title to each such Innovation and as may be necessary or convenient to obtain United States and foreign patents, copyrights and trademarks thereon to the extent the Company may so choose.

(d) If and to the extent that the provisions of this Section 2 are ineffective or insufficient to assign and transfer to the Company all right, title and interest in and to any Innovation applicable to the business of the Company (including any Prior Innovation), Employee hereby grants to the Company or its designees an irrevocable, royalty free, worldwide license to practice all applicable patent, copyright, moral right, mask work, trade secret and other intellectual

property rights relating to any such Innovation (including any Prior Innovation). Further, if and to the extent that any of the rights, title and interest in and to any such Innovation (including any Prior Innovation) cannot be licensed by Employee to the Company, Employee hereby irrevocably waives and agrees never to assert such non-licensable rights, title and interest against the Company or any of the Company's successors in interest to such non-licensable rights.

(e) If the Company is unable for any reason to secure Employee's signature to any document required to file, prosecute, register, or memorialize the assignment of any patent, copyright, mask work or other applications or to enforce any patent, copyright, mask work, moral right, trade secret or other proprietary right under any Confidential Information (including improvements thereof) or any Innovations (including derivative works, improvements, renewals, extensions, continuations, divisionals, continuations in part, continuing patent applications, reissues, and reexaminations), Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Employee's agents and attorneys-in-fact to act for and on behalf of Employee, (i) to execute, file, prosecute, register and memorialize the assignment of any such application, (ii) to execute and file any documentation required for such enforcement, and (iii) to do all other lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of patents, copyrights, mask works, moral rights, trade secrets or other rights under any Confidential Information or Innovation, all with the same legal force and effect as if executed by Employee.

3. Remedies.

Employee agrees that money damages would not be a sufficient remedy for any breach or threatened breach of the terms of this Agreement and that, in addition to all other remedies available hereunder or otherwise, the Company shall be entitled to equitable relief, including temporary and permanent injunctive relief (without any requirement to post any bond or other security), in the event of any such breach, and that Employee shall not oppose the granting of such relief. Such relief shall not be exclusive but shall be cumulative and shall be in addition to damages and any other rights or remedies otherwise available to the Company at law or in equity. In addition to all other relief to which they shall be entitled, the Company shall be entitled to recover all litigation costs and reasonable attorneys' fees incurred by it in enforcing any provision of this Agreement.

4. Independent Covenants.

All of the covenants in this Agreement shall be construed as agreements independent of any other provision of this Agreement or any other agreement between the parties hereto, and the existence of any claim or cause of action by any party hereto against any other party or other person, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement of this Agreement, and no material or other breach of any contractual or legal duty by any party shall be held sufficient to excuse or terminate Employee's obligations under this Agreement or to preclude the Company from obtaining injunctive relief as aforesaid.

5. Severability.

The invalidity or unenforceability of any provisions of this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement, which shall remain in full force and effect. Should any clause, portion or provision of this Agreement be unenforceable or invalid for any reason, such unenforceability or invalidity shall not affect the enforceability or validity of the remainder of such provision or of this Agreement. Should any covenant, restriction, provision or clause of this Agreement be held unreasonable or contrary to public policy for any reason the parties agree that such provision shall automatically be deemed modified such that the contested provision will have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so modified to whatever extent would be reasonable and enforceable under applicable law.

6. Amendment; Waiver.

No provision of this Agreement may be waived, amended or otherwise modified unless such waiver, amendment or modification is agreed to in a writing and signed by the parties hereto. No waiver of any breach of any provision of this Agreement shall be deemed a waiver of similar or dissimilar provisions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement.

7. Assignment; Successors.

This Agreement may not be assigned by Employee but shall be binding upon and inure to the benefit of Employee and the Company and its successors and assigns, by operation of law or otherwise (whether by merger, consolidation, sale of all or substantially all of the Company's assets or otherwise). The Company may assign or transfer its rights and obligations under this Agreement without notice or further consent.

8. Survival.

The respective obligations of, and benefits accorded to, the parties as provided in shall survive termination of Employee's employment with the Company.

9. Counterparts.

This Agreement may be executed in the original or by telecopy or electronic transmission of a .pdf file containing an executed signature page, in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

10. Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of the State of Michigan, without regard to the conflicts of laws principles thereof.

11. Arbitration.

The Parties acknowledge and agree that any controversy or claim arising out of Employee's employment with the Company (including, but not limited to, any claim of discrimination, retaliation or harassment; any claim under any state or federal civil rights statute or common law; and any claim for breach of this Agreement) shall be settled solely by arbitration in the County of Kent, State of Michigan, in accordance with the rules of the American Arbitration Association then pertaining. This paragraph, however, does not prevent or prohibit the Company from seeking and obtaining temporary or preliminary injunctive relief from a court of law due to Employee's actual or threatened breach of paragraphs 1 or 2 above. Seeking such equitable relief in a court of law shall not prejudice the Company's right to demand Arbitration under this Paragraph in order to seek equitable or legal relief.

The decision of the Arbitrator shall be final and binding and neither party shall have any right of appeal therefrom. Judgment upon the award rendered by the Arbitrator may be entered in the Circuit Court for the County of Kent.

The demand for arbitration must be submitted, in writing, to Company or to Employee and to the American Arbitration Association at 1101 Laurel Oak Road, Suite 100, Voorhees, NJ 08043. The demand must be received by the American Arbitration Association within one hundred eighty (180) days after the alleged violation, misconduct, breach or incident which gives rise to the request for arbitration. Failure to file the demand with the American Arbitration Association within the said one hundred eighty (180) day time period shall constitute a full and complete waiver of the claim, and a complete waiver of any right to compensation, benefits or damages. If the written demand for arbitration is not filed within the said one hundred eighty (180) day period, it is forever barred. The Parties shall bear their own attorneys fees associated with the arbitration except as otherwise provided by paragraph 3 of this Agreement.

EMPLOYEE UNDERSTANDS THAT THIS AGREEMENT CONSTITUTES A WAIVER OF ANY RIGHT TO ADJUDICATE CLAIMS AGAINST THE COMPANY IN COURT, AND THAT EMPLOYEE IS OPTING INSTEAD TO ARBITRATE ANY SUCH CLAIMS.

12. <u>At-Will Status</u>.

This Agreement in no way affects the Employee's at-will status. The Parties agree that Employee's employment can be terminated with or without cause, and with or without notice, at any time, at the option of either the Company or the Employee.

IN WITNESS WHEREOF, this Confidentiality, Proprietary Rights and Arbitration Agreement has been duly executed and delivered by each of the parties hereto as of the date first written above.

GRAND RIVER ASEPTIC MANUFACTURING, INC.

By _____
Jill Quillen, HR Manager

"EMPLOYEE":

_____

Name Printed: Jerrod Weidenfeller

Date: 2/15/19

Exhibit 4

CONFIDENTIALITY, PROPRIETARY RIGHTS, AND ARBITRATION AGREEMENT

This CONFIDENTIALITY, PROPRIETARY RIGHTS, AND ARBITRATION AGREEMENT (this "Agreement"), dated March 1, 2019, between Grand River Aseptic Manufacturing, Inc., a Delaware corporation (the "Company"), and Sherri Scott (the "Employee").

RECITALS

A. The Company has employed Employee and desires reasonable protection of its confidential information and proprietary rights and innovations which it has developed and will develop at substantial expense.

B. The execution and delivery of this Agreement is a condition to the Company's willingness to employ or continue to Employee, and Employee desires to make his or her agreements set forth herein.

AGREEMENT

NOW, THEREFORE, in consideration of Employee's employment or continued employment with the Company, the parties hereto hereby agree as follows:

1. Confidential Information.

(a) During the term of Employee's employment with the Company, and after the termination of such employment for any reason whatsoever, Employee shall not disclose, divulge or furnish any Confidential Information (as hereinafter defined) to any individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof (a "Person"), other than the Company or upon its written request, or use any Confidential Information directly or indirectly for Employee's own benefit or for the benefit of any other Person other than the Company, as such Confidential Information is strictly confidential and shall at all times remain the property of the Company. Upon the termination of Employee's employment for any reason whatsoever, Employee shall promptly turn over to the Company all business correspondence, letters, papers, reports, customer lists, financial statements, credit reports or Confidential Information or other documents or property of the Company in the possession or control of Employee, all of which are and shall continue to be the sole and exclusive property of the Company.

(b) For purposes of this Agreement, the term "Confidential Information" means any trade secret, confidential or proprietary information of the Company all other information and data that is not generally known to the Company's competitors including, without limitation, any confidential studies, data, calculations, software storage media or other compilation of information, patent, patent application, copyright, trademark, trade name, service mark, service name, "know-how," customer or prospect lists, details of client or customer contracts, pricing policies, sales techniques, confidential information relating to suppliers or providers, information relating to the special and particular needs of the Company's customers, operational methods, marketing plans or strategies, products and formulae, product development techniques or plans, business acquisition plans, computer programs (including source of object codes), processes, procedures, research or technical data, improvements or other proprietary or intellectual property

of the Company including, without limitation, all Innovations (as hereinafter defined); whether or not in written or tangible form, and whether or not registered, and including all files, records, manuals, books, catalogues, memoranda, notes, summaries, plans, reports, records, documents and other evidence thereof.

2. Innovations and Inventions.

(a) For purposes of this Agreement, the term "Innovations" means all processes, machines, manufactures, compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), mask works, trademarks, trade names, trade dress, trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and all other subject matter protectable under patent, copyright, moral rights, mask work, trademark, trade secret or other laws, and includes without limitation all new or useful art, combinations, discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software, and designs. "Innovations" includes "Inventions," which is defined to mean any inventions protectable under patent laws. It is also understood that Innovations subject to copyright shall be works made for hire.

(b) Employee represents that Employee has neither conceived, reduced to practice, created, derived, developed nor made any Innovations applicable to the business of the Company or relating in any way to its demonstrably anticipated research and development prior to the date of this Agreement (collectively, the "Prior Innovations") to which Employee has any rights.

(c) In addition, Employee hereby agrees promptly to disclose and describe to the Company, and hereby does and will assign to the Company or the Company's designee, Employee's entire right, title, and interest in and to, each of the Innovations, and any associated intellectual property rights, which Employee may solely or jointly conceive, reduce to practice, create, derive, develop or make during the period of his employment with the Company, which either (i) relate, at the time of conception, reduction to practice, creation, derivation, development, or making of such Innovation, to the Company's business or actual or demonstrably anticipated research or development, or (ii) were developed on any amount of the Company's time or with the use of any of the Company's equipment, supplies, facilities or trade secret information, or (iii) resulted from any work performed by Employee for the Company. Employee will execute such applications, assignments or other documents as may be necessary or convenient to vest in the Company full title to each such Innovation and as may be necessary or convenient to obtain United States and foreign patents, copyrights and trademarks thereon to the extent the Company may so choose.

(d) If and to the extent that the provisions of this Section 2 are ineffective or insufficient to assign and transfer to the Company all right, title and interest in and to any Innovation applicable to the business of the Company (including any Prior Innovation), Employee hereby grants to the Company or its designees an irrevocable, royalty free, worldwide license to practice all applicable patent, copyright, moral right, mask work, trade secret and other intellectual property rights relating to any such Innovation (including any Prior Innovation). Further, if and to

the extent that any of the rights, title and interest in and to any such Innovation (including any Prior Innovation) cannot be licensed by Employee to the Company, Employee hereby irrevocably waives and agrees never to assert such non-licensable rights, title and interest against the Company or any of the Company's successors in interest to such non-licensable rights.

(e) If the Company is unable for any reason to secure Employee's signature to any document required to file, prosecute, register, or memorialize the assignment of any patent, copyright, mask work or other applications or to enforce any patent, copyright, mask work, moral right, trade secret or other proprietary right under any Confidential Information (including improvements thereof) or any Innovations (including derivative works, improvements, renewals, extensions, continuations, divisionals, continuations in part, continuing patent applications, reissues, and reexaminations), Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Employee's agents and attorneys-in-fact to act for and on behalf of Employee, (i) to execute, file, prosecute, register and memorialize the assignment of any such application, (ii) to execute and file any documentation required for such enforcement, and (iii) to do all other lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of patents, copyrights, mask works, moral rights, trade secrets or other rights under any Confidential Information or Innovation, all with the same legal force and effect as if executed by Employee.

3. Remedies.

Employee agrees that money damages would not be a sufficient remedy for any breach or threatened breach of the terms of this Agreement and that, in addition to all other remedies available hereunder or otherwise, the Company shall be entitled to equitable relief, including temporary and permanent injunctive relief (without any requirement to post any bond or other security), in the event of any such breach, and that Employee shall not oppose the granting of such relief. Such relief shall not be exclusive but shall be cumulative and shall be in addition to damages and any other rights or remedies otherwise available to the Company at law or in equity. In addition to all other relief to which they shall be entitled, the Company shall be entitled to recover all litigation costs and reasonable attorneys' fees incurred by it in enforcing any provision of this Agreement.

4. Independent Covenants.

All of the covenants in this Agreement shall be construed as agreements independent of any other provision of this Agreement or any other agreement between the parties hereto, and the existence of any claim or cause of action by any party hereto against any other party or other person, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement of this Agreement, and no material or other breach of any contractual or legal duty by any party shall be held sufficient to excuse or terminate Employee's obligations under this Agreement or to preclude the Company from obtaining injunctive relief as aforesaid.

5. Severability.

The invalidity or unenforceability of any provisions of this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement, which shall remain in full force and effect. Should any clause, portion or provision of this Agreement be unenforceable or invalid for any reason, such unenforceability or invalidity shall not affect the enforceability or validity of the remainder of such provision or of this Agreement. Should any covenant, restriction, provision or clause of this Agreement be held unreasonable or contrary to public policy for any reason the parties agree that such provision shall automatically be deemed modified such that the contested provision will have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so modified to whatever extent would be reasonable and enforceable under applicable law.

6. Amendment; Waiver.

No provision of this Agreement may be waived, amended or otherwise modified unless such waiver, amendment or modification is agreed to in a writing and signed by the parties hereto. No waiver of any breach of any provision of this Agreement shall be deemed a waiver of similar or dissimilar provisions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement.

7. Assignment; Successors.

This Agreement may not be assigned by Employee but shall be binding upon and inure to the benefit of Employee and the Company and its successors and assigns, by operation of law or otherwise (whether by merger, consolidation, sale of all or substantially all of the Company's assets or otherwise). The Company may assign or transfer its rights and obligations under this Agreement without notice or further consent.

8. Survival.

The respective obligations of, and benefits accorded to, the parties as provided in shall survive termination of Employee's employment with the Company.

9. Counterparts.

This Agreement may be executed in the original or by telecopy or electronic transmission of a .pdf file containing an executed signature page, in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

10. Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of the State of Michigan, without regard to the conflicts of laws principles thereof.

11. Arbitration.

The Parties acknowledge and agree that any controversy or claim arising out of Employee's employment with the Company (including, but not limited to, any claim of discrimination, retaliation or harassment; any claim under any state or federal civil rights statute or common law; and any claim for breach of this Agreement) shall be settled solely by arbitration in the County of Kent, State of Michigan, in accordance with the rules of the American Arbitration Association then pertaining. This paragraph, however, does not prevent or prohibit the Company from seeking and obtaining temporary or preliminary injunctive relief from a court of law due to Employee's actual or threatened breach of paragraphs 1 or 2 above. Seeking such equitable relief in a court of law shall not prejudice the Company's right to demand Arbitration under this Paragraph in order to seek equitable or legal relief.

The decision of the Arbitrator shall be final and binding and neither party shall have any right of appeal therefrom. Judgment upon the award rendered by the Arbitrator may be entered in the Circuit Court for the County of Kent.

The demand for arbitration must be submitted, in writing, to Company or to Employee and to the American Arbitration Association at 1101 Laurel Oak Road, Suite 100, Voorhees, NJ 08043. The demand must be received by the American Arbitration Association within one hundred eighty (180) days after the alleged violation, misconduct, breach or incident which gives rise to the request for arbitration. Failure to file the demand with the American Arbitration Association within the said one hundred eighty (180) day time period shall constitute a full and complete waiver of the claim, and a complete waiver of any right to compensation, benefits or damages. If the written demand for arbitration is not filed within the said one hundred eighty (180) day period, it is forever barred. The Parties shall bear their own attorneys fees associated with the arbitration except as otherwise provided by paragraph 3 of this Agreement.

EMPLOYEE UNDERSTANDS THAT THIS AGREEMENT CONSTITUTES A WAIVER OF ANY RIGHT TO ADJUDICATE CLAIMS AGAINST THE COMPANY IN COURT, AND THAT EMPLOYEE IS OPTING INSTEAD TO ARBITRATE ANY SUCH CLAIMS.

12. <u>At-Will Status</u>.

This Agreement in no way affects the Employee's at-will status. The Parties agree that Employee's employment can be terminated with or without cause, and with or without notice, at any time, at the option of either the Company or the Employee.

IN WITNESS WHEREOF, this Confidentiality, Proprietary Rights and Arbitration Agreement has been duly executed and delivered by each of the parties hereto as of the date first written above.

GRAND RIVER ASEPTIC MANUFACTURING, INC.

By Jill Quillen
Jill Quillen, HR Manager

"EMPLOYEE":

Name Printed: Sherri Scott

Date: 3/4/19

Exhibit 5

NON-COMPETE, NON-SOLICITATION, AND ARBITRATION AGREEMENT

This Non-Compete, Non-Solicitation, and Arbitration Agreement ("Agreement") is entered into and effective as of March 1, 2019, by and between Grand River Aseptic Manufacturing, Inc., a Delaware corporation ("Company"), and Sherri Scott ("Employee").

Recitals

WHEREAS, in the course of Employee's employment with the Company, Employee has had or will have access to information concerning the Company's unique business strategies and processes, specialized procedures, research and development plans and results, operations procedures, designs, financial information, services, pricing, and customers;

WHEREAS, Employee has had or will have direct contact with Company's customers, and likely has been or will be involved in the Company's relationships with its customers;

WHEREAS, Employee has also been provided with information and training concerning the Company's unique processes and techniques, services, practices and customers, which is not generally known in the industry;

WHEREAS, Employee recognizes that the Company has made a substantial investment in training Employee, that the information provided to Employee by the Company is confidential and provides a business advantage to the Company and/or its customers, and that the Company's relationships with its customers are of substantial value to the Company;

WHEREAS, Employee acknowledges that, for the above stated reasons, the restrictions contained in this Agreement are reasonable to protect the Company, its customers, and their respective business interests, business information, and relationships.

Agreement

NOW, THEREFORE, in consideration for the Employee's employment or continued employment with the Company, the parties agree as follows:

1. At-Will Status. This Agreement in no way affects the Employee's at-will status. The Parties agree that Employee's employment can be terminated with or without cause, and with or without notice, at any time, at the option of either the Company or the Employee.

2. Non-Compete. Employee agrees that for a period of twelve (12) months from the date on which Employee's employment with Company ends, regardless of the reason, s/he will not directly or indirectly engage in Competition with Company anywhere in the United States of America ("USA") as Company conducts business throughout the USA. "Competition" means competing with the Company on Employee's own behalf, or having ownership in, operating, managing or working, as an agent, employee, representative or consultant, for a person or entity that produces clinical trial materials for the pharmaceutical industry, including, without limitation, aseptic or lyophilized compounds.

3. Non-Solicitation of Customers. Employee specifically acknowledges that during the term of this Agreement, Employee will obtain and have access to, confidential information pertaining to Company's customers, prospective customers, that such data is a valuable and unique asset of Company's business and that the success or failure of Company's business is dependent to a significant degree upon its ability to establish and maintain close and continuing personal contacts and working relationships with customers and prospective customers and to develop services and proposals that are specifically devised, refined and adjusted to meet, satisfy and coincide with the interests and requirements of customers and prospective customers. Employee agrees that during the course of Employee's employment with the Company and for a period of twelve (12) months following the termination of that employment for any reason, Employee will not directly or indirectly, on Employee's own behalf or on behalf of any other person or entity, solicit, attempt to obtain, divert, take away, do business with any current customer(s) or prospective customer(s) of the Company or interfere in any way with the business relationship between the Company and any of its customers or prospective customers. For purposes of this Agreement, "current customer" shall mean a person or entity that has purchased goods or services from the Company within twenty-four (24) months preceding the date of termination of Employee's employment with the Company and any leads or prospects on which Employee and/or the Company were working or from whom Employee and/or the Company solicited business during the twelve (12) months preceding the date of termination of Employee's employment with the Company.

4. Non-Solicitation of Employees. Employee agrees that for a period of twelve (12) months following the termination of Employee's employment with the Company for any reason, Employee will not directly or indirectly, on Employee's own behalf or on behalf of any other person or entity, solicit, recruit or hire any person who is an employee of Company or who was an employee of Company during the two (2) year period prior to termination of the Employee's employment with the Company, or encourage in any manner any of Company's employees or agents to terminate their employment or agency with Company.

5. Reasonable Restrictions. Employee acknowledges and agrees that the terms of this Agreement are reasonable with respect to their duration, geographical area and scope, and that the restrictions imposed upon Employee under this Agreement are reasonable and necessary for the protection of the Company's Confidential Information, customer and employee relationships and business goodwill. Employee further acknowledges and agrees that the restrictions imposed hereunder will not pose any substantial hardship on Employee and that Employee will reasonably be able to earn a livelihood without violating any provision of this Agreement.

6. Judicial/Arbitral Modification of Agreement. If any provision of this Agreement is found to be invalid or unenforceable, it shall be modified by an arbitrator or court of competent jurisdiction in such a manner as to be valid and fully enforceable to the maximum extent permitted by law.

7. Enforcement. Employee understands and acknowledges that if s/he violates any provision of this Agreement, Company will be entitled to immediate injunctive relief prohibiting Employee from further violating this Agreement, as well as money damages and any other relief available by law. In addition, Employee will pay Company's reasonable attorney's fees and costs

involved in enforcing this Agreement. In the event Employee violates any provision this Agreement in which there is a specific time period during which Employee is prohibited from taking certain actions or from engaging in certain activities, then, in such event, such violation shall toll the running of such time period from the date of such violation until such violation shall cease. Employee acknowledges and agrees that his obligations under this Agreement shall apply regardless of the reason for the termination of his employment with Company and regardless of whether the termination was initiated by Company or Employee.

8. Choice of Law. This Agreement shall be governed by and construed according to the laws of the State of Michigan.

9. Arbitration. The Parties acknowledge and agree that any controversy or claim arising out of Employee's employment with the Company (including, but not limited to, any claim of discrimination, retaliation or harassment; any claim under any state or federal civil rights statute or common law; and any claim for breach of this Agreement) shall be settled solely by arbitration in the County of Kent, State of Michigan, in accordance with the rules of the American Arbitration Association then pertaining. This paragraph, however, does not prevent or prohibit the Company from seeking and obtaining temporary or preliminary injunctive relief from a court of law due to Employee's actual or threatened breach of paragraphs 2 through 4 above. Seeking such equitable relief in a court of law shall not prejudice the Company's right to demand Arbitration under this Paragraph in order to seek equitable or legal relief.

The decision of the Arbitrator shall be final and binding and neither party shall have any right of appeal therefrom. Judgment upon the award rendered by the Arbitrator may be entered in the Circuit Court for the County of Kent.

The demand for arbitration must be submitted, in writing, to Company or to Employee and to the American Arbitration Association at 1101 Laurel Oak Road, Suite 100, Voorhees, NJ 08043. The demand must be received by the American Arbitration Association within one hundred eighty (180) days after the alleged violation, misconduct, breach or incident which gives rise to the request for arbitration. Failure to file the demand with the American Arbitration Association within the said one hundred eighty (180) day time period shall constitute a full and complete waiver of the claim, and a complete waiver of any right to compensation, benefits or damages. If the written demand for arbitration is not filed within the said one hundred eighty (180) day period, it is forever barred. The Parties shall bear their own attorneys fees associated with the arbitration except as otherwise provided by paragraph 7 of this Agreement.

EMPLOYEE UNDERSTANDS THAT THIS AGREEMENT CONSTITUTES A WAIVER OF ANY RIGHT TO ADJUDICATE CLAIMS AGAINST THE COMPANY IN COURT, AND THAT EMPLOYEE IS OPTING INSTEAD TO ARBITRATE ANY SUCH CLAIMS.

10. Survival. The respective obligations of, and benefits accorded to, the parties as provided in shall survive termination of Employee's employment with the Company.

11. Counterparts. This Agreement may be executed in the original or by telecopy or electronic transmission of a .pdf file containing an executed signature page, in any number of

counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, this Non-Compete, Non-Solicitation and Arbitration Agreement has been duly executed and delivered by each of the parties hereto as of the date first written above.

GRAND RIVER ASEPTIC MANUFACTURING, INC.

By Jill Quillen
Jill Quillen, HR Manager

"EMPLOYEE":

Name Printed: Sherri Scott

Date: 3/4/19

Exhibit 6

Founded in 1852
by Sidney Davy Miller

MILLER CANFIELD

MICHIGAN
ILLINOIS
NEW YORK
OHIO
WASHINGTON, D.C.
CANADA
CHINA
MEXICO
POLAND
QATAR

LEIGH M. SCHULTZ
TEL (269) 388-6810
FAX (269) 382-0244
E-MAILschultzl@millercanfield.com

Miller, Canfield, Paddock and Stone, P.L.C.
277 South Rose Street, Suite 5000
Kalamazoo, Michigan 49007
TEL (269) 381-7030
FAX (269) 382-0244
www.millercanfield.com

December 28, 2020

VIA OVERNIGHT MAIL
Sherri Scott
2024 Westfield Drive
Gurnee, IL 60031
missbers@aol.com

Re: Grand River Aseptic Manufacturing Inc. Confidentiality, Proprietary Rights, and Non-Competition Agreement

Dear Ms. Scott,

Please be advised that we represent Grand River Aseptic Manufacturing Inc. ("GRAM" or the "Company"). We understand that you resigned from your employment with GRAM on or about August 12, 2020. We are writing to remind you that, despite your resignation, you have continuing obligations to GRAM under the Non-Compete, Non-Solicitation, and Arbitration Agreement (the "Non-Compete Agreement") that you signed on or about March 4, 2019.

Specifically, you agreed that:

> For a period of twelve (12) months following the termination of [your] employment with the Company for any reason, [you] will not directly or indirectly, on [your] own behalf or on behalf of any other person or entity, solicit, recruit, or hire any person who is an employee of Company or who was an employee of Company during the two (2) year period prior to termination of [your] employment with the Company, or encourage in any manner any of Company's employees or agents to terminate their employment or agency with Company.

You also agreed that you would not ever divulge or furnish any of the Company's Confidential Information to any third-party, and/or use any of the Company's Confidential Information directly or indirectly for your own benefit or for the benefit of any third-party. In addition, you agreed that you would not engage in any competition with the Company or solicit or do business with customers of the Company for a period of 12 months after your employment ended.

You also signed a separate Confidentiality, Proprietary Rights, and Arbitration Agreement that remains in full force and effect. I have enclosed an additional copy of both Agreements for your records.

It has come to GRAM's attention that you may be attempting to solicit GRAM employees in violation of the Non-Compete Agreement. The letter is to remind you of your contractual obligations and to notify you that if you engage in any conduct that violates either Agreement or Michigan law, GRAM will take all necessary steps to enforce the applicable Agreement and will seek payment from your for any costs and attorneys' fees that the Company incurs as a result.

Very truly yours,

MILLER, CANFIELD, PADDOCK AND STONE, P.L.C.

Leigh M. Schultz

LMS/cjs

Enclosures

cc: Grand River Aseptic Manufacturing, Inc.

NON-COMPETE, NON-SOLICITATION, AND ARBITRATION AGREEMENT

This Non-Compete, Non-Solicitation, and Arbitration Agreement ("Agreement") is entered into and effective as of March 1, 2019, by and between Grand River Aseptic Manufacturing, Inc., a Delaware corporation ("Company"), and Sherri Scott ("Employee").

Recitals

WHEREAS, in the course of Employee's employment with the Company, Employee has had or will have access to information concerning the Company's unique business strategies and processes, specialized procedures, research and development plans and results, operations procedures, designs, financial information, services, pricing, and customers;

WHEREAS, Employee has had or will have direct contact with Company's customers, and likely has been or will be involved in the Company's relationships with its customers;

WHEREAS, Employee has also been provided with information and training concerning the Company's unique processes and techniques, services, practices and customers, which is not generally known in the industry;

WHEREAS, Employee recognizes that the Company has made a substantial investment in training Employee, that the information provided to Employee by the Company is confidential and provides a business advantage to the Company and/or its customers, and that the Company's relationships with its customers are of substantial value to the Company;

WHEREAS, Employee acknowledges that, for the above stated reasons, the restrictions contained in this Agreement are reasonable to protect the Company, its customers, and their respective business interests, business information, and relationships.

Agreement

NOW, THEREFORE, in consideration for the Employee's employment or continued employment with the Company, the parties agree as follows:

1. At-Will Status. This Agreement in no way affects the Employee's at-will status. The Parties agree that Employee's employment can be terminated with or without cause, and with or without notice, at any time, at the option of either the Company or the Employee.

2. Non-Compete. Employee agrees that for a period of twelve (12) months from the date on which Employee's employment with Company ends, regardless of the reason, s/he will not directly or indirectly engage in Competition with Company anywhere in the United States of America ("USA") as Company conducts business throughout the USA. "Competition" means competing with the Company on Employee's own behalf, or having ownership in, operating, managing or working, as an agent, employee, representative or consultant, for a person or entity that produces clinical trial materials for the pharmaceutical industry, including, without limitation, aseptic or lyophilized compounds.

3. Non-Solicitation of Customers. Employee specifically acknowledges that during the term of this Agreement, Employee will obtain and have access to, confidential information pertaining to Company's customers, prospective customers, that such data is a valuable and unique asset of Company's business and that the success or failure of Company's business is dependent to a significant degree upon its ability to establish and maintain close and continuing personal contacts and working relationships with customers and prospective customers and to develop services and proposals that are specifically devised, refined and adjusted to meet, satisfy and coincide with the interests and requirements of customers and prospective customers. Employee agrees that during the course of Employee's employment with the Company and for a period of twelve (12) months following the termination of that employment for any reason, Employee will not directly or indirectly, on Employee's own behalf or on behalf of any other person or entity, solicit, attempt to obtain, divert, take away, do business with any current customer(s) or prospective customer(s) of the Company or interfere in any way with the business relationship between the Company and any of its customers or prospective customers. For purposes of this Agreement, "current customer" shall mean a person or entity that has purchased goods or services from the Company within twenty-four (24) months preceding the date of termination of Employee's employment with the Company and any leads or prospects on which Employee and/or the Company were working or from whom Employee and/or the Company solicited business during the twelve (12) months preceding the date of termination of Employee's employment with the Company.

4. Non-Solicitation of Employees. Employee agrees that for a period of twelve (12) months following the termination of Employee's employment with the Company for any reason, Employee will not directly or indirectly, on Employee's own behalf or on behalf of any other person or entity, solicit, recruit or hire any person who is an employee of Company or who was an employee of Company during the two (2) year period prior to termination of the Employee's employment with the Company, or encourage in any manner any of Company's employees or agents to terminate their employment or agency with Company.

5. Reasonable Restrictions. Employee acknowledges and agrees that the terms of this Agreement are reasonable with respect to their duration, geographical area and scope, and that the restrictions imposed upon Employee under this Agreement are reasonable and necessary for the protection of the Company's Confidential Information, customer and employee relationships and business goodwill. Employee further acknowledges and agrees that the restrictions imposed hereunder will not pose any substantial hardship on Employee and that Employee will reasonably be able to earn a livelihood without violating any provision of this Agreement.

6. Judicial/Arbitral Modification of Agreement. If any provision of this Agreement is found to be invalid or unenforceable, it shall be modified by an arbitrator or court of competent jurisdiction in such a manner as to be valid and fully enforceable to the maximum extent permitted by law.

7. Enforcement. Employee understands and acknowledges that if s/he violates any provision of this Agreement, Company will be entitled to immediate injunctive relief prohibiting Employee from further violating this Agreement, as well as money damages and any other relief available by law. In addition, Employee will pay Company's reasonable attorney's fees and costs

involved in enforcing this Agreement. In the event Employee violates any provision this Agreement in which there is a specific time period during which Employee is prohibited from taking certain actions or from engaging in certain activities, then, in such event, such violation shall toll the running of such time period from the date of such violation until such violation shall cease. Employee acknowledges and agrees that his obligations under this Agreement shall apply regardless of the reason for the termination of his employment with Company and regardless of whether the termination was initiated by Company or Employee.

8. Choice of Law. This Agreement shall be governed by and construed according to the laws of the State of Michigan.

9. Arbitration. The Parties acknowledge and agree that any controversy or claim arising out of Employee's employment with the Company (including, but not limited to, any claim of discrimination, retaliation or harassment; any claim under any state or federal civil rights statute or common law; and any claim for breach of this Agreement) shall be settled solely by arbitration in the County of Kent, State of Michigan, in accordance with the rules of the American Arbitration Association then pertaining. This paragraph, however, does not prevent or prohibit the Company from seeking and obtaining temporary or preliminary injunctive relief from a court of law due to Employee's actual or threatened breach of paragraphs 2 through 4 above. Seeking such equitable relief in a court of law shall not prejudice the Company's right to demand Arbitration under this Paragraph in order to seek equitable or legal relief.

The decision of the Arbitrator shall be final and binding and neither party shall have any right of appeal therefrom. Judgment upon the award rendered by the Arbitrator may be entered in the Circuit Court for the County of Kent.

The demand for arbitration must be submitted, in writing, to Company or to Employee and to the American Arbitration Association at 1101 Laurel Oak Road, Suite 100, Voorhees, NJ 08043. The demand must be received by the American Arbitration Association within one hundred eighty (180) days after the alleged violation, misconduct, breach or incident which gives rise to the request for arbitration. Failure to file the demand with the American Arbitration Association within the said one hundred eighty (180) day time period shall constitute a full and complete waiver of the claim, and a complete waiver of any right to compensation, benefits or damages. If the written demand for arbitration is not filed within the said one hundred eighty (180) day period, it is forever barred. The Parties shall bear their own attorneys fees associated with the arbitration except as otherwise provided by paragraph 7 of this Agreement.

EMPLOYEE UNDERSTANDS THAT THIS AGREEMENT CONSTITUTES A WAIVER OF ANY RIGHT TO ADJUDICATE CLAIMS AGAINST THE COMPANY IN COURT, AND THAT EMPLOYEE IS OPTING INSTEAD TO ARBITRATE ANY SUCH CLAIMS.

10. Survival. The respective obligations of, and benefits accorded to, the parties as provided in shall survive termination of Employee's employment with the Company.

11. Counterparts. This Agreement may be executed in the original or by telecopy or electronic transmission of a .pdf file containing an executed signature page, in any number of

counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, this Non-Compete, Non-Solicitation and Arbitration Agreement has been duly executed and delivered by each of the parties hereto as of the date first written above.

GRAND RIVER ASEPTIC MANUFACTURING, INC.

By Jill Quillen
Jill Quillen, HR Manager

"EMPLOYEE":

Name Printed: Sherri Scott

Date: 3/4/19

CONFIDENTIALITY, PROPRIETARY RIGHTS, AND ARBITRATION AGREEMENT

This CONFIDENTIALITY, PROPRIETARY RIGHTS, AND ARBITRATION AGREEMENT (this "Agreement"), dated March 1, 2019, between Grand River Aseptic Manufacturing, Inc., a Delaware corporation (the "Company"), and Sherri Scott (the "Employee").

RECITALS

A. The Company has employed Employee and desires reasonable protection of its confidential information and proprietary rights and innovations which it has developed and will develop at substantial expense.

B. The execution and delivery of this Agreement is a condition to the Company's willingness to employ or continue to Employee, and Employee desires to make his or her agreements set forth herein.

AGREEMENT

NOW, THEREFORE, in consideration of Employee's employment or continued employment with the Company, the parties hereto hereby agree as follows:

1. Confidential Information.

(a) During the term of Employee's employment with the Company, and after the termination of such employment for any reason whatsoever, Employee shall not disclose, divulge or furnish any Confidential Information (as hereinafter defined) to any individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof (a "Person"), other than the Company or upon its written request, or use any Confidential Information directly or indirectly for Employee's own benefit or for the benefit of any other Person other than the Company, as such Confidential Information is strictly confidential and shall at all times remain the property of the Company. Upon the termination of Employee's employment for any reason whatsoever, Employee shall promptly turn over to the Company all business correspondence, letters, papers, reports, customer lists, financial statements, credit reports or Confidential Information or other documents or property of the Company in the possession or control of Employee, all of which are and shall continue to be the sole and exclusive property of the Company.

(b) For purposes of this Agreement, the term "Confidential Information" means any trade secret, confidential or proprietary information of the Company all other information and data that is not generally known to the Company's competitors including, without limitation, any confidential studies, data, calculations, software storage media or other compilation of information, patent, patent application, copyright, trademark, trade name, service mark, service name, "know-how," customer or prospect lists, details of client or customer contracts, pricing policies, sales techniques, confidential information relating to suppliers or providers, information relating to the special and particular needs of the Company's customers, operational methods, marketing plans or strategies, products and formulae, product development techniques or plans, business acquisition plans, computer programs (including source of object codes), processes, procedures, research or technical data, improvements or other proprietary or intellectual property

of the Company including, without limitation, all Innovations (as hereinafter defined); whether or not in written or tangible form, and whether or not registered, and including all files, records, manuals, books, catalogues, memoranda, notes, summaries, plans, reports, records, documents and other evidence thereof.

2. Innovations and Inventions.

(a) For purposes of this Agreement, the term "Innovations" means all processes, machines, manufactures, compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), mask works, trademarks, trade names, trade dress, trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and all other subject matter protectable under patent, copyright, moral rights, mask work, trademark, trade secret or other laws, and includes without limitation all new or useful art, combinations, discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software, and designs. "Innovations" includes "Inventions," which is defined to mean any inventions protectable under patent laws. It is also understood that Innovations subject to copyright shall be works made for hire.

(b) Employee represents that Employee has neither conceived, reduced to practice, created, derived, developed nor made any Innovations applicable to the business of the Company or relating in any way to its demonstrably anticipated research and development prior to the date of this Agreement (collectively, the "Prior Innovations") to which Employee has any rights.

(c) In addition, Employee hereby agrees promptly to disclose and describe to the Company, and hereby does and will assign to the Company or the Company's designee, Employee's entire right, title, and interest in and to, each of the Innovations, and any associated intellectual property rights, which Employee may solely or jointly conceive, reduce to practice, create, derive, develop or make during the period of his employment with the Company, which either (i) relate, at the time of conception, reduction to practice, creation, derivation, development, or making of such Innovation, to the Company's business or actual or demonstrably anticipated research or development, or (ii) were developed on any amount of the Company's time or with the use of any of the Company's equipment, supplies, facilities or trade secret information, or (iii) resulted from any work performed by Employee for the Company. Employee will execute such applications, assignments or other documents as may be necessary or convenient to vest in the Company full title to each such Innovation and as may be necessary or convenient to obtain United States and foreign patents, copyrights and trademarks thereon to the extent the Company may so choose.

(d) If and to the extent that the provisions of this Section 2 are ineffective or insufficient to assign and transfer to the Company all right, title and interest in and to any Innovation applicable to the business of the Company (including any Prior Innovation), Employee hereby grants to the Company or its designees an irrevocable, royalty free, worldwide license to practice all applicable patent, copyright, moral right, mask work, trade secret and other intellectual property rights relating to any such Innovation (including any Prior Innovation). Further, if and to

the extent that any of the rights, title and interest in and to any such Innovation (including any Prior Innovation) cannot be licensed by Employee to the Company, Employee hereby irrevocably waives and agrees never to assert such non-licensable rights, title and interest against the Company or any of the Company's successors in interest to such non-licensable rights.

(e) If the Company is unable for any reason to secure Employee's signature to any document required to file, prosecute, register, or memorialize the assignment of any patent, copyright, mask work or other applications or to enforce any patent, copyright, mask work, moral right, trade secret or other proprietary right under any Confidential Information (including improvements thereof) or any Innovations (including derivative works, improvements, renewals, extensions, continuations, divisionals, continuations in part, continuing patent applications, reissues, and reexaminations), Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Employee's agents and attorneys-in-fact to act for and on behalf of Employee, (i) to execute, file, prosecute, register and memorialize the assignment of any such application, (ii) to execute and file any documentation required for such enforcement, and (iii) to do all other lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of patents, copyrights, mask works, moral rights, trade secrets or other rights under any Confidential Information or Innovation, all with the same legal force and effect as if executed by Employee.

3. Remedies.

Employee agrees that money damages would not be a sufficient remedy for any breach or threatened breach of the terms of this Agreement and that, in addition to all other remedies available hereunder or otherwise, the Company shall be entitled to equitable relief, including temporary and permanent injunctive relief (without any requirement to post any bond or other security), in the event of any such breach, and that Employee shall not oppose the granting of such relief. Such relief shall not be exclusive but shall be cumulative and shall be in addition to damages and any other rights or remedies otherwise available to the Company at law or in equity. In addition to all other relief to which they shall be entitled, the Company shall be entitled to recover all litigation costs and reasonable attorneys' fees incurred by it in enforcing any provision of this Agreement.

4. Independent Covenants.

All of the covenants in this Agreement shall be construed as agreements independent of any other provision of this Agreement or any other agreement between the parties hereto, and the existence of any claim or cause of action by any party hereto against any other party or other person, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement of this Agreement, and no material or other breach of any contractual or legal duty by any party shall be held sufficient to excuse or terminate Employee's obligations under this Agreement or to preclude the Company from obtaining injunctive relief as aforesaid.

5. Severability.

The invalidity or unenforceability of any provisions of this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement, which shall remain in full force and effect. Should any clause, portion or provision of this Agreement be unenforceable or invalid for any reason, such unenforceability or invalidity shall not affect the enforceability or validity of the remainder of such provision or of this Agreement. Should any covenant, restriction, provision or clause of this Agreement be held unreasonable or contrary to public policy for any reason the parties agree that such provision shall automatically be deemed modified such that the contested provision will have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so modified to whatever extent would be reasonable and enforceable under applicable law.

6. Amendment; Waiver.

No provision of this Agreement may be waived, amended or otherwise modified unless such waiver, amendment or modification is agreed to in a writing and signed by the parties hereto. No waiver of any breach of any provision of this Agreement shall be deemed a waiver of similar or dissimilar provisions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement.

7. Assignment; Successors.

This Agreement may not be assigned by Employee but shall be binding upon and inure to the benefit of Employee and the Company and its successors and assigns, by operation of law or otherwise (whether by merger, consolidation, sale of all or substantially all of the Company's assets or otherwise). The Company may assign or transfer its rights and obligations under this Agreement without notice or further consent.

8. Survival.

The respective obligations of, and benefits accorded to, the parties as provided in shall survive termination of Employee's employment with the Company.

9. Counterparts.

This Agreement may be executed in the original or by telecopy or electronic transmission of a .pdf file containing an executed signature page, in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

10. Governing Law.

This Agreement shall be governed by and construed in accordance with the laws of the State of Michigan, without regard to the conflicts of laws principles thereof.

11. Arbitration.

The Parties acknowledge and agree that any controversy or claim arising out of Employee's employment with the Company (including, but not limited to, any claim of discrimination, retaliation or harassment; any claim under any state or federal civil rights statute or common law; and any claim for breach of this Agreement) shall be settled solely by arbitration in the County of Kent, State of Michigan, in accordance with the rules of the American Arbitration Association then pertaining. This paragraph, however, does not prevent or prohibit the Company from seeking and obtaining temporary or preliminary injunctive relief from a court of law due to Employee's actual or threatened breach of paragraphs 1 or 2 above. Seeking such equitable relief in a court of law shall not prejudice the Company's right to demand Arbitration under this Paragraph in order to seek equitable or legal relief.

The decision of the Arbitrator shall be final and binding and neither party shall have any right of appeal therefrom. Judgment upon the award rendered by the Arbitrator may be entered in the Circuit Court for the County of Kent.

The demand for arbitration must be submitted, in writing, to Company or to Employee and to the American Arbitration Association at 1101 Laurel Oak Road, Suite 100, Voorhees, NJ 08043. The demand must be received by the American Arbitration Association within one hundred eighty (180) days after the alleged violation, misconduct, breach or incident which gives rise to the request for arbitration. Failure to file the demand with the American Arbitration Association within the said one hundred eighty (180) day time period shall constitute a full and complete waiver of the claim, and a complete waiver of any right to compensation, benefits or damages. If the written demand for arbitration is not filed within the said one hundred eighty (180) day period, it is forever barred. The Parties shall bear their own attorneys fees associated with the arbitration except as otherwise provided by paragraph 3 of this Agreement.

EMPLOYEE UNDERSTANDS THAT THIS AGREEMENT CONSTITUTES A WAIVER OF ANY RIGHT TO ADJUDICATE CLAIMS AGAINST THE COMPANY IN COURT, AND THAT EMPLOYEE IS OPTING INSTEAD TO ARBITRATE ANY SUCH CLAIMS.

12. <u>At-Will Status</u>.

This Agreement in no way affects the Employee's at-will status. The Parties agree that Employee's employment can be terminated with or without cause, and with or without notice, at any time, at the option of either the Company or the Employee.

IN WITNESS WHEREOF, this Confidentiality, Proprietary Rights and Arbitration Agreement has been duly executed and delivered by each of the parties hereto as of the date first written above.

GRAND RIVER ASEPTIC MANUFACTURING, INC.

By _____
Jill Quillen, HR Manager

"EMPLOYEE":

_____

Name Printed: Sherri Scott

Date: 3/4/19

Exhibit 7

Document #	Doc ID Beg	File Name
1	GRAMNEXUS0000000001	BTR_FIRST_QC_LYT_001_Page_01.png
2	GRAMNEXUS0000000002	BTR_FIRST_QC_LYT_001_Page_02.png
3	GRAMNEXUS0000000003	BTR_FIRST_QC_LYT_001_Page_03.png
4	GRAMNEXUS0000000004	BTR_FIRST_QC_LYT_001_Page_04.png
5	GRAMNEXUS0000000005	BTR_FIRST_QC_LYT_001_Page_05.png
6	GRAMNEXUS0000000006	BTR_FIRST_QC_LYT_001_Page_06.png
7	GRAMNEXUS0000000007	BTR_FIRST_QC_LYT_001_Page_07.png
8	GRAMNEXUS0000000008	BTR_FIRST_QC_LYT_001_Page_08.png
9	GRAMNEXUS0000000009	BTR_FIRST_QC_LYT_001_Page_09.png
10	GRAMNEXUS0000000010	BTR_FIRST_QC_LYT_001_Page_10.png
11	GRAMNEXUS0000000011	BTR_FIRST_QC_LYT_001_Page_11.png
12	GRAMNEXUS0000000012	BTR_FIRST_QC_LYT_001_Page_12.png
13	GRAMNEXUS0000000013	BTR_FIRST_QC_LYT_001_Page_13.png
14	GRAMNEXUS0000000014	BTR_FIRST_QC_LYT_001_Page_14.png
15	GRAMNEXUS0000000015	BTR_FIRST_QC_LYT_001_Page_15.png
16	GRAMNEXUS0000000016	BTR_FIRST_QC_LYT_001_Page_16.png
17	GRAMNEXUS0000000017	BTR_FIRST_QC_LYT_001_Page_17.png
18	GRAMNEXUS0000000018	BTR_FIRST_QC_LYT_001_Page_18.png
19	GRAMNEXUS0000000019	BTR_FIRST_QC_LYT_001_Page_19.png
20	GRAMNEXUS0000000020	BTR_FIRST_QC_LYT_001_Page_20.png
21	GRAMNEXUS0000000021	BTR_FIRST_QC_LYT_001_Page_21.png
22	GRAMNEXUS0000000022	BTR_FIRST_QC_LYT_001_Page_22.png
23	GRAMNEXUS0000000023	BTR_FIRST_QC_LYT_001_Page_23.png
24	GRAMNEXUS0000000024	BTR_FIRST_QC_LYT_001_Page_24.png
25	GRAMNEXUS0000000025	BTR_FIRST_QC_LYT_001_Page_25.png
26	GRAMNEXUS0000000026	Autoclave SOP.docx
27	GRAMNEXUS0000000027	Copy of GRAM Micro Documents to Draft(SAS)(CCH)1.xlsx
28	GRAMNEXUS0000000028	CORP-SOP-0027 revision (SAS).docx
29	GRAMNEXUS0000000029	CORP-SOP-0077 Compressed Gas Sampling.docx
30	GRAMNEXUS0000000030	CORP-SOP-0101 rev 05(SAS)(JLL) (AZ).docx
31	GRAMNEXUS0000000031	LAB-FRM-103A Compressed Gas QC Report.docx
32	GRAMNEXUS0000000032	Template-0001 rev 03.docx
33	GRAMNEXUS0000000033	VITEK 2 Compact (V9) Admin SOP.docx
34	GRAMNEXUS0000000034	VITEK 2 Compact (V9) Operational SOP.docx
35	GRAMNEXUS0000000035	202 CAPA.docx
36	GRAMNEXUS0000000036	Audit Commitment Extension Memo.docx
37	GRAMNEXUS0000000037	CA 170015 extension.docx
38	GRAMNEXUS0000000038	CA-170004 closure.docx
39	GRAMNEXUS0000000039	CA-170004 extension 2.docx
40	GRAMNEXUS0000000040	CA-170004 extension 3.docx
41	GRAMNEXUS0000000041	CA-170004 extension.docx
42	GRAMNEXUS0000000042	CA-170016 completion memo.docx
43	GRAMNEXUS0000000043	CA-170016 extension 2.docx
44	GRAMNEXUS0000000044	CA-170016 extension 3.docx
45	GRAMNEXUS0000000045	CA-170016 extension.docx
46	GRAMNEXUS0000000046	CAPA EM mold.docx
47	GRAMNEXUS0000000047	CAPA Extension Memo Template.docx
48	GRAMNEXUS0000000048	CAPA Form for EIR-180091.docx
49	GRAMNEXUS0000000049	CAPA-160011 eff memo.docx
50	GRAMNEXUS0000000050	CAPA-170027 Extension 2.docx
51	GRAMNEXUS0000000051	CAPA-170027 update for Nexus.docx
52	GRAMNEXUS0000000052	CAPA-180039.docx
53	GRAMNEXUS0000000053	CAPA-180045.docx
54	GRAMNEXUS0000000054	COR-170007.docx
55	GRAMNEXUS0000000055	COR-170008 ext.docx
56	GRAMNEXUS0000000056	COR-170019.docm
57	GRAMNEXUS0000000057	COR-170020.docm
58	GRAMNEXUS0000000058	COR-180021 ext 1.docx
59	GRAMNEXUS0000000059	Corrective Action Due Date Extension Template.docx
60	GRAMNEXUS0000000060	dis eff ext audit - hesperian.docx
61	GRAMNEXUS0000000061	dis eff ext audit.docx
62	GRAMNEXUS0000000062	Diseff ext.docx
63	GRAMNEXUS0000000063	INTCAPA-170013 ext 1.docx

64	GRAMNEXUS0000000064	INTCAPA-170013 ext 2.docx
65	GRAMNEXUS0000000065	INTCAPA-170018.docx
66	GRAMNEXUS0000000066	INTCAPA-180004 ext 1.docx
67	GRAMNEXUS0000000067	INTCAPA-180005 ext 1.docx
68	GRAMNEXUS0000000068	INTCAPA-180016 ext 1.docx
69	GRAMNEXUS0000000069	INTCAPA-180016 ext 2.docx
70	GRAMNEXUS0000000070	INTCAPA-180016 ext 3.docx
71	GRAMNEXUS0000000071	INTCAPA-180020 ext 1.docx
72	GRAMNEXUS0000000072	INTCAPA-180025 ext 1.docx
73	GRAMNEXUS0000000073	INTCAPA-180025 ext 2.docx
74	GRAMNEXUS0000000074	INTCAPA-180028 ext 1.docx
75	GRAMNEXUS0000000075	LAB-TM-127 Conductivity in Bulk Water.docx
76	GRAMNEXUS0000000076	LIR-180015 Corrections.docm
77	GRAMNEXUS0000000077	Memo for CA-160095.docx
78	GRAMNEXUS0000000078	Memo for CA-170015.docx
79	GRAMNEXUS0000000079	Memo for CAPA-170027.pdf
80	GRAMNEXUS0000000080	Memo INTCAPA-170030.docx
81	GRAMNEXUS0000000081	Memo INTCAPA-180017.docx
82	GRAMNEXUS0000000082	Memo INTCAPA-180030.docx
83	GRAMNEXUS0000000083	Nonconformance Correction Form.docm
84	GRAMNEXUS0000000084	PA 150012 extension 2 sas.docx
85	GRAMNEXUS0000000085	PA 150012 extension.docx
86	GRAMNEXUS0000000086	PA-170004 ext1.docx
87	GRAMNEXUS0000000087	PA-170004 task 5.docx
88	GRAMNEXUS0000000088	PA-170004 task 6.docx
89	GRAMNEXUS0000000089	PA170004 Plan.docx
90	GRAMNEXUS0000000090	Q4 2019 Godfrey Water(SAS).docx
91	GRAMNEXUS0000000091	Sherri Scott.docx
92	GRAMNEXUS0000000092	NCR-0418 211 N-2 (SAS).docx
93	GRAMNEXUS0000000093	Scott_Sherri1.doc
94	GRAMNEXUS0000000094	Sr. Validation Engineer Application.docx
95	GRAMNEXUS0000000095	20-025 Sr. Validation Engineer.docx
96	GRAMNEXUS0000000096	026-146B.pdf
97	GRAMNEXUS0000000097	026-146A.pdf
98	GRAMNEXUS0000000098	PQ cal July.docx
99	GRAMNEXUS0000000099	Microworks Sample Sub 5-21-20.doc
100	GRAMNEXUS0000000100	June Cal.docx
101	GRAMNEXUS0000000101	CORP-SOP-0249 Annual Requalification SOP Dynamic (JW) (002)-KNB.docx
102	GRAMNEXUS0000000101.0001	Microsoft_Visio_Drawing14.vsdx
103	GRAMNEXUS0000000101.0002	Microsoft_Visio_Drawing16.vsdx
104	GRAMNEXUS0000000101.0003	Microsoft_Visio_Drawing15.vsdx
105	GRAMNEXUS0000000101.0004	Microsoft_Visio_Drawing.vsdx
106	GRAMNEXUS0000000101.0005	Microsoft_Visio_Drawing1.vsdx
107	GRAMNEXUS0000000101.0006	Microsoft_Visio_Drawing2.vsdx
108	GRAMNEXUS0000000101.0007	Microsoft_Visio_Drawing3.vsdx
109	GRAMNEXUS0000000101.0008	Microsoft_Visio_Drawing4.vsdx
110	GRAMNEXUS0000000101.0009	Microsoft_Visio_Drawing5.vsdx
111	GRAMNEXUS0000000101.0010	Microsoft_Visio_Drawing6.vsdx
112	GRAMNEXUS0000000101.0011	Microsoft_Visio_Drawing7.vsdx
113	GRAMNEXUS0000000101.0012	Microsoft_Visio_Drawing8.vsdx
114	GRAMNEXUS0000000101.0013	Microsoft_Visio_Drawing9.vsdx
115	GRAMNEXUS0000000101.0014	Microsoft_Visio_Drawing10.vsdx
116	GRAMNEXUS0000000101.0015	Microsoft_Visio_Drawing11.vsdx
117	GRAMNEXUS0000000101.0016	Microsoft_Visio_Drawing12.vsdx
118	GRAMNEXUS0000000101.0017	Microsoft_Visio_Drawing13.vsdx
119	GRAMNEXUS0000000102	GRAM Capabilities - Quality Control.pptx
120	GRAMNEXUS0000000103	Today's things.docx
121	GRAMNEXUS0000000104	PO spore susp.xlsx
122	GRAMNEXUS0000000105	020-148 Endo Test Dilution.pdf
123	GRAMNEXUS0000000106	PQ Protocol - Vial Washer 20_03-31(SAS).docx
124	GRAMNEXUS0000000107	lexus 2020.pdf
125	GRAMNEXUS0000000108	subaru 2020.pdf
126	GRAMNEXUS0000000109	Mold Memo.doc
127	GRAMNEXUS0000000110	Q4 2019 Front Water(SAS).docx

128	GRAMNEXUS0000000111	GRAM Change of Status.docx
129	GRAMNEXUS0000000112	Micro Fluff.docx
130	GRAMNEXUS0000000113	Argos Box Mold.pdf
131	GRAMNEXUS0000000114	Micro ID Process Training.pptx
132	GRAMNEXUS0000000115	bugs.docx
133	GRAMNEXUS0000000116	colony morphology.docx
134	GRAMNEXUS0000000117	WD NVP Data.docx
135	GRAMNEXUS0000000118	VAL-1617-SUM (Weigh and Dispense Booth EMPQ)(SAS)(JW) .docx
136	GRAMNEXUS0000000119	Copy of VAL-1617 Trending(sas).xlsx
137	GRAMNEXUS0000000120	Q3 2019 EM (SAS).docx
138	GRAMNEXUS0000000121	Q3 2019 Godfrey Water.docx
139	GRAMNEXUS0000000122	Q3 2019 Godfrey Water (SAS).docx
140	GRAMNEXUS0000000123	Q3 2019 Front Water (SAS).docx
141	GRAMNEXUS0000000124	Q3 2019 Compressed Gas (SAS).docx
142	GRAMNEXUS0000000125	TOC Training Capex.docx
143	GRAMNEXUS0000000126	Sample Plan Table_2 (SAS).docx
144	GRAMNEXUS0000000127	List for James.docx
145	GRAMNEXUS0000000128	CAPEX Form Template.docx
146	GRAMNEXUS0000000129	WD EM Scchedule.docx
147	GRAMNEXUS0000000130	NCR-0218(SAS).docx
148	GRAMNEXUS0000000130.0001	Microsoft_Visio_Drawing.vsdx
149	GRAMNEXUS0000000131	CORP-SOP-0556(SAS).docx
150	GRAMNEXUS0000000132	Test Cyp Endotoxin.xlsx
151	GRAMNEXUS0000000133	CHM-0050(SAS).docx
152	GRAMNEXUS0000000134	PO MW Benz.xlsx
153	GRAMNEXUS0000000135	Copy of 2020 Headcount Planning - Colleen (2019.09.03)SAS.xlsx
154	GRAMNEXUS0000000136	MicroWorks Sample Submission Form Benz.doc
155	GRAMNEXUS0000000137	Purchase Order Template.xlsx
156	GRAMNEXUS0000000138	GRAM Disciplinary Form VJ(SAS).docx
157	GRAMNEXUS0000000139	GRAM Disciplinary Form VJ (SAS).docx
158	GRAMNEXUS0000000140	Baseline Static SAS.vsdx
159	GRAMNEXUS0000000141	Butterworth Incubator Refrigerator Freezers(SAS).docx
160	GRAMNEXUS0000000142	Weigh Dispense EMPQ (CCH).docx
161	GRAMNEXUS0000000143	Q2 2019 Water Final.docx
162	GRAMNEXUS0000000144	Q2 2019 EM.docx
163	GRAMNEXUS0000000145	weigh dispense matrix.docx
164	GRAMNEXUS0000000146	Q2 2019 Water (SAS).docx
165	GRAMNEXUS0000000147	CORP-SOP-0088 rev 12(sas).docx
166	GRAMNEXUS0000000147.0001	Microsoft_Visio_Drawing.vsdx
167	GRAMNEXUS0000000148	Contamination Control Policy SAS.docx
168	GRAMNEXUS0000000148.0001	Microsoft_Visio_Drawing.vsdx
169	GRAMNEXUS0000000148.0002	Microsoft_Visio_Drawing1.vsdx
170	GRAMNEXUS0000000149	Sr QA CC interview questions.docx
171	GRAMNEXUS0000000150	Quality Control - Capex Assessment Form-Weigh-Dispense.docx
172	GRAMNEXUS0000000151	Quality Control - Capex Assessment Form-Rev1.docx
173	GRAMNEXUS0000000152	STA-0005 T0 Data.pdf
174	GRAMNEXUS0000000153	Contam Control.vsdx
175	GRAMNEXUS0000000154	michbio stuff.docx
176	GRAMNEXUS0000000155	MichBio- Lab Slides(SAS).pptx
177	GRAMNEXUS0000000156	Contam Control.pdf
178	GRAMNEXUS0000000157	Contamination Control Policy 5-21-19.docx
179	GRAMNEXUS0000000157.0001	Microsoft_Visio_Drawing.vsdx
180	GRAMNEXUS0000000158	Copy of Current Clients and Associated Drug Products 5.13.19.xlsx
181	GRAMNEXUS0000000159	Copy of GRAM Lab Equipment List - CRB(SAS).xls
182	GRAMNEXUS0000000160	NCR Extension request template (CCH).docx
183	GRAMNEXUS0000000161	Tech Transfer Plan 018-154A(SAS).docx
184	GRAMNEXUS0000000161.0001	Microsoft_Visio_Drawing.vsdx
185	GRAMNEXUS0000000162	LIR Media Fill VAL-1485 190015 (SAS).docx
186	GRAMNEXUS0000000163	interview questions - girard.docx
187	GRAMNEXUS0000000164	Attachment 1 to LIR-190014(SAS).docx
188	GRAMNEXUS0000000164.0001	Microsoft_Visio_Drawing.vsdx
189	GRAMNEXUS0000000165	Purchase Order Dis Eff new floor.xlsx
190	GRAMNEXUS0000000166	EI-2_SCORES_SHERRI_SCOTT.pdf
191	GRAMNEXUS0000000167	Micro responses FDA (DMF).docx

192	GRAMNEXUS0000000168	FDA deficiency 3 (a) (b) Review(SAS).docx
193	GRAMNEXUS0000000169	Attachment #1 to NCR-0059 - Report.docx
194	GRAMNEXUS0000000169.0001	Microsoft_Visio_Drawing.vsdx
195	GRAMNEXUS0000000169.0002	Microsoft_Visio_Drawing1.vsdx
196	GRAMNEXUS0000000170	NCR-0064 (Deviation)(SAS).docx
197	GRAMNEXUS0000000171	2018 Summary EM Report(SAS).docx
198	GRAMNEXUS0000000172	CORP-FRM-0464 Annual Requalifcation Grey side(SAS).docx
199	GRAMNEXUS0000000173	CORP-SOP-0249_Annual Room Requal(SAS).docx
200	GRAMNEXUS0000000173.0001	Microsoft_Visio_Drawing1.vsdx
201	GRAMNEXUS0000000173.0002	Microsoft_Visio_Drawing.vsdx
202	GRAMNEXUS0000000173.0003	Microsoft_Visio_Drawing4.vsdx
203	GRAMNEXUS0000000173.0004	Microsoft_Visio_Drawing3.vsdx
204	GRAMNEXUS0000000173.0005	Microsoft_Visio_Drawing2.vsdx
205	GRAMNEXUS0000000174	2018 Q4 EM Report (SAS).docx
206	GRAMNEXUS0000000175	USP EM.PNG
207	GRAMNEXUS0000000176	DCR for STA-0005.docx
208	GRAMNEXUS0000000177	STA-0005 In-Use Micro final.docx
209	GRAMNEXUS0000000178	C albicans 10K.pdf
210	GRAMNEXUS0000000179	P aeruginosa 10K.pdf
211	GRAMNEXUS0000000180	S aureus 10K.pdf
212	GRAMNEXUS0000000181	E coli 10K.pdf
213	GRAMNEXUS0000000182	Position Request and Approval Form Supervisor.docx
214	GRAMNEXUS0000000183	org chart.vsdx
215	GRAMNEXUS0000000184	Position Request and Approval Form.docx
216	GRAMNEXUS0000000185	STA-0005 In-Use Micro final(SAS).docx
217	GRAMNEXUS0000000186	Template-0102_Vendor Chg. Notification - stoppers.docm
218	GRAMNEXUS0000000187	2018 Q4 EM Report(SAS).docx
219	GRAMNEXUS0000000188	Micro SOP TM Forms.xls
220	GRAMNEXUS0000000189	020 stability data sheet.docx
221	GRAMNEXUS0000000190	EndotoxinSampleTestingForm 015 API.pdf
222	GRAMNEXUS0000000191	DCR for MD13022.docx
223	GRAMNEXUS0000000192	Facility Readiness 02.docx
224	GRAMNEXUS0000000193	006 Endotoxin.docx
225	GRAMNEXUS0000000194	015 stability failure chart.docx
226	GRAMNEXUS0000000195	2018 Q4 QMR Water(JW).docx
227	GRAMNEXUS0000000196	2018 Q4 QMR Water (SAS).docx
228	GRAMNEXUS0000000197	STA-0005 In-Use Micro.docx
229	GRAMNEXUS0000000198	List of Micro Equipment.xlsx
230	GRAMNEXUS0000000199	[redacted] list.docx
231	GRAMNEXUS0000000200	Copy of Master Calibration List.xlsx
232	GRAMNEXUS0000000201	CHM-0038_rev 01(IDV)SAS.docx
233	GRAMNEXUS0000000202	BSC EM.pdf
234	GRAMNEXUS0000000203	Copy of GRAM Lab Equipment List - CRB final.xls
235	GRAMNEXUS0000000204	API-0011(TMH)_ARR(comments)SAS.docx
236	GRAMNEXUS0000000205	2019 Goals QC Micro.xlsx
237	GRAMNEXUS0000000206	2019 Goal SAS.docx
238	GRAMNEXUS0000000207	Levo micro in-use protocol-GRAM(SAS).docx
239	GRAMNEXUS0000000208	QA-160 cal report.pdf
240	GRAMNEXUS0000000209	020 In Use Protocol.docx
241	GRAMNEXUS0000000210	Levo micro in-use protocol-GRAM.docx
242	GRAMNEXUS0000000211	[redacted] Injection Comp.docx
243	GRAMNEXUS0000000212	Micro January Weekend Schedule.docx
244	GRAMNEXUS0000000213	CORP-SOP-0477 CCIT Template-0001 rev 03x(SAS).docx
245	GRAMNEXUS0000000214	2018 Q3 EM Report(SAS).docx
246	GRAMNEXUS0000000215	2018 Q3 QMR Water(SAS).docx
247	GRAMNEXUS0000000216	rabs.docx
248	GRAMNEXUS0000000217	EIR-180077 rev.docx
249	GRAMNEXUS0000000217.0001	Microsoft_Visio_Drawing1.vsdx
250	GRAMNEXUS0000000217.0002	Microsoft_Visio_Drawing.vsdx
251	GRAMNEXUS0000000218	EM Changes SAS.docx
252	GRAMNEXUS0000000219	NVP.pdf
253	GRAMNEXUS0000000220	CORP-SOP-0074 Rev. 21(SAS)(CCH)(JLLv2).docx
254	GRAMNEXUS0000000220.0001	Microsoft_Visio_Drawing10.vsdx
255	GRAMNEXUS0000000220.0002	Microsoft_Visio_Drawing11.vsdx

256	GRAMNEXUS0000000220.0003	Microsoft_Visio_Drawing9.vsdx
257	GRAMNEXUS0000000220.0004	Microsoft_Visio_Drawing8.vsdx
258	GRAMNEXUS0000000220.0005	Microsoft_Visio_Drawing1.vsdx
259	GRAMNEXUS0000000220.0006	Microsoft_Visio_Drawing.vsdx
260	GRAMNEXUS0000000220.0007	Microsoft_Visio_Drawing2.vsdx
261	GRAMNEXUS0000000220.0008	Microsoft_Visio_Drawing7.vsdx
262	GRAMNEXUS0000000220.0009	Microsoft_Visio_Drawing3.vsdx
263	GRAMNEXUS0000000220.0010	Microsoft_Visio_Drawing6.vsdx
264	GRAMNEXUS0000000220.0011	Microsoft_Visio_Drawing5.vsdx
265	GRAMNEXUS0000000220.0012	Microsoft_Visio_Drawing4.vsdx
266	GRAMNEXUS0000000221	November Stability Schedule.docx
267	GRAMNEXUS0000000222	CORP-FRM-0413 rev 05 (JW)(SAS)(JLL) reformat.docx
268	GRAMNEXUS0000000223	Cont NVP chart.docx
269	GRAMNEXUS0000000224	024-142A-FOR_v02a(SAS).docx
270	GRAMNEXUS0000000225	VAL-1389_Protocol_Client 024-142A(SAS).docx
271	GRAMNEXUS0000000226	CC-0055 Memo.docx
272	GRAMNEXUS0000000227	API-0029 C of A with sample prep.docx
273	GRAMNEXUS0000000228	Benefits login.docx
274	GRAMNEXUS0000000229	CORP-FRM-0416 rev 02.docx
275	GRAMNEXUS0000000230	CORP-FRM-0247 rev 03.docx
276	GRAMNEXUS0000000231	Copy of API spreadsheet(SAS).xlsx
277	GRAMNEXUS0000000232	Bacillus timeline post fixed.docx
278	GRAMNEXUS0000000232.0001	Microsoft_Visio_Drawing.vsdx
279	GRAMNEXUS0000000233	Aseptic Qual memo for Deseree.docx
280	GRAMNEXUS0000000234	VAL-1229-SUM 9-20-18 (JLL comments)SAS.docm
281	GRAMNEXUS0000000235	EndotoxinSampleTestingForm 015 FP.pdf
282	GRAMNEXUS0000000236	EndotoxinSampleTestingForm 015 stability.pdf
283	GRAMNEXUS0000000237	2018-118 - QC lab layout and UPS system - Signed.pdf
284	GRAMNEXUS0000000238	EP Viable Limits.docx
285	GRAMNEXUS0000000239	LIR-180030 SAS.docx
286	GRAMNEXUS0000000240	2018 Q2 EM Report.docx
287	GRAMNEXUS0000000241	32p35 (SAS).doc
288	GRAMNEXUS0000000242	010 hydroxy.doc
289	GRAMNEXUS0000000243	[redacted] Injection Work Order - v1(SAS).docx
290	GRAMNEXUS0000000244	Facility Changes for [redacted]docx
291	GRAMNEXUS0000000245	[redacted] Injection Work Order 006-02-0000 v1(SAS).docx
292	GRAMNEXUS0000000246	INTCAPA-180009 Memo (002)SAS.docx
293	GRAMNEXUS0000000247	CR Memo for 015.docx
294	GRAMNEXUS0000000248	EndotoxinSampleTestingForm.pdf
295	GRAMNEXUS0000000249	Copy of Copy of GRAM Lab Equipment List - CRB(SAS) - JW Updates - 08.01.18 - SAS updates 8-3-18.xls
296	GRAMNEXUS0000000250	June-July EM numbers.xlsx
297	GRAMNEXUS0000000251	SGS letter.docx
298	GRAMNEXUS0000000252	Expense report Jolly Pumpkin.xlsx
299	GRAMNEXUS0000000253	organism calendar.xlsx
300	GRAMNEXUS0000000254	CORP-FRM-0005 5-22(SAS).docx
301	GRAMNEXUS0000000255	Sample Submission Form SGS.pdf
302	GRAMNEXUS0000000256	2018 Q1 EM Report (SAS).docx
303	GRAMNEXUS0000000257	2018 Q1 Water Report.pdf
304	GRAMNEXUS0000000258	2018 Q1 EM Report.pdf
305	GRAMNEXUS0000000259	2018 Q1 QMR WaterSAS.docx
306	GRAMNEXUS0000000260	EIR's FDA.xlsx
307	GRAMNEXUS0000000261	Media fill GP results.xlsx
308	GRAMNEXUS0000000262	NV EIR Data thru Q1 2018.xlsx
309	GRAMNEXUS0000000263	Copy of NV EIR Data.xlsx
310	GRAMNEXUS0000000264	bioballs 10K.PNG
311	GRAMNEXUS0000000265	Copy of Q1 2018 Recovery Rates.xlsx
312	GRAMNEXUS0000000266	Investigation questions for SGS.docx
313	GRAMNEXUS0000000267	APR NV Trend.docx
314	GRAMNEXUS0000000268	Steritest brochure.pdf
315	GRAMNEXUS0000000269	NCR Log_2018 SAS working.xlsx
316	GRAMNEXUS0000000270	Cleaning Solution LpH.docx
317	GRAMNEXUS0000000271	Data Integrity PA.xlsx
318	GRAMNEXUS0000000272	Copy of Lab Equipment and Personnel for Expansion (SAS).xlsx
319	GRAMNEXUS0000000273	Syringe Fill Forms.docx

320	GRAMNEXUS0000000274	2017 Q4 EM Report.docx
321	GRAMNEXUS0000000275	micro 1 micro tech.docx
322	GRAMNEXUS0000000276	SCOTT Certification of Health Care Provider.pdf
323	GRAMNEXUS0000000277	Copy of Q3-Q4 white side NV for EIR.xlsx
324	GRAMNEXUS0000000278	EL calculation for 015.docx
325	GRAMNEXUS0000000279	QC MIcro TM's.docx
326	GRAMNEXUS0000000280	Scott - 2017 Performance Assessment (DRAFT)(SAS).docx
327	GRAMNEXUS0000000281	Lab Equipment.xlsx
328	GRAMNEXUS0000000282	FPRS-0049 018-139A(RB)_Formatted(DWF)(SAS)(RB)SAS.docx
329	GRAMNEXUS0000000283	PA170003 Data Integrity Micro.xlsx
330	GRAMNEXUS0000000284	2016 compressed gas.docx
331	GRAMNEXUS0000000285	Disinfectant efficacy protocol.pdf
332	GRAMNEXUS0000000286	Disinfectant Efficacy Final Report.pdf
333	GRAMNEXUS0000000287	020-132A_Submission Sample Plan (RB)(SAS).docx
334	GRAMNEXUS0000000288	VAL-1118 Thermal Cycling Stability Study (020)(IDV).docx
335	GRAMNEXUS0000000289	PA-170004 (CCH)(SAS).docx
336	GRAMNEXUS0000000290	Aseptic Qual memo for Cody.docx
337	GRAMNEXUS0000000291	AutoIDCards.docx
338	GRAMNEXUS0000000292	AutoIDCards.pdf
339	GRAMNEXUS0000000293	lab plan.pdf
340	GRAMNEXUS0000000294	bioburden refs.PNG
341	GRAMNEXUS0000000295	outstanding cofa's.xlsx
342	GRAMNEXUS0000000296	Batch Release Schedule - 2017.04.14 SAS updates.xlsx
343	GRAMNEXUS0000000297	Copy of 2017 Job Code Review(SAS).xlsx
344	GRAMNEXUS0000000298	Copy of Site Goals - QA Support (SAS).xlsx
345	GRAMNEXUS0000000299	Doug stuff 2.docx
346	GRAMNEXUS0000000300	Doug stuff.docx
347	GRAMNEXUS0000000301	Bioburden Notification.docx
348	GRAMNEXUS0000000302	BI Memo.docx
349	GRAMNEXUS0000000303	Nexus CMC ANDA Info (DMF)SAS comments.docx
350	GRAMNEXUS0000000304	Audit Commitment Extension Memo.docx
351	GRAMNEXUS0000000305	Client 009 Notification(SAS).docx
352	GRAMNEXUS0000000306	ISO 6 and 7 trend limits.xlsx
353	GRAMNEXUS0000000307	Custopharm Proposal - Calcitonin - JW v1 (SAS).docx
354	GRAMNEXUS0000000308	DRAFT - Technical Microbiology Specialist Job Description.docx
355	GRAMNEXUS0000000309	Memo Template.docx
356	GRAMNEXUS0000000310	Q4 slides.pptx
357	GRAMNEXUS0000000310.0001	oleObject3
358	GRAMNEXUS0000000310.0002	oleObject2
359	GRAMNEXUS0000000310.0003	oleObject1
360	GRAMNEXUS0000000310.0004	Microsoft_Excel_Worksheet1.xlsx
361	GRAMNEXUS0000000310.0005	Microsoft_Excel_Worksheet2.xlsx
362	GRAMNEXUS0000000310.0006	Microsoft_Excel_Worksheet4.xlsx
363	GRAMNEXUS0000000310.0007	Microsoft_Excel_Worksheet3.xlsx
364	GRAMNEXUS0000000310.0008	Microsoft_Excel_Worksheet5.xlsx
365	GRAMNEXUS0000000310.0009	Microsoft_Excel_Worksheet8.xlsx
366	GRAMNEXUS0000000310.0010	Microsoft_Excel_Worksheet6.xlsx
367	GRAMNEXUS0000000310.0011	Microsoft_Excel_Worksheet7.xlsx
368	GRAMNEXUS0000000311	Copy of Purchase Order Template.xlsx
369	GRAMNEXUS0000000312	management review.PNG
370	GRAMNEXUS0000000313	Perrigo batches.docx
371	GRAMNEXUS0000000314	December 6th GRAM Management Meeting Minutes.docx
372	GRAMNEXUS0000000315	Fill EM for MFG Training Outline - comment.docx
373	GRAMNEXUS0000000316	2016-1020_New Work First Floor - v4.docx
374	GRAMNEXUS0000000317	Notes.docx
375	GRAMNEXUS0000000318	EI-2_SCORES_SHERRI_SCOTT.pdf
376	GRAMNEXUS0000000319	~$R-180034.docx
377	GRAMNEXUS0000000320	Copy of Copy of GRAM Lab Equipment List - CRB(SAS) - JW Updates - 08.01.18 - SAS updates 8-3-18.xls
378	GRAMNEXUS0000000321	Copy of GRAM Lab Equipment List - CRB final.xls
379	GRAMNEXUS0000000322	Copy of GRAM Lab Equipment List - CRB(SAS).xls
380	GRAMNEXUS0000000323	deviation blanket.vsdx
381	GRAMNEXUS0000000324	Welcome Packet.pdf
382	GRAMNEXUS0000000325	Membership Agreement & Disclosures.pdf
383	GRAMNEXUS0000000326	Micro SOP TM Forms.xls

384	GRAMNEXUS0000000327	~$ch Transfer Plan 018-154A(SAS).docx
385	GRAMNEXUS0000000328	~$I Memo.docx
386	GRAMNEXUS0000000329	~$mo Template.docx
387	GRAMNEXUS0000000330	~$ott_Sherri1.doc
388	GRAMNEXUS0000000331	~WRL0001.tmp
389	GRAMNEXUS0000000332	~WRL0002.tmp
390	GRAMNEXUS0000000333	~WRL0003.tmp
391	GRAMNEXUS0000000334	~WRL0004.tmp
392	GRAMNEXUS0000000335	~WRL0005.tmp
393	GRAMNEXUS0000000336	~WRL0605.tmp
394	GRAMNEXUS0000000337	~WRL2047.tmp
395	GRAMNEXUS0000000338	Colleen report 01-07-19.docx
396	GRAMNEXUS0000000339	Colleen report 01-14-19.docx
397	GRAMNEXUS0000000340	Colleen report 01-21-19.docx
398	GRAMNEXUS0000000341	Colleen report 01-28-19.docx
399	GRAMNEXUS0000000342	Colleen report 02-11-19.docx
400	GRAMNEXUS0000000343	Colleen report 02-18-19.docx
401	GRAMNEXUS0000000344	Colleen report 03-04-19.docx
402	GRAMNEXUS0000000345	Colleen report 03-11-19.docx
403	GRAMNEXUS0000000346	Colleen report 03-19-19.docx
404	GRAMNEXUS0000000347	Colleen report 03-25-19.docx
405	GRAMNEXUS0000000348	Colleen report 04-01-19.docx
406	GRAMNEXUS0000000349	Colleen report 04-08-19.docx
407	GRAMNEXUS0000000350	Colleen report 04-15-19.docx
408	GRAMNEXUS0000000351	Colleen report 04-22-19.docx
409	GRAMNEXUS0000000352	Colleen report 04-29-19.docx
410	GRAMNEXUS0000000353	Colleen report 05-06-19.docx
411	GRAMNEXUS0000000354	Colleen report 05-13-19.docx
412	GRAMNEXUS0000000355	Colleen report 05-20-19.docx
413	GRAMNEXUS0000000356	Colleen report 05-28-19.docx
414	GRAMNEXUS0000000357	Colleen report 06-10-19.docx
415	GRAMNEXUS0000000358	Colleen report 08-12-19.docx
416	GRAMNEXUS0000000359	Colleen report 08-19-19.docx
417	GRAMNEXUS0000000360	Colleen report 09-03-19.docx
418	GRAMNEXUS0000000361	Colleen report 09-09-19.docx
419	GRAMNEXUS0000000362	Colleen report 09-16-19.docx
420	GRAMNEXUS0000000363	Colleen report 09-23-19.docx
421	GRAMNEXUS0000000364	Colleen report 09-30-19.docx
422	GRAMNEXUS0000000365	Colleen report 10-07-19.docx
423	GRAMNEXUS0000000366	Colleen report 10-1-18.docx
424	GRAMNEXUS0000000367	Colleen report 10-15-18.docx
425	GRAMNEXUS0000000368	Colleen report 10-22-18.docx
426	GRAMNEXUS0000000369	Colleen report 10-22-19.docx
427	GRAMNEXUS0000000370	Colleen report 10-28-19.docx
428	GRAMNEXUS0000000371	Colleen report 10-29-18.docx
429	GRAMNEXUS0000000372	Colleen report 10-8-18.docx
430	GRAMNEXUS0000000373	Colleen report 11-04-19.docx
431	GRAMNEXUS0000000374	Colleen report 11-05-18.docx
432	GRAMNEXUS0000000375	Colleen report 11-12-18.docx
433	GRAMNEXUS0000000376	Colleen report 11-18-19.docx
434	GRAMNEXUS0000000377	Colleen report 11-26-18.docx
435	GRAMNEXUS0000000378	Colleen report 12-03-18.docx
436	GRAMNEXUS0000000379	Colleen report 12-10-18.docx
437	GRAMNEXUS0000000380	Colleen report 7-16-18.docx
438	GRAMNEXUS0000000381	Colleen report 7-2-18.docx
439	GRAMNEXUS0000000382	Colleen report 7-23-18.docx
440	GRAMNEXUS0000000383	Colleen report 7-30-18.docx
441	GRAMNEXUS0000000384	Colleen report 7-9-18.docx
442	GRAMNEXUS0000000385	Colleen report 8-20-18.docx
443	GRAMNEXUS0000000386	Colleen report 8-27-18.docx
444	GRAMNEXUS0000000387	Colleen report 8-6-18.docx
445	GRAMNEXUS0000000388	Colleen report 9-10-18.docx
446	GRAMNEXUS0000000389	Colleen report 9-17-18.docx
447	GRAMNEXUS0000000390	Colleen report 9-24-18.docx

448	GRAMNEXUS0000000391	Colleen report 9-4-18.docx
449	GRAMNEXUS0000000392	Colleen weekly document 5-21-18.docx
450	GRAMNEXUS0000000393	Colleen weekly document 5-29-18.docx
451	GRAMNEXUS0000000394	Colleen weekly document 6-25-18.docx
452	GRAMNEXUS0000000395	Colleen weekly document 6-5-18.docx
453	GRAMNEXUS0000000396	Copy of GRAM Micro Documents to Draft(SAS).xlsx
454	GRAMNEXUS0000000397	TOC Training Capex(SAS).docx
455	GRAMNEXUS0000000398	~$lleen report 06-10-19.docx
456	GRAMNEXUS0000000399	Custopharm-Calcitonin Injection - Meeting Agenda - 2017 07 31.pdf
457	GRAMNEXUS0000000400	146F92DC.tmp
458	GRAMNEXUS0000000400.0001	Microsoft_Excel_Worksheet2.xlsx
459	GRAMNEXUS0000000400.0002	Microsoft_Excel_Worksheet1.xlsx
460	GRAMNEXUS0000000401	170059 Att 1.docx
461	GRAMNEXUS0000000402	29678004.tmp
462	GRAMNEXUS0000000402.0001	Microsoft_Excel_Worksheet2.xlsx
463	GRAMNEXUS0000000402.0002	Microsoft_Excel_Worksheet3.xlsx
464	GRAMNEXUS0000000402.0003	Microsoft_Excel_Worksheet1.xlsx
465	GRAMNEXUS0000000402.0004	Microsoft_Excel_Worksheet4.xlsx
466	GRAMNEXUS0000000402.0005	Microsoft_Excel_Worksheet5.xlsx
467	GRAMNEXUS0000000403	2D4D7FE8.tmp
468	GRAMNEXUS0000000403.0001	Microsoft_Excel_Worksheet1.xlsx
469	GRAMNEXUS0000000403.0002	Microsoft_Excel_Worksheet2.xlsx
470	GRAMNEXUS0000000403.0003	Microsoft_Excel_Worksheet4.xlsx
471	GRAMNEXUS0000000403.0004	Microsoft_Excel_Worksheet3.xlsx
472	GRAMNEXUS0000000404	6D468A4F.tmp
473	GRAMNEXUS0000000404.0001	Microsoft_Excel_Worksheet1.xlsx
474	GRAMNEXUS0000000404.0002	Microsoft_Excel_Worksheet2.xlsx
475	GRAMNEXUS0000000404.0003	Microsoft_Excel_Worksheet4.xlsx
476	GRAMNEXUS0000000404.0004	Microsoft_Excel_Worksheet3.xlsx
477	GRAMNEXUS0000000405	9CBAD4C3.tmp
478	GRAMNEXUS0000000405.0001	Microsoft_Excel_Worksheet1.xlsx
479	GRAMNEXUS0000000405.0002	Microsoft_Excel_Worksheet2.xlsx
480	GRAMNEXUS0000000405.0003	Microsoft_Excel_Worksheet4.xlsx
481	GRAMNEXUS0000000405.0004	Microsoft_Excel_Worksheet3.xlsx
482	GRAMNEXUS0000000406	Copy of 010 lot endotoxin results.xlsx
483	GRAMNEXUS0000000407	D5AA1D2D.tmp
484	GRAMNEXUS0000000407.0001	Microsoft_Excel_Worksheet2.xlsx
485	GRAMNEXUS0000000407.0002	Microsoft_Excel_Worksheet1.xlsx
486	GRAMNEXUS0000000408	DR-160176 Review.docx
487	GRAMNEXUS0000000409	DR-170010 - List of Affected Products.docx
488	GRAMNEXUS0000000410	dr-170010 Attachment 3 010 Scope (SAS).docx
489	GRAMNEXUS0000000411	DR-170010 FINAL(SAS).docx
490	GRAMNEXUS0000000412	DR-170024 (Client Review) Comments MD 06APR17(SAS).docx
491	GRAMNEXUS0000000413	DR-170024 (KR)(SAS) (CCH)1.docx
492	GRAMNEXUS0000000414	DR-170024 (KR)(SAS).docx
493	GRAMNEXUS0000000415	DR-170024(SAS).docx
494	GRAMNEXUS0000000416	DR-170059.docx
495	GRAMNEXUS0000000417	DR-170154 SAS comments.docx
496	GRAMNEXUS0000000418	DR-170154 SAS KEL with RC.docx
497	GRAMNEXUS0000000419	DR-170177 (KR updated after converstaion) SWB v2 (002)(CCH)SAS.docx
498	GRAMNEXUS0000000420	DR-170177 (KR updated after converstaion) SWB v2 SAS.docx
499	GRAMNEXUS0000000421	GRAM Change of Status.docx
500	GRAMNEXUS0000000422	NaCl correction COR-170017.docm
501	GRAMNEXUS0000000423	Nonconformance Correction Form.docm
502	GRAMNEXUS0000000424	Q4 2019 EM(SAS).docx
503	GRAMNEXUS0000000425	Q4 slides.pptx
504	GRAMNEXUS0000000425.0001	Microsoft_Excel_Worksheet2.xlsx
505	GRAMNEXUS0000000425.0002	Microsoft_Excel_Worksheet3.xlsx
506	GRAMNEXUS0000000425.0003	Microsoft_Excel_Worksheet1.xlsx
507	GRAMNEXUS0000000425.0004	Microsoft_Excel_Worksheet4.xlsx
508	GRAMNEXUS0000000425.0005	Microsoft_Excel_Worksheet5.xlsx
509	GRAMNEXUS0000000426	Root cause investigation DR17024 (CCH)(SAS).docx
510	GRAMNEXUS0000000427	Root cause investigation DR17024 final.docx
511	GRAMNEXUS0000000428	Root cause investigation NaCl buffer.docx

512	GRAMNEXUS0000000429	160089 pic.docx
513	GRAMNEXUS0000000430	EIR-160081.docx
514	GRAMNEXUS0000000431	EIR-160082 SWBv1 SAS1.docx
515	GRAMNEXUS0000000431.0001	Microsoft_Visio_Drawing1.vsdx
516	GRAMNEXUS0000000432	EIR-160085.docx
517	GRAMNEXUS0000000433	EIR-160086 (CCH)(SAS) (2).docx
518	GRAMNEXUS0000000434	EIR-160086 (CCH)(SAS).docx
519	GRAMNEXUS0000000435	EIR-160086 SWBv1 SAS.docx
520	GRAMNEXUS0000000436	EIR-160086.docx
521	GRAMNEXUS0000000437	EIR-160087(SAS).docx
522	GRAMNEXUS0000000438	EIR-160087.docx
523	GRAMNEXUS0000000439	EIR-160089.docx
524	GRAMNEXUS0000000440	EIR-170021 SWBv1(SAS).docx
525	GRAMNEXUS0000000441	EIR-170021 SWBv2(SAS).docx
526	GRAMNEXUS0000000442	EIR-170025.docx
527	GRAMNEXUS0000000443	EIR-170052 Extension.docx
528	GRAMNEXUS0000000444	EIR-170063 SWB v01 SAS v01.docx
529	GRAMNEXUS0000000444.0001	Microsoft_Visio_Drawing1.vsdx
530	GRAMNEXUS0000000445	EIR-170063 SWB v01 SAS.docx
531	GRAMNEXUS0000000445.0001	Microsoft_Visio_Drawing1.vsdx
532	GRAMNEXUS0000000446	EIR-170063 SWB v02 SAS v02.docx
533	GRAMNEXUS0000000446.0001	Microsoft_Visio_Drawing1.vsdx
534	GRAMNEXUS0000000447	EIR-170063 SWB v02 SAS v03.docx
535	GRAMNEXUS0000000447.0001	Microsoft_Visio_Drawing1.vsdx
536	GRAMNEXUS0000000448	EIR-170064 SAS.docx
537	GRAMNEXUS0000000448.0001	Microsoft_Visio_Drawing1.vsdx
538	GRAMNEXUS0000000449	EIR-170084.docx
539	GRAMNEXUS0000000449.0001	Microsoft_Visio_Drawing1.vsdx
540	GRAMNEXUS0000000450	EIR-180001.pdf
541	GRAMNEXUS0000000451	EIR-180002.pdf
542	GRAMNEXUS0000000452	EIR-180003.pdf
543	GRAMNEXUS0000000453	EIR-180004.pdf
544	GRAMNEXUS0000000454	EIR-180005.pdf
545	GRAMNEXUS0000000455	EIR-180006.pdf
546	GRAMNEXUS0000000456	EIR-180007.pdf
547	GRAMNEXUS0000000457	EIR-180008 Extension 2.docx
548	GRAMNEXUS0000000458	EIR-180014 Extension 1.docx
549	GRAMNEXUS0000000459	EIR-180014.pdf
550	GRAMNEXUS0000000460	EIR-180015 Extension 1.docx
551	GRAMNEXUS0000000461	EIR-180016.pdf
552	GRAMNEXUS0000000462	EIR-180019 Extension 1.docx
553	GRAMNEXUS0000000463	EIR-180020.docx
554	GRAMNEXUS0000000464	EIR-180020.pdf
555	GRAMNEXUS0000000465	EIR-180021.docx
556	GRAMNEXUS0000000466	EIR-180021.pdf
557	GRAMNEXUS0000000467	EIR-180022 Extension 1.docx
558	GRAMNEXUS0000000468	EIR-180022.pdf
559	GRAMNEXUS0000000469	EIR-180025.pdf
560	GRAMNEXUS0000000470	EIR-180027.pdf
561	GRAMNEXUS0000000471	EIR-180028.pdf
562	GRAMNEXUS0000000472	EIR-180029.pdf
563	GRAMNEXUS0000000473	EIR-180030.pdf
564	GRAMNEXUS0000000474	EIR-180031.pdf
565	GRAMNEXUS0000000475	EIR-180034.pdf
566	GRAMNEXUS0000000476	EIR-180036.pdf
567	GRAMNEXUS0000000477	EIR-180037.pdf
568	GRAMNEXUS0000000478	EIR-180038.pdf
569	GRAMNEXUS0000000479	EIR-180047.pdf
570	GRAMNEXUS0000000480	EIR-180049.pdf
571	GRAMNEXUS0000000481	EIR-180050.pdf
572	GRAMNEXUS0000000482	EIR-180052.pdf
573	GRAMNEXUS0000000483	EIR-180053.pdf
574	GRAMNEXUS0000000484	EIR-180055.pdf
575	GRAMNEXUS0000000485	EIR-180057.pdf

576	GRAMNEXUS0000000486	EIR-180058.pdf
577	GRAMNEXUS0000000487	EIR-180060 SAS.docx
578	GRAMNEXUS0000000487.0001	Microsoft_Visio_Drawing.vsdx
579	GRAMNEXUS0000000487.0002	Microsoft_Visio_Drawing1.vsdx
580	GRAMNEXUS0000000488	EIR-180061.docx
581	GRAMNEXUS0000000488.0001	Microsoft_Visio_Drawing.vsdx
582	GRAMNEXUS0000000489	EIR-180061.pdf
583	GRAMNEXUS0000000490	EIR-180062.pdf
584	GRAMNEXUS0000000491	EIR-180064.pdf
585	GRAMNEXUS0000000492	EIR-180074.pdf
586	GRAMNEXUS0000000493	EIR-180075.pdf
587	GRAMNEXUS0000000494	NCR-0177.docx
588	GRAMNEXUS0000000495	NCR-0178.docx
589	GRAMNEXUS0000000495.0001	Microsoft_Visio_Drawing1.vsdx
590	GRAMNEXUS0000000495.0002	Microsoft_Visio_Drawing.vsdx
591	GRAMNEXUS0000000495.0003	Microsoft_Visio_Drawing2.vsdx
592	GRAMNEXUS0000000496	NCR-0206 DS #7 (SAS).docx
593	GRAMNEXUS0000000497	Q3 white side NV for EIR.xlsx
594	GRAMNEXUS0000000498	Room 211 Non viable trends.docx
595	GRAMNEXUS0000000499	EIR 170015.pdf
596	GRAMNEXUS0000000500	EIR-170001.pdf
597	GRAMNEXUS0000000501	EIR-170002.pdf
598	GRAMNEXUS0000000502	EIR-170003.pdf
599	GRAMNEXUS0000000503	EIR-170004.pdf
600	GRAMNEXUS0000000504	EIR-170005.pdf
601	GRAMNEXUS0000000505	EIR-170010.pdf
602	GRAMNEXUS0000000506	EIR-170014.pdf
603	GRAMNEXUS0000000507	EIR-170016.pdf
604	GRAMNEXUS0000000508	EIR-170019.pdf
605	GRAMNEXUS0000000509	EIR-170024.pdf
606	GRAMNEXUS0000000510	EIR-170032.pdf
607	GRAMNEXUS0000000511	EIR-170035.pdf
608	GRAMNEXUS0000000512	EIR-170038.pdf
609	GRAMNEXUS0000000513	EIR-170039.pdf
610	GRAMNEXUS0000000514	EIR-170043.pdf
611	GRAMNEXUS0000000515	EIR-170045.pdf
612	GRAMNEXUS0000000516	EIR-170046.pdf
613	GRAMNEXUS0000000517	EIR-170048.pdf
614	GRAMNEXUS0000000518	EIR-170051.pdf
615	GRAMNEXUS0000000519	EIR-170052.pdf
616	GRAMNEXUS0000000520	EIR-170054.pdf
617	GRAMNEXUS0000000521	EIR-170058.pdf
618	GRAMNEXUS0000000522	EIR-170063.pdf
619	GRAMNEXUS0000000523	EIR-170064.pdf
620	GRAMNEXUS0000000524	EIR-170065.pdf
621	GRAMNEXUS0000000525	EIR-170073 Revised.pdf
622	GRAMNEXUS0000000526	EIR-170081.pdf
623	GRAMNEXUS0000000527	EIR-170082.pdf
624	GRAMNEXUS0000000528	EIR-170084.pdf
625	GRAMNEXUS0000000529	EIR-170085.pdf
626	GRAMNEXUS0000000530	EIR-170089.pdf
627	GRAMNEXUS0000000531	EIR-170090.pdf
628	GRAMNEXUS0000000532	EIR-170091.pdf
629	GRAMNEXUS0000000533	EIR-170095.pdf
630	GRAMNEXUS0000000534	EIR-170096.pdf
631	GRAMNEXUS0000000535	EIR-170003 (003).docx
632	GRAMNEXUS0000000536	EIR-170004 (002) SAS.docx
633	GRAMNEXUS0000000537	EIR-170004 (002) table added.docx
634	GRAMNEXUS0000000538	EIR-170015.pdf
635	GRAMNEXUS0000000539	EIR-170021.docx
636	GRAMNEXUS0000000540	EIR-170026 SWBv01 (SAS).docx
637	GRAMNEXUS0000000541	EIR-170041 swbv01 sas.docx
638	GRAMNEXUS0000000542	NCR-0361 BLP #5 (SAS).docx
639	GRAMNEXUS0000000543	PQ Requirements.docx

640	GRAMNEXUS0000000544	2020 Micro Butterworth Budget.xlsx
641	GRAMNEXUS0000000545	ANA Agar PO.pdf
642	GRAMNEXUS0000000546	ANA Agar PO.xlsx
643	GRAMNEXUS0000000547	butter equip setpoints.xlsx
644	GRAMNEXUS0000000548	Butterworth Classififed Spaces IOQ.docx
645	GRAMNEXUS0000000549	Butterworth EMPQ C-D MC reformat.docx
646	GRAMNEXUS0000000550	Butterworth EMPQ C-D.docx
647	GRAMNEXUS0000000551	Butterworth room dimensions.docx
648	GRAMNEXUS0000000552	Carboy PO.xlsx
649	GRAMNEXUS0000000553	CART order.xlsx
650	GRAMNEXUS0000000554	Cart PO.xlsx
651	GRAMNEXUS0000000555	CC-0175 Scope (SAS) REV.docx
652	GRAMNEXUS0000000556	Copy of Copy of WO 2307 MFG and LAB BTR On-Boarding.xlsx
653	GRAMNEXUS0000000557	Copy of GRAM Micro Documents to Draft(SAS)(CCH).xlsx
654	GRAMNEXUS0000000558	Copy of GRAM Micro Documents to Draft(SAS)(CCH)1.xlsx
655	GRAMNEXUS0000000559	Cycle Decn BI #1.pdf
656	GRAMNEXUS0000000560	Cycle Decon BI#2.pdf
657	GRAMNEXUS0000000561	Dis Eff Matrix surfaces.xlsx
658	GRAMNEXUS0000000562	Dis Eff Matrix.xlsx
659	GRAMNEXUS0000000563	EM media PO 2-8 11449.xlsx
660	GRAMNEXUS0000000564	EM media PO 2.xlsx
661	GRAMNEXUS0000000565	EM media PO.xlsx
662	GRAMNEXUS0000000566	EMQ_GRAM Butterworth Facility_SCN 20APR20_DRAFT for REVIEW.docx
663	GRAMNEXUS0000000567	GRAM PO 11410.pdf
664	GRAMNEXUS0000000568	GRAM SOP Administration of the Vitek 2 Compact System.docx
665	GRAMNEXUS0000000569	IC-XT 100mm CofA.pdf
666	GRAMNEXUS0000000570	IC-XT Rodac CofA.pdf
667	GRAMNEXUS0000000571	Iso Run 1 with ID.pdf
668	GRAMNEXUS0000000572	Iso Run 2.pdf
669	GRAMNEXUS0000000573	Iso Run 3.pdf
670	GRAMNEXUS0000000574	lab stools PO.xlsx
671	GRAMNEXUS0000000575	Lab water memo.doc
672	GRAMNEXUS0000000576	M10-20-00 - EQUIPMENT PLAN LEVEL 2 OVERALL_R2 (002).pdf
673	GRAMNEXUS0000000577	Manuals Memo.pdf
674	GRAMNEXUS0000000578	Memo for AI-0363.pdf
675	GRAMNEXUS0000000579	MicroWorks Sample Submission Form endo.doc
676	GRAMNEXUS0000000580	MW EMPQ PO.xlsx
677	GRAMNEXUS0000000581	MW Endo PO.xlsx
678	GRAMNEXUS0000000582	office PO.xlsx
679	GRAMNEXUS0000000583	PO 11120 VWR.pdf
680	GRAMNEXUS0000000584	PO 11359 Charles River 5-27-20.pdf
681	GRAMNEXUS0000000585	PO for hose barbs.xlsx
682	GRAMNEXUS0000000586	PQ Requirements.docx
683	GRAMNEXUS0000000587	STERIVAP SL_np_en 2018-02_V03_USA.pdf
684	GRAMNEXUS0000000588	STERIVAP SL_ns_en 2015-07_V1.01.pdf
685	GRAMNEXUS0000000589	VAL-1702 Tunnel Protocol Deviation 1 10mL vials.docx
686	GRAMNEXUS0000000590	VW run 3 2ml.xlsx
687	GRAMNEXUS0000000591	vwr order.xlsx
688	GRAMNEXUS0000000592	Weigh Dispense EMPQ.docx
689	GRAMNEXUS0000000592.0001	Microsoft_Visio_Drawing4.vsdx
690	GRAMNEXUS0000000592.0002	Microsoft_Visio_Drawing.vsdx
691	GRAMNEXUS0000000592.0003	Microsoft_Visio_Drawing1.vsdx
692	GRAMNEXUS0000000592.0004	Microsoft_Visio_Drawing2.vsdx
693	GRAMNEXUS0000000592.0005	Microsoft_Visio_Drawing5.vsdx
694	GRAMNEXUS0000000592.0006	Microsoft_Visio_Drawing6.vsdx
695	GRAMNEXUS0000000592.0007	Microsoft_Visio_Drawing7.vsdx
696	GRAMNEXUS0000000592.0008	Microsoft_Visio_Drawing3.vsdx
697	GRAMNEXUS0000000593	~$tterworth EMPQ C-D.docx
698	GRAMNEXUS0000000594	1325.pdf
699	GRAMNEXUS0000000595	BTR_FIRST_QC_LYT_001 1325.pdf
700	GRAMNEXUS0000000596	Butterworth EMPQ C-D MC.docx
701	GRAMNEXUS0000000597	13693 Harvest Lane Energy Costs.docx
702	GRAMNEXUS0000000598	2017 Scott S Form 1040 Individual Tax Return_Records.pdf
703	GRAMNEXUS0000000599	2018 Scott S Form 1040 Individual Tax Return_Records.pdf

704	GRAMNEXUS0000000600	20190419_BANK_four_star_checking_8440.pdf
705	GRAMNEXUS0000000601	20190430_BANK_bonus_savings_0613.pdf
706	GRAMNEXUS0000000602	20190520_BANK_four_star_checking_8440.pdf
707	GRAMNEXUS0000000603	20190531_BANK_bonus_savings_0613.pdf
708	GRAMNEXUS0000000604	20190619_BANK_four_star_checking_8440.pdf
709	GRAMNEXUS0000000605	Consumers usage.pdf
710	GRAMNEXUS0000000606	Gas usage.docx
711	GRAMNEXUS0000000607	House Checklist.docx
712	GRAMNEXUS0000000608	https___docs.libertymutual.pdf
713	GRAMNEXUS0000000609	license.pdf
714	GRAMNEXUS0000000610	Micro Tech questions.docx
715	GRAMNEXUS0000000611	Pay 5-31-19.pdf
716	GRAMNEXUS0000000612	Pay 6-14-19.pdf
717	GRAMNEXUS0000000613	purchase agreement.pdf
718	GRAMNEXUS0000000614	Scott - Fremont Home Application 2017-05-26.pdf
719	GRAMNEXUS0000000615	scott home only.pdf
720	GRAMNEXUS0000000616	Scott Prequal.pdf
721	GRAMNEXUS0000000617	Scott.2017-04-21.pdf
722	GRAMNEXUS0000000618	Scott.2017-05-05.pdf
723	GRAMNEXUS0000000619	Sell Letter.docx
724	GRAMNEXUS0000000620	Sheri Scott on Beechwood 6-19-17.pdf
725	GRAMNEXUS0000000621	Sherri Scott 2015 Tax Return_T15_For_Filing.pdf
726	GRAMNEXUS0000000622	Sparrow receipt.docx
727	GRAMNEXUS0000000623	W2 17-18.pdf
728	GRAMNEXUS0000000624	~2016 Scott S Form 1040 Individual Tax Return_Records.pdf
729	GRAMNEXUS0000000625	custom.hpdata
730	GRAMNEXUS0000000626	190015 Hypothesis(SAS).docx
731	GRAMNEXUS0000000627	Attachment #1 to LIR-190015 final.docx
732	GRAMNEXUS0000000628	Attachment #3 LIR-180015.docx
733	GRAMNEXUS0000000629	Attachment 1 to LIR-190014 4-23-19 (SAS).docx
734	GRAMNEXUS0000000630	Attachment 1 to LIR-190014 4-23-19(sas).docx
735	GRAMNEXUS0000000631	Attachment 1 to LIR-190021.docx
736	GRAMNEXUS0000000632	Attachment 1 to LIR-190026(SAS).docx
737	GRAMNEXUS0000000633	Attachment 1 to LIR-190040 final.docx
738	GRAMNEXUS0000000634	Attachment 1 to LIR-190057(SAS).docx
739	GRAMNEXUS0000000635	Attachment 1 to LIR-190065 (CMD)(SAS).docx
740	GRAMNEXUS0000000636	Attachment 1 to LIR-190065 (SAS).docx
741	GRAMNEXUS0000000637	CLIR Extension 170008-2.docx
742	GRAMNEXUS0000000638	CLIR Extension 170008.docx
743	GRAMNEXUS0000000639	CLIR-170008.docx
744	GRAMNEXUS0000000640	CLIR-170008.pdf
745	GRAMNEXUS0000000641	CLIR-180002.docx
746	GRAMNEXUS0000000642	CLIR-180002.pdf
747	GRAMNEXUS0000000643	LIR 170007.docx
748	GRAMNEXUS0000000644	LIR 170014.docx
749	GRAMNEXUS0000000645	LIR 180006 A1.docx
750	GRAMNEXUS0000000646	LIR Extension 170007.docx
751	GRAMNEXUS0000000647	LIR Extension 170010.docx
752	GRAMNEXUS0000000648	LIR Extension 170014-2.docx
753	GRAMNEXUS0000000649	LIR Extension 170014-3.docx
754	GRAMNEXUS0000000650	LIR Extension 170014.docx
755	GRAMNEXUS0000000651	LIR Extension 170032.docx
756	GRAMNEXUS0000000652	LIR Extension 170033.docx
757	GRAMNEXUS0000000653	LIR-170007 QA impact (CCH)(SAS).docx
758	GRAMNEXUS0000000654	LIR-170010.docx
759	GRAMNEXUS0000000655	LIR-170014 ext.pdf
760	GRAMNEXUS0000000656	LIR-170023 - Attachment #5 SAS.docx
761	GRAMNEXUS0000000657	LIR-170023.docx
762	GRAMNEXUS0000000658	LIR-170023.pdf
763	GRAMNEXUS0000000659	LIR-170032.docx
764	GRAMNEXUS0000000660	LIR-170032.pdf
765	GRAMNEXUS0000000661	LIR-170033.docx
766	GRAMNEXUS0000000662	LIR-170033.pdf
767	GRAMNEXUS0000000663	LIR-180006.pdf

768	GRAMNEXUS0000000664	LIR-180007 Attachment 2.docx
769	GRAMNEXUS0000000665	LIR-180007 Attachment 3.docx
770	GRAMNEXUS0000000666	LIR-180007.pdf
771	GRAMNEXUS0000000667	LIR-180015 (CCH).docx
772	GRAMNEXUS0000000668	LIR-180015.docx
773	GRAMNEXUS0000000669	LIR-180015_JLL comments SAS.docx
774	GRAMNEXUS0000000670	LIR-180016 _comments.docx
775	GRAMNEXUS0000000671	LIR-180016.docx
776	GRAMNEXUS0000000672	LIR-180016.pdf
777	GRAMNEXUS0000000673	LIR-180030 Att 2.docx
778	GRAMNEXUS0000000674	LIR-190012(SAS) (002).docx
779	GRAMNEXUS0000000675	LIR-190012(SAS).docx
780	GRAMNEXUS0000000676	LIR-190012(SAS)1.docx
781	GRAMNEXUS0000000677	LIR-190012.docx
782	GRAMNEXUS0000000678	LIR-190014 05-09-19.docx
783	GRAMNEXUS0000000679	LIR-190014 05-13-19(SAS).docx
784	GRAMNEXUS0000000680	LIR-190015 FINAL.docx
785	GRAMNEXUS0000000681	LIR-190015(SAS) (JLL)1.docx
786	GRAMNEXUS0000000682	LIR-190015(SAS).docx
787	GRAMNEXUS0000000683	LIR-190021(SAS).docx
788	GRAMNEXUS0000000684	LIR-190021.pdf
789	GRAMNEXUS0000000685	LIR-190026 Final.docx
790	GRAMNEXUS0000000686	LIR-190026(SAS).docx
791	GRAMNEXUS0000000687	LIR-190026.pdf
792	GRAMNEXUS0000000688	LIR-190029 7-16-19 (CMD) (003)(SAS).docx
793	GRAMNEXUS0000000689	LIR-190031 Endotoxin OOS API-0003 (CMD).docx
794	GRAMNEXUS0000000690	LIR-190031 Endotoxin OOS API-0003(SAS).docx
795	GRAMNEXUS0000000691	LIR-190031 Endotoxin OOS API-0003.docx
796	GRAMNEXUS0000000692	LIR-190031 Hypothesis Testing CK 7-31-2019(SAS).docx
797	GRAMNEXUS0000000693	LIR-190031 Hypothesis Testing.docx
798	GRAMNEXUS0000000694	LIR-190032 (CCH).docx
799	GRAMNEXUS0000000695	LIR-190032.docx
800	GRAMNEXUS0000000696	LIR-190032.pdf
801	GRAMNEXUS0000000697	LIR-190036 (SAS) (CMD) Final.docx
802	GRAMNEXUS0000000698	LIR-190036 (SAS).docx
803	GRAMNEXUS0000000699	LIR-190040 final.docx
804	GRAMNEXUS0000000700	LIR-190057(SAS).docx
805	GRAMNEXUS0000000701	LIR-190065 (CMD)(SAS).docx
806	GRAMNEXUS0000000702	LIR-190065 (SAS).docx
807	GRAMNEXUS0000000703	LIR-190066 (SAS).docx
808	GRAMNEXUS0000000704	LIR-190070(SAS)(JLL).docx
809	GRAMNEXUS0000000705	LIR-190070(SAS).docx
810	GRAMNEXUS0000000706	LIR-200017.docx
811	GRAMNEXUS0000000707	water and steam butter.docx
812	GRAMNEXUS0000000708	006-138A validation protocol (SAS).docx
813	GRAMNEXUS0000000708.0001	Microsoft_Visio_Drawing.vsdx
814	GRAMNEXUS0000000709	020-132A PPQ_01b(SAS).docx
815	GRAMNEXUS0000000710	020-148B COA template_rev 01(SAS).docx
816	GRAMNEXUS0000000711	020-148C COA template_rev 01(SAS).docx
817	GRAMNEXUS0000000712	18-154A COA Template (SAS).docx
818	GRAMNEXUS0000000713	55-60 Benchtop Incubator(SAS).docm
819	GRAMNEXUS0000000714	API-0005 VAl-1012_Report(SAS).docm
820	GRAMNEXUS0000000715	API-0007 (5)_formatted (SAS).docx
821	GRAMNEXUS0000000716	API-0008 (2)(SAS).docx
822	GRAMNEXUS0000000717	API-0008 DCR2 (SAS).docx
823	GRAMNEXUS0000000718	API-0008(SAS).docx
824	GRAMNEXUS0000000719	API-0012 rev 02(IDV)(SAS).docx
825	GRAMNEXUS0000000720	API-0018 rev 04(SAS).docx
826	GRAMNEXUS0000000721	API-0022(RB) (1)SAS.docx
827	GRAMNEXUS0000000722	API-0024 (RB) BB_Formatted (003) - PMN TRACK CHANGES (sas).docx
828	GRAMNEXUS0000000723	API-0025 RW(RB) (1) (1) (RB)(SAS).docx
829	GRAMNEXUS0000000724	API-0026 (002)(SAS).docx
830	GRAMNEXUS0000000725	API-0029 rev 01(SAS).docx
831	GRAMNEXUS0000000726	API-0030 rev 01(SAS).docx

832	GRAMNEXUS0000000727	API-0033_final draft .docx
833	GRAMNEXUS0000000728	APR SOP with responsibilities and table(SAS).docx
834	GRAMNEXUS0000000729	BB water form.docx
835	GRAMNEXUS0000000730	BD Rodac CofA.pdf
836	GRAMNEXUS0000000731	Benchtop Incubator URS(SAS).docm
837	GRAMNEXUS0000000732	BI Strip or Ampule Test Form(SAS).docx
838	GRAMNEXUS0000000733	BTL-0002 v04 DCR.docx
839	GRAMNEXUS0000000734	c albicans MDA19003 rev 02.docx
840	GRAMNEXUS0000000735	c albicans MDA19003.docx
841	GRAMNEXUS0000000736	CAPA-0013 Plan.docx
842	GRAMNEXUS0000000737	CHM-0007 rev 03(SAS).docx
843	GRAMNEXUS0000000738	CHM-0007 rev 03(SAS)1.docx
844	GRAMNEXUS0000000739	CHM-0009 SAS.docx
845	GRAMNEXUS0000000740	CHM-0023 (2)SAS.docx
846	GRAMNEXUS0000000741	CHM-0023_Acetic Acid USP SAS.docx
847	GRAMNEXUS0000000742	CHM-0024_Phenol USP SAS.docx
848	GRAMNEXUS0000000743	CHM-0025 (3)(SAS).docx
849	GRAMNEXUS0000000744	CHM-0025_Sodium Acetate USP SAS.docx
850	GRAMNEXUS0000000745	CHM-0026_Castor Oil SAS.docx
851	GRAMNEXUS0000000746	CHM-0029 rev 02.docx
852	GRAMNEXUS0000000747	CHM-0038_rev 01(SAS).docx
853	GRAMNEXUS0000000748	CHM-0040_rev 01 dw(SAS).docx
854	GRAMNEXUS0000000749	CHM-0047 Spec (DJS)(SAS).docx
855	GRAMNEXUS0000000750	CHM-0050(SAS).docx
856	GRAMNEXUS0000000751	Compressed Gas QC Report - SAS.docx
857	GRAMNEXUS0000000752	Conductivity result form.docm
858	GRAMNEXUS0000000753	Containment Room EM.docx
859	GRAMNEXUS0000000753.0001	Microsoft_Visio_Drawing.vsdx
860	GRAMNEXUS0000000754	Contam Control.pdf
861	GRAMNEXUS0000000755	Contamination Control Policy -KNB (1)(SAS).docx
862	GRAMNEXUS0000000755.0001	Microsoft_Visio_Drawing.vsdx
863	GRAMNEXUS0000000756	Controlled Area Monitoring SOP SAS.docx
864	GRAMNEXUS0000000756.0001	Microsoft_Visio_Drawing12.vsdx
865	GRAMNEXUS0000000756.0002	Microsoft_Visio_Drawing13.vsdx
866	GRAMNEXUS0000000756.0003	Microsoft_Visio_Drawing14.vsdx
867	GRAMNEXUS0000000756.0004	Microsoft_Visio_Drawing15.vsdx
868	GRAMNEXUS0000000756.0005	Microsoft_Visio_Drawing.vsdx
869	GRAMNEXUS0000000756.0006	Microsoft_Visio_Drawing1.vsdx
870	GRAMNEXUS0000000756.0007	Microsoft_Visio_Drawing2.vsdx
871	GRAMNEXUS0000000756.0008	Microsoft_Visio_Drawing3.vsdx
872	GRAMNEXUS0000000756.0009	Microsoft_Visio_Drawing4.vsdx
873	GRAMNEXUS0000000756.0010	Microsoft_Visio_Drawing5.vsdx
874	GRAMNEXUS0000000756.0011	Microsoft_Visio_Drawing6.vsdx
875	GRAMNEXUS0000000756.0012	Microsoft_Visio_Drawing7.vsdx
876	GRAMNEXUS0000000756.0013	Microsoft_Visio_Drawing8.vsdx
877	GRAMNEXUS0000000756.0014	Microsoft_Visio_Drawing9.vsdx
878	GRAMNEXUS0000000756.0015	Microsoft_Visio_Drawing10.vsdx
879	GRAMNEXUS0000000756.0016	Microsoft_Visio_Drawing11.vsdx
880	GRAMNEXUS0000000757	CORP-FRM-0005 6-29-18.docx
881	GRAMNEXUS0000000758	CORP-FRM-0022 (SAS).docx
882	GRAMNEXUS0000000759	CORP-FRM-0022.docx
883	GRAMNEXUS0000000760	CORP-FRM-0044 Gowning Requalification Form.docx
884	GRAMNEXUS0000000761	CORP-FRM-0045 Rev 11 (JW)(SAS).docx
885	GRAMNEXUS0000000762	CORP-FRM-0045 Rev 11 (JW)(SAS)reformat.docx
886	GRAMNEXUS0000000763	CORP-FRM-0045.docx
887	GRAMNEXUS0000000764	CORP-FRM-0046 rev 15 (JW)(JLL)(SAS).docx
888	GRAMNEXUS0000000765	CORP-FRM-0046 rev 15.docx
889	GRAMNEXUS0000000766	CORP-FRM-0046 Whiteside EM Form(SAS).docx
890	GRAMNEXUS0000000767	CORP-FRM-0055 rev 04.docx
891	GRAMNEXUS0000000768	CORP-FRM-0055(SAS).docx
892	GRAMNEXUS0000000769	CORP-FRM-0055(SAS)1.docx
893	GRAMNEXUS0000000770	corp-frm-0055.docx
894	GRAMNEXUS0000000771	CORP-FRM-0057 DCR.docx
895	GRAMNEXUS0000000772	CORP-FRM-0139 Rev 07.docx

896	GRAMNEXUS0000000773	CORP-FRM-0192 R05 DCR.docx
897	GRAMNEXUS0000000774	CORP-FRM-0192 _Annual Requal Form(SAS).docx
898	GRAMNEXUS0000000775	CORP-FRM-0247 rev 03 (JLLv2)SAS.docx
899	GRAMNEXUS0000000776	CORP-FRM-0247 rev 03.docx
900	GRAMNEXUS0000000777	CORP-FRM-0273 APA Operator Qual.docx
901	GRAMNEXUS0000000778	CORP-FRM-0413 3-12-19(SAS).docx
902	GRAMNEXUS0000000779	CORP-FRM-0413 CK 2-26-19(SAS).docx
903	GRAMNEXUS0000000780	CORP-FRM-0413 rev 05 (JW)(SAS)(JLL) 12pt.docx
904	GRAMNEXUS0000000781	CORP-FRM-0413 rev 05 (JW)(SAS)(JLL) reformat 2.docx
905	GRAMNEXUS0000000782	CORP-FRM-0413 rev 05 (JW)(SAS)(JLL).docx
906	GRAMNEXUS0000000783	CORP-FRM-0413 rev 05 (JW)(SAS).docx
907	GRAMNEXUS0000000784	CORP-FRM-0413 rev 05.docx
908	GRAMNEXUS0000000785	CORP-FRM-0416 R02 new template (JLL).docm
909	GRAMNEXUS0000000786	CORP-FRM-0416 R02 new template.docm
910	GRAMNEXUS0000000787	CORP-FRM-0416 R03.docm
911	GRAMNEXUS0000000788	CORP-FRM-0416 rev 02 (JLL)Reformat (1).docx
912	GRAMNEXUS0000000789	CORP-FRM-0416 rev 02 (JLL)Reformat.docx
913	GRAMNEXUS0000000790	CORP-FRM-0416 rev 02 rebuild.docx
914	GRAMNEXUS0000000791	CORP-FRM-0416 rev 02 rebuild.pdf
915	GRAMNEXUS0000000792	CORP-FRM-0416 rev 02.docx
916	GRAMNEXUS0000000793	CORP-FRM-0438(SAS).docm
917	GRAMNEXUS0000000794	CORP-FRM-0438.docx
918	GRAMNEXUS0000000795	CORP-FRM-0438_02.docm
919	GRAMNEXUS0000000796	CORP-FRM-0464 R01 DCR.docx
920	GRAMNEXUS0000000797	CORP-FRM-0466 rev 02 (JW)(SAS).docx
921	GRAMNEXUS0000000798	CORP-FRM-0466.docx
922	GRAMNEXUS0000000799	CORP-FRM-0527 DCR.docx
923	GRAMNEXUS0000000800	CORP-FRM-0591 DCR.docx
924	GRAMNEXUS0000000801	CORP-LOG-0044.docx
925	GRAMNEXUS0000000802	CORP-LOG-0047 Microbiology Lab Sanitization Check Log (SAS).docx
926	GRAMNEXUS0000000803	CORP-LOG-0141 SAS.docm
927	GRAMNEXUS0000000804	CORP-LOG-0141.docm
928	GRAMNEXUS0000000805	CORP-LOG-0151 DCR.docx
929	GRAMNEXUS0000000806	CORP-LOG-0151_Lab Cleaning Log.docm
930	GRAMNEXUS0000000807	CORP-LOG-0153 Micro EM Log(SAS).docx
931	GRAMNEXUS0000000808	CORP-LOG-0161 rev 02.docx
932	GRAMNEXUS0000000809	CORP-LOG-0161.docx
933	GRAMNEXUS0000000810	CORP-POL-0013 Laboratory Safety-Chemicall Hygiene.docx
934	GRAMNEXUS0000000811	CORP-RAR-0017 (JLL)(SAS).docx
935	GRAMNEXUS0000000812	CORP-SOP-0010 7-11-18(SAS).docx
936	GRAMNEXUS0000000813	CORP-SOP-0027 revision (SAS).docx
937	GRAMNEXUS0000000814	CORP-SOP-0027 revision 20.docx
938	GRAMNEXUS0000000815	CORP-SOP-0027 Water and Pure Steam Sampling FINAL(SAS).docx
939	GRAMNEXUS0000000816	CORP-SOP-0045 (1-16-19)(SAS).docx
940	GRAMNEXUS0000000817	CORP-SOP-0051 EIR.docx
941	GRAMNEXUS0000000818	CORP-SOP-0051 Environmental Investigation Reports (AVB) (CCH) (SAS).docx
942	GRAMNEXUS0000000819	CORP-SOP-0051 Environmental Investigation Reports.docx
943	GRAMNEXUS0000000820	CORP-SOP-0051 rev 08.docx
944	GRAMNEXUS0000000821	CORP-SOP-0071 7-02-18(SAS).docx
945	GRAMNEXUS0000000822	CORP-SOP-0073 Aseptic Gowning Qualification Program(JLL)(SAS).docx
946	GRAMNEXUS0000000823	CORP-SOP-0074 DCR.docx
947	GRAMNEXUS0000000824	CORP-SOP-0074 Rev 20 (SAS).docx
948	GRAMNEXUS0000000824.0001	Microsoft_Visio_Drawing11.vsdx
949	GRAMNEXUS0000000824.0002	Microsoft_Visio_Drawing9.vsdx
950	GRAMNEXUS0000000824.0003	Microsoft_Visio_Drawing10.vsdx
951	GRAMNEXUS0000000824.0004	Microsoft_Visio_Drawing8.vsdx
952	GRAMNEXUS0000000824.0005	Microsoft_Visio_Drawing7.vsdx
953	GRAMNEXUS0000000824.0006	Microsoft_Visio_Drawing1.vsdx
954	GRAMNEXUS0000000824.0007	Microsoft_Visio_Drawing.vsdx
955	GRAMNEXUS0000000824.0008	Microsoft_Visio_Drawing2.vsdx
956	GRAMNEXUS0000000824.0009	Microsoft_Visio_Drawing3.vsdx
957	GRAMNEXUS0000000824.0010	Microsoft_Visio_Drawing6.vsdx
958	GRAMNEXUS0000000824.0011	Microsoft_Visio_Drawing5.vsdx
959	GRAMNEXUS0000000824.0012	Microsoft_Visio_Drawing4.vsdx

960	GRAMNEXUS0000000825	CORP-SOP-0074 Rev. 19(SAS).docx
961	GRAMNEXUS0000000825.0001	Microsoft_Visio_Drawing11.vsdx
962	GRAMNEXUS0000000825.0002	Microsoft_Visio_Drawing9.vsdx
963	GRAMNEXUS0000000825.0003	Microsoft_Visio_Drawing10.vsdx
964	GRAMNEXUS0000000825.0004	Microsoft_Visio_Drawing2.vsdx
965	GRAMNEXUS0000000825.0005	Microsoft_Visio_Drawing8.vsdx
966	GRAMNEXUS0000000825.0006	Microsoft_Visio_Drawing1.vsdx
967	GRAMNEXUS0000000825.0007	Microsoft_Visio_Drawing.vsdx
968	GRAMNEXUS0000000825.0008	Microsoft_Visio_Drawing7.vsdx
969	GRAMNEXUS0000000825.0009	Microsoft_Visio_Drawing6.vsdx
970	GRAMNEXUS0000000825.0010	Microsoft_Visio_Drawing3.vsdx
971	GRAMNEXUS0000000825.0011	Microsoft_Visio_Drawing5.vsdx
972	GRAMNEXUS0000000825.0012	Microsoft_Visio_Drawing4.vsdx
973	GRAMNEXUS0000000826	CORP-SOP-0074 Rev. 21(SAS)(CCH)(JLLv2).docx
974	GRAMNEXUS0000000826.0001	Microsoft_Visio_Drawing10.vsdx
975	GRAMNEXUS0000000826.0002	Microsoft_Visio_Drawing11.vsdx
976	GRAMNEXUS0000000826.0003	Microsoft_Visio_Drawing9.vsdx
977	GRAMNEXUS0000000826.0004	Microsoft_Visio_Drawing1.vsdx
978	GRAMNEXUS0000000826.0005	Microsoft_Visio_Drawing.vsdx
979	GRAMNEXUS0000000826.0006	Microsoft_Visio_Drawing3.vsdx
980	GRAMNEXUS0000000826.0007	Microsoft_Visio_Drawing2.vsdx
981	GRAMNEXUS0000000826.0008	Microsoft_Visio_Drawing4.vsdx
982	GRAMNEXUS0000000826.0009	Microsoft_Visio_Drawing8.vsdx
983	GRAMNEXUS0000000826.0010	Microsoft_Visio_Drawing7.vsdx
984	GRAMNEXUS0000000826.0011	Microsoft_Visio_Drawing6.vsdx
985	GRAMNEXUS0000000826.0012	Microsoft_Visio_Drawing5.vsdx
986	GRAMNEXUS0000000827	CORP-SOP-0074 Rev. 21(SAS)(CCH)1.docx
987	GRAMNEXUS0000000827.0001	Microsoft_Visio_Drawing10.vsdx
988	GRAMNEXUS0000000827.0002	Microsoft_Visio_Drawing11.vsdx
989	GRAMNEXUS0000000827.0003	Microsoft_Visio_Drawing9.vsdx
990	GRAMNEXUS0000000827.0004	Microsoft_Visio_Drawing3.vsdx
991	GRAMNEXUS0000000827.0005	Microsoft_Visio_Drawing2.vsdx
992	GRAMNEXUS0000000827.0006	Microsoft_Visio_Drawing.vsdx
993	GRAMNEXUS0000000827.0007	Microsoft_Visio_Drawing1.vsdx
994	GRAMNEXUS0000000827.0008	Microsoft_Visio_Drawing4.vsdx
995	GRAMNEXUS0000000827.0009	Microsoft_Visio_Drawing8.vsdx
996	GRAMNEXUS0000000827.0010	Microsoft_Visio_Drawing7.vsdx
997	GRAMNEXUS0000000827.0011	Microsoft_Visio_Drawing6.vsdx
998	GRAMNEXUS0000000827.0012	Microsoft_Visio_Drawing5.vsdx
999	GRAMNEXUS0000000828	CORP-SOP-0074 Rev. 21(SAS).docx
1000	GRAMNEXUS0000000828.0001	Microsoft_Visio_Drawing10.vsdx
1001	GRAMNEXUS0000000828.0002	Microsoft_Visio_Drawing11.vsdx
1002	GRAMNEXUS0000000828.0003	Microsoft_Visio_Drawing9.vsdx
1003	GRAMNEXUS0000000828.0004	Microsoft_Visio_Drawing3.vsdx
1004	GRAMNEXUS0000000828.0005	Microsoft_Visio_Drawing2.vsdx
1005	GRAMNEXUS0000000828.0006	Microsoft_Visio_Drawing.vsdx
1006	GRAMNEXUS0000000828.0007	Microsoft_Visio_Drawing1.vsdx
1007	GRAMNEXUS0000000828.0008	Microsoft_Visio_Drawing4.vsdx
1008	GRAMNEXUS0000000828.0009	Microsoft_Visio_Drawing8.vsdx
1009	GRAMNEXUS0000000828.0010	Microsoft_Visio_Drawing7.vsdx
1010	GRAMNEXUS0000000828.0011	Microsoft_Visio_Drawing6.vsdx
1011	GRAMNEXUS0000000828.0012	Microsoft_Visio_Drawing5.vsdx
1012	GRAMNEXUS0000000829	CORP-SOP-0074(SAS).docx
1013	GRAMNEXUS0000000829.0001	Microsoft_Visio_Drawing.vsdx
1014	GRAMNEXUS0000000830	CORP-SOP-0076 rev 17 (JLL)(SAS).docx
1015	GRAMNEXUS0000000831	CORP-SOP-0076 rev 17 (JLL)(SAS)1.docx
1016	GRAMNEXUS0000000832	CORP-SOP-0088 Use and Sanitization of the Microbiology Lab Hood(SAS).docx
1017	GRAMNEXUS0000000833	CORP-SOP-0088 Use and Sanitization of the Microbiology Lab HoodEWY8-17(SAS).docx
1018	GRAMNEXUS0000000834	CORP-SOP-0091 RCA 082118SAS.docx
1019	GRAMNEXUS0000000835	CORP-SOP-0091 RCA2.docx
1020	GRAMNEXUS0000000836	CORP-SOP-0093 Operation of the Drager Aerotest (SAS).docx
1021	GRAMNEXUS0000000836.0001	Microsoft_Visio_Drawing1.vsdx
1022	GRAMNEXUS0000000837	CORP-SOP-0097 Non-Viable Air Particulate Sampling v9.docx
1023	GRAMNEXUS0000000838	CORP-SOP-0098(SAS).docx

1024	GRAMNEXUS0000000839	CORP-SOP-0101 rev 05(SAS).docx
1025	GRAMNEXUS0000000840	CORP-SOP-0132 rev 09(SAS).docx
1026	GRAMNEXUS0000000841	CORP-SOP-0194 OMC GE Sievers 900 TOC Analyzer and Autosampler.docx
1027	GRAMNEXUS0000000842	CORP-SOP-0227 Population verification of Bioball Multishot-550 7-2-18(SAS).docx
1028	GRAMNEXUS0000000843	CORP-SOP-0236 Product Sampling-v08_10Dec2018(SAS).docx
1029	GRAMNEXUS0000000844	CORP-SOP-0249 Annual Requalification SOP Dynamic (JW).docx
1030	GRAMNEXUS0000000844.0001	Microsoft_Visio_Drawing14.vsdx
1031	GRAMNEXUS0000000844.0002	Microsoft_Visio_Drawing16.vsdx
1032	GRAMNEXUS0000000844.0003	Microsoft_Visio_Drawing15.vsdx
1033	GRAMNEXUS0000000844.0004	Microsoft_Visio_Drawing.vsdx
1034	GRAMNEXUS0000000844.0005	Microsoft_Visio_Drawing1.vsdx
1035	GRAMNEXUS0000000844.0006	Microsoft_Visio_Drawing2.vsdx
1036	GRAMNEXUS0000000844.0007	Microsoft_Visio_Drawing3.vsdx
1037	GRAMNEXUS0000000844.0008	Microsoft_Visio_Drawing4.vsdx
1038	GRAMNEXUS0000000844.0009	Microsoft_Visio_Drawing5.vsdx
1039	GRAMNEXUS0000000844.0010	Microsoft_Visio_Drawing6.vsdx
1040	GRAMNEXUS0000000844.0011	Microsoft_Visio_Drawing7.vsdx
1041	GRAMNEXUS0000000844.0012	Microsoft_Visio_Drawing8.vsdx
1042	GRAMNEXUS0000000844.0013	Microsoft_Visio_Drawing9.vsdx
1043	GRAMNEXUS0000000844.0014	Microsoft_Visio_Drawing10.vsdx
1044	GRAMNEXUS0000000844.0015	Microsoft_Visio_Drawing11.vsdx
1045	GRAMNEXUS0000000844.0016	Microsoft_Visio_Drawing12.vsdx
1046	GRAMNEXUS0000000844.0017	Microsoft_Visio_Drawing13.vsdx
1047	GRAMNEXUS0000000845	CORP-SOP-0249 Annual Requalification SOP v4.docx
1048	GRAMNEXUS0000000845.0001	Microsoft_Visio_Drawing2.vsdx
1049	GRAMNEXUS0000000845.0002	Microsoft_Visio_Drawing3.vsdx
1050	GRAMNEXUS0000000845.0003	Microsoft_Visio_Drawing4.vsdx
1051	GRAMNEXUS0000000845.0004	Microsoft_Visio_Drawing.vsdx
1052	GRAMNEXUS0000000845.0005	Microsoft_Visio_Drawing1.vsdx
1053	GRAMNEXUS0000000846	CORP-SOP-0249 DCR.docx
1054	GRAMNEXUS0000000847	CORP-SOP-0249_Annual Room Requal(SAS).docx
1055	GRAMNEXUS0000000847.0001	Microsoft_Visio_Drawing4.vsdx
1056	GRAMNEXUS0000000847.0002	Microsoft_Visio_Drawing.vsdx
1057	GRAMNEXUS0000000847.0003	Microsoft_Visio_Drawing3.vsdx
1058	GRAMNEXUS0000000847.0004	Microsoft_Visio_Drawing2.vsdx
1059	GRAMNEXUS0000000847.0005	Microsoft_Visio_Drawing1.vsdx
1060	GRAMNEXUS0000000848	CORP-SOP-0251 Rev 06.docx
1061	GRAMNEXUS0000000849	CORP-SOP-0290 Facility Start Up(SAS).docm
1062	GRAMNEXUS0000000850	CORP-SOP-0405 DCR.docx
1063	GRAMNEXUS0000000851	CORP-SOP-0405 Lab Cleaning v02.docm
1064	GRAMNEXUS0000000852	CORP-SOP-0405 R04.docm
1065	GRAMNEXUS0000000853	CORP-SOP-0432 R02.docx
1066	GRAMNEXUS0000000854	CORP-SOP-0464 rev 02.docx
1067	GRAMNEXUS0000000854.0001	Microsoft_Visio_Drawing.vsdx
1068	GRAMNEXUS0000000855	CORP-SOP-0549 DCR.docx
1069	GRAMNEXUS0000000856	CORP-SOP-0550 DCR.docx
1070	GRAMNEXUS0000000857	CORP-SOP-0554 Rabs Monitoring (2).docx
1071	GRAMNEXUS0000000857.0001	Microsoft_Visio_Drawing.vsdx
1072	GRAMNEXUS0000000857.0002	Microsoft_Visio_Drawing1.vsdx
1073	GRAMNEXUS0000000857.0003	Microsoft_Visio_Drawing2.vsdx
1074	GRAMNEXUS0000000857.0004	Microsoft_Visio_Drawing3.vsdx
1075	GRAMNEXUS0000000857.0005	Microsoft_Visio_Drawing4.vsdx
1076	GRAMNEXUS0000000858	CORP-SOP-0556 (GRAM).docx
1077	GRAMNEXUS0000000859	CORP-SOP-0562.docx
1078	GRAMNEXUS0000000859.0001	Microsoft_Visio_Drawing.vsdx
1079	GRAMNEXUS0000000860	CORP-SOP-0591 Compressed Gas Sampling at Butterworth SAS.docx
1080	GRAMNEXUS0000000861	CORP-SOP-0591 Compressed Gas Sampling at Butterworth.docx
1081	GRAMNEXUS0000000862	CORP-SOP-0591 DCR.docx
1082	GRAMNEXUS0000000863	CORP-SOP-0591 R02 DCR.docx
1083	GRAMNEXUS0000000864	CR-17-0671 Settling Plate Form V.2 SAS.docx
1084	GRAMNEXUS0000000865	CR-18-0926 EM SOP Rev. 21(SAS)(JLL)1.docx
1085	GRAMNEXUS0000000866	CR-18-0926 EM SOP Rev. 21(SAS).docx
1086	GRAMNEXUS0000000867	CR-18-1166.docx
1087	GRAMNEXUS0000000868	CR-20-0787 BI Strip.docx

1088	GRAMNEXUS0000000869	DCR Corp-frm-0044 Gowning Requalification Form Rev 8.docx
1089	GRAMNEXUS0000000870	DCR CORP-FRM-0139.docx
1090	GRAMNEXUS0000000871	DCR CORP-LOG-0187 12-6-19.docx
1091	GRAMNEXUS0000000872	DCR for CHM-0029.docx
1092	GRAMNEXUS0000000873	DCR for CORP-DS-0003.docx
1093	GRAMNEXUS0000000874	DCR for CORP-FRM-0022.docx
1094	GRAMNEXUS0000000875	DCR for CORP-FRM-0044.docx
1095	GRAMNEXUS0000000876	DCR For CORP-FRM-0045 R11.docx
1096	GRAMNEXUS0000000877	DCR For CORP-FRM-0046 R15 (JW)(JLL)(SAS).docx
1097	GRAMNEXUS0000000878	DCR For CORP-FRM-0046 R15.docx
1098	GRAMNEXUS0000000879	DCR for CORP-FRM-0055 rev 05.docx
1099	GRAMNEXUS0000000880	DCR for CORP-FRM-0055.docx
1100	GRAMNEXUS0000000881	DCR for CORP-FRM-0077.docx
1101	GRAMNEXUS0000000882	DCR For CORP-FRM-0247 R03 (JLL).docx
1102	GRAMNEXUS0000000883	DCR For CORP-FRM-0247 R03.docx
1103	GRAMNEXUS0000000884	DCR for CORP-FRM-0247.docx
1104	GRAMNEXUS0000000885	DCR for CORP-FRM-0273.docx
1105	GRAMNEXUS0000000886	DCR For CORP-FRM-0413 R05 (JLL)SAS.docx
1106	GRAMNEXUS0000000887	DCR For CORP-FRM-0413 R05.docx
1107	GRAMNEXUS0000000888	DCR for CORP-FRM-0413.docx
1108	GRAMNEXUS0000000889	DCR For CORP-FRM-0416 R02.docx
1109	GRAMNEXUS0000000890	DCR For CORP-FRM-0416 R03.docx
1110	GRAMNEXUS0000000891	DCR for CORP-FRM-0438 rev 04.docx
1111	GRAMNEXUS0000000892	DCR for CORP-FRM-0438.docx
1112	GRAMNEXUS0000000893	DCR For CORP-FRM-0466 R02.docx
1113	GRAMNEXUS0000000894	DCR For CORP-FRM-0468 R02.docx
1114	GRAMNEXUS0000000895	DCR for CORP-FRM-0523.docx
1115	GRAMNEXUS0000000896	DCR for CORP-FRM-0532.docx
1116	GRAMNEXUS0000000897	DCR for CORP-LOG-0014.docx
1117	GRAMNEXUS0000000898	DCR for CORP-LOG-0044.docx
1118	GRAMNEXUS0000000899	DCR for CORP-LOG-0046.docx
1119	GRAMNEXUS0000000900	DCR for CORP-LOG-0047.docx
1120	GRAMNEXUS0000000901	DCR for CORP-LOG-0053.docx
1121	GRAMNEXUS0000000902	DCR for CORP-LOG-0141 SAS.docx
1122	GRAMNEXUS0000000903	DCR for CORP-LOG-0141.docx
1123	GRAMNEXUS0000000904	DCR for CORP-LOG-0161.docx
1124	GRAMNEXUS0000000905	DCR for CORP-POL-0013.docx
1125	GRAMNEXUS0000000906	DCR for CORP-SOP-0010 1-30-20.docx
1126	GRAMNEXUS0000000907	DCR For CORP-SOP-0010.docx
1127	GRAMNEXUS0000000908	DCR for CORP-SOP-0027 rev 20.docx
1128	GRAMNEXUS0000000909	DCR for CORP-SOP-0027.docx
1129	GRAMNEXUS0000000910	DCR for CORP-SOP-0051.docx
1130	GRAMNEXUS0000000911	DCR for CORP-SOP-0073.docx
1131	GRAMNEXUS0000000912	DCR for CORP-SOP-0088.docx
1132	GRAMNEXUS0000000913	DCR for CORP-SOP-0093.docx
1133	GRAMNEXUS0000000914	DCR For CORP-SOP-0097 V09.docx
1134	GRAMNEXUS0000000915	DCR for CORP-SOP-0097.docx
1135	GRAMNEXUS0000000916	DCR for CORP-SOP-0098.docx
1136	GRAMNEXUS0000000917	DCR for CORP-SOP-0130 rev.docx
1137	GRAMNEXUS0000000918	DCR for CORP-SOP-0130.docx
1138	GRAMNEXUS0000000919	DCR for CORP-SOP-0194.docx
1139	GRAMNEXUS0000000920	DCR for CORP-SOP-0251.docx
1140	GRAMNEXUS0000000921	DCR for CORP-SOP-0405.docx
1141	GRAMNEXUS0000000922	DCR for CORP-SOP-0432 R03.docx
1142	GRAMNEXUS0000000923	DCR for CORP-SOP-0432.docx
1143	GRAMNEXUS0000000924	DCR for CORP-SOP-0464.docx
1144	GRAMNEXUS0000000925	DCR for CORP-SOP-0558.docx
1145	GRAMNEXUS0000000926	DCR for CORP-SOP-0608.docx
1146	GRAMNEXUS0000000927	DCR for GRAM-MTM-1000 6-29-18(sas).docx
1147	GRAMNEXUS0000000928	DCR for GRAM-TM-0001(SAS).docx
1148	GRAMNEXUS0000000929	DCR for GRAM-TM-0004 rev 08.docx
1149	GRAMNEXUS0000000930	DCR for GRAM-TM-0004.docx
1150	GRAMNEXUS0000000931	DCR for GRAM-TM-0010.docx
1151	GRAMNEXUS0000000932	DCR for GRAM-TM-0013.docx

1152	GRAMNEXUS0000000933	DCR for GRAM-TM-0016 (SAS).docx
1153	GRAMNEXUS0000000934	DCR for GRAM-TM-0016.docx
1154	GRAMNEXUS0000000935	DCR for GRAM-TM-0018 rev 05.docx
1155	GRAMNEXUS0000000936	DCR for GRAM-TM-0018.docx
1156	GRAMNEXUS0000000937	DCR for GRAM-TM-0026.docx
1157	GRAMNEXUS0000000938	DCR for GRAM-TM-0030.docx
1158	GRAMNEXUS0000000939	DCR for GS13077.docx
1159	GRAMNEXUS0000000940	DCR for MD11001.docx
1160	GRAMNEXUS0000000941	DCR For MD11013.docx
1161	GRAMNEXUS0000000942	DCR for MD13022.docx
1162	GRAMNEXUS0000000943	DCR for MDA17002.docx
1163	GRAMNEXUS0000000944	DCR for MDA19001.docx
1164	GRAMNEXUS0000000945	DCR for MDA19002 rev 02.docx
1165	GRAMNEXUS0000000946	DCR for MDA19002.docx
1166	GRAMNEXUS0000000947	DCR for MDA19003 rev 02.docx
1167	GRAMNEXUS0000000948	DCR for MDA19003.docx
1168	GRAMNEXUS0000000949	DCR for MDA19004 rev 02.docx
1169	GRAMNEXUS0000000950	DCR for MDA19004.docx
1170	GRAMNEXUS0000000951	DCR for MDA19005 rev 02.docx
1171	GRAMNEXUS0000000952	DCR for MDA19005.docx
1172	GRAMNEXUS0000000953	DCR for MDA19006.docx
1173	GRAMNEXUS0000000954	DCR for MDA20003.docx
1174	GRAMNEXUS0000000955	DCR for MDA20006.docx
1175	GRAMNEXUS0000000956	DCR for MDA20007.docx
1176	GRAMNEXUS0000000957	DCR for MDA20008.docx
1177	GRAMNEXUS0000000958	DCR for STA-0005-SUM.docx
1178	GRAMNEXUS0000000959	DCR for STA-0005.docx
1179	GRAMNEXUS0000000960	DCR for VAL-1141.docx
1180	GRAMNEXUS0000000961	DCR for VAL-1162-AD1-SUM.docx
1181	GRAMNEXUS0000000962	DCR for VAL-1162-AD1.docx
1182	GRAMNEXUS0000000963	DCR for VAL-1162-SUM.docx
1183	GRAMNEXUS0000000964	DCR for VAL-1162.docx
1184	GRAMNEXUS0000000965	DCR for VAL-1252.docx
1185	GRAMNEXUS0000000966	DCR for VAL-1378-SUM.docx
1186	GRAMNEXUS0000000967	DCR for VAL-1414.docx
1187	GRAMNEXUS0000000968	DCR for VAL-1617.docx
1188	GRAMNEXUS0000000969	DCR MDA18001 2-2-18 (SAS).docx
1189	GRAMNEXUS0000000970	DCR TM-0026 v7 SAS.docx
1190	GRAMNEXUS0000000971	DCRF GRAM-TM-0007 .docx
1191	GRAMNEXUS0000000972	de gown em.docx
1192	GRAMNEXUS0000000972.0001	Microsoft_Visio_Drawing.vsdx
1193	GRAMNEXUS0000000973	deviation blanket.vsdx
1194	GRAMNEXUS0000000974	Disinfectant Efficacy Final Report.pdf
1195	GRAMNEXUS0000000975	Disinfectant Efficacy Protocol.pdf
1196	GRAMNEXUS0000000976	Double Door Refrigerator URS(SAS).docm
1197	GRAMNEXUS0000000977	Draft Sterilizer SOP 051220 dm_eas comment.docx
1198	GRAMNEXUS0000000978	e coli MDA19005 rev 02.docx
1199	GRAMNEXUS0000000979	e coli MDA19005.docx
1200	GRAMNEXUS0000000980	Endotoxin URS(SAS).docx
1201	GRAMNEXUS0000000981	FPRS-0044_rev 02 (SAS).docx
1202	GRAMNEXUS0000000982	FPRS-0049 018-139A(RB)_Formatted(DWF)(SAS).docx
1203	GRAMNEXUS0000000983	FPRS-0049 sas.docx
1204	GRAMNEXUS0000000984	FPRS-0049, 018-139A, Template-0002 Rev4 Update (IDV) dw SAS.docx
1205	GRAMNEXUS0000000985	FPRS-0050 (SAS).docx
1206	GRAMNEXUS0000000986	FPRS-0064 rev 01(SAS).docx
1207	GRAMNEXUS0000000987	FPRS-0065_empty vial(SAS).docx
1208	GRAMNEXUS0000000988	FPRS-0068 rev 01(SAS).docx
1209	GRAMNEXUS0000000989	FPRS-0071_redline.docx
1210	GRAMNEXUS0000000990	FPRS-0073 rev 01 Draft.docx
1211	GRAMNEXUS0000000991	FPRS0004 010-117B Rev8 (2)(SAS).docx
1212	GRAMNEXUS0000000992	FPRS0004 010-117B Rev9 (SAS).docx
1213	GRAMNEXUS0000000993	FPRS0004 DCR Rev8(SAS).docx
1214	GRAMNEXUS0000000994	FPRS0006 Rev08 (2)(SAS).docx
1215	GRAMNEXUS0000000995	FPRS0021 rev 04 (SAS).docx

1216	GRAMNEXUS0000000996	FPRS0027, 014-121A, Template-0002, Rev4 dw(SAS).docx
1217	GRAMNEXUS0000000997	FPRS0031 rev 04 (SAS).docx
1218	GRAMNEXUS0000000998	gowning room EM.docx
1219	GRAMNEXUS0000000998.0001	Microsoft_Visio_Drawing.vsdx
1220	GRAMNEXUS0000000999	GRAM Vitek 2 Compact Analyst Qualification Form (1).docx
1221	GRAMNEXUS0000001000	GRAM Vitek 2 Compact Identification Result Form (1).docx
1222	GRAMNEXUS0000001001	GRAM Vitek 2 Compact QC Card Release Form.docx
1223	GRAMNEXUS0000001002	GRAM-MTM-1000 7-2-18 (SAS)_.docx
1224	GRAMNEXUS0000001002.0001	Microsoft_Visio_Drawing.vsdx
1225	GRAMNEXUS0000001002.0001.0001	Microsoft_Word_Document.docx
1226	GRAMNEXUS0000001003	GRAM-TM-0001 5-22(SAS)(JLL)rev.docx
1227	GRAMNEXUS0000001004	GRAM-TM-0001 5-22(SAS).docx
1228	GRAMNEXUS0000001005	GRAM-TM-0001 6-29-18(SAS).docx
1229	GRAMNEXUS0000001006	GRAM-TM-0004 SAS (CCH) 1.docx
1230	GRAMNEXUS0000001007	GRAM-TM-0004 SAS.docx
1231	GRAMNEXUS0000001008	GRAM-TM-0004(SAS).docx
1232	GRAMNEXUS0000001009	GRAM-TM-0010 TOC Analysis of WFI and Pure Steam-1.docx
1233	GRAMNEXUS0000001010	GRAM-TM-0010 TOC Analysis of WFI and Pure Steam.docx
1234	GRAMNEXUS0000001011	GRAM-TM-0011 5-23(SAS).docx
1235	GRAMNEXUS0000001012	GRAM-TM-0012 DCR.docx
1236	GRAMNEXUS0000001013	GRAM-TM-0012 Microbial Count of Water Samples (JW).docx
1237	GRAMNEXUS0000001014	GRAM-TM-0013 11May18 (SAS).docx
1238	GRAMNEXUS0000001015	GRAM-TM-0016 (SAS).docx
1239	GRAMNEXUS0000001016	GRAM-TM-0016 Revision 10 SAS (CCH) 1.docx
1240	GRAMNEXUS0000001017	GRAM-TM-0016 Revision 10 SAS.docx
1241	GRAMNEXUS0000001018	GRAM-TM-0018 Conductivity in Bulk Water (SAS).docx
1242	GRAMNEXUS0000001019	GRAM-TM-0018 Conductivity in Bulk Water rev 05.docx
1243	GRAMNEXUS0000001020	GRAM-TM-0018.docx
1244	GRAMNEXUS0000001021	GRAM-TM-0026 SAS.docx
1245	GRAMNEXUS0000001022	GRAM-TM-0043 (SAS).docx
1246	GRAMNEXUS0000001023	GRAM-TM-0065 Bioburden Validation.docm
1247	GRAMNEXUS0000001024	GS13077 (SAS).docx
1248	GRAMNEXUS0000001025	GS13077 new temp.docx
1249	GRAMNEXUS0000001026	GxP Assessment Particle Counter-1.docx
1250	GRAMNEXUS0000001027	Incubator URS VAL-1432(SAS).docm
1251	GRAMNEXUS0000001028	IOQ Protocol - TOC -jsg-11-11-19 formated (SAS).docx
1252	GRAMNEXUS0000001029	LAB-LOG-118B Microbiology Lab Sanitization Check Log (SAS).docx
1253	GRAMNEXUS0000001030	LpH prep Log.docm
1254	GRAMNEXUS0000001031	Machinability Study - VAL-1698 BS Fill Line 6R Container 061620(SAS).docx
1255	GRAMNEXUS0000001032	Material Specification Template SAB DEX.docx
1256	GRAMNEXUS0000001033	Material Specification Template.docx
1257	GRAMNEXUS0000001034	MD11013.docx
1258	GRAMNEXUS0000001035	MD13020(SAS).docx
1259	GRAMNEXUS0000001036	MD13020(SAS1).docx
1260	GRAMNEXUS0000001037	MD13022 2-11-19.docx
1261	GRAMNEXUS0000001038	MD13022 2-21-19.docx
1262	GRAMNEXUS0000001039	MD13022 Specification.docx
1263	GRAMNEXUS0000001040	MD13024 (SAS).docx
1264	GRAMNEXUS0000001041	MDA17001_Geobacillus(SAS).docx
1265	GRAMNEXUS0000001042	MDA17002 400 ml.docx
1266	GRAMNEXUS0000001043	MDA17002_TSA Pour Plate(SAS).docx
1267	GRAMNEXUS0000001044	MDA17003_SDA Pour Plate(SAS).docx
1268	GRAMNEXUS0000001045	MDA18001Mini Spore StripsEWY2-2-18.1(SAS).docx
1269	GRAMNEXUS0000001046	MDA19001.docx
1270	GRAMNEXUS0000001047	MDA19001SAS.docx
1271	GRAMNEXUS0000001048	MDA19006 SDA with Anti (JLL)(SAS).docx
1272	GRAMNEXUS0000001049	MDA19006 SDA with Anti Rev.docx
1273	GRAMNEXUS0000001050	MDA19006 SDA with Anti.docx
1274	GRAMNEXUS0000001051	MDA20004.docx
1275	GRAMNEXUS0000001052	MDA20006.docx
1276	GRAMNEXUS0000001053	MDA20007.docx
1277	GRAMNEXUS0000001054	MDA20008.docx
1278	GRAMNEXUS0000001055	MET ONE 3400 Portable Air Particle Counter.docx
1279	GRAMNEXUS0000001056	Micro ID Log 12-5-19.docm

1280	GRAMNEXUS0000001057	Micro ID System URS(SAS).docm
1281	GRAMNEXUS0000001058	Nitrates Form(SAS).docm
1282	GRAMNEXUS0000001059	Nitrates TM (1) CK(SAS).docx
1283	GRAMNEXUS0000001059.0001	Microsoft_Visio_Drawing1.vsdx
1284	GRAMNEXUS0000001059.0001.0001	Microsoft_Word_Document.docx
1285	GRAMNEXUS0000001060	Nitrates TM (1) CK(SAS)IVO.docx
1286	GRAMNEXUS0000001060.0001	Microsoft_Visio_Drawing1.vsdx
1287	GRAMNEXUS0000001060.0001.0001	Microsoft_Word_Document.docx
1288	GRAMNEXUS0000001061	p aeruginosa MDA19002 rev 02.docx
1289	GRAMNEXUS0000001062	p aeruginosa MDA19002.docx
1290	GRAMNEXUS0000001063	pH Meter URS val-1417(SAS).docm
1291	GRAMNEXUS0000001064	PQ Protocol - OVN Tunnel 20_04-29.docx
1292	GRAMNEXUS0000001065	RABS Bird's Eye View.vsdx
1293	GRAMNEXUS0000001066	Rev CORP-FRM-0138 Media Growth Promotion Form DE VJ (change after Sherri comments).docx
1294	GRAMNEXUS0000001067	s aureus MDA19004 rev 02.docx
1295	GRAMNEXUS0000001068	s aureus MDA19004.docx
1296	GRAMNEXUS0000001069	Settling Plate Form V.2.docx
1297	GRAMNEXUS0000001070	Single Door Fridge URS(SAS).docm
1298	GRAMNEXUS0000001071	SOP OMC M9 TOC.docx
1299	GRAMNEXUS0000001072	STA-0005 Approval.pdf
1300	GRAMNEXUS0000001073	STA-0005 In-Use Micro final(SAS)(JH)BB.docx
1301	GRAMNEXUS0000001074	STA-0005 In-Use Micro final.docx
1302	GRAMNEXUS0000001075	STA-0005-SUM Final.docm
1303	GRAMNEXUS0000001076	STA-0005-SUM.docm
1304	GRAMNEXUS0000001077	STA-0005_in USE micro growth stability report for T0 time_approved page.pdf
1305	GRAMNEXUS0000001078	STP-0006 V02(SAS).docx
1306	GRAMNEXUS0000001079	STP-0007 V03(SAS).docx
1307	GRAMNEXUS0000001080	STP-0008 v04(SAS).docx
1308	GRAMNEXUS0000001081	STP-0022 v01 Final.docx
1309	GRAMNEXUS0000001082	STP-0022 v01c.docx
1310	GRAMNEXUS0000001083	Syring Filler Study report(SAS).docm
1311	GRAMNEXUS0000001084	Syringe Filler Disinfection Validation(SAS).docm
1312	GRAMNEXUS0000001085	Syringe Filler EM Protocol - DP.docm
1313	GRAMNEXUS0000001086	Syringe Filler EM Protocol.docm
1314	GRAMNEXUS0000001087	Template-0014 rev 03.docx
1315	GRAMNEXUS0000001088	Template-0017 rev 03 (SAS).docx
1316	GRAMNEXUS0000001089	Testosterone Enanthate API-0032(SAS).docx
1317	GRAMNEXUS0000001090	transition room em.docx
1318	GRAMNEXUS0000001090.0001	Microsoft_Visio_Drawing.vsdx
1319	GRAMNEXUS0000001091	TSA storage.pdf
1320	GRAMNEXUS0000001092	VAL-1093 (SAS).docx
1321	GRAMNEXUS0000001093	VAL-1094 Validation Template-1 EWY 7-17-18(SAS)_.docm
1322	GRAMNEXUS0000001094	VAL-1141 Settling Plate Exposure study SAS.docm
1323	GRAMNEXUS0000001095	VAL-1141 Settling Plate Exposure study summary.docm
1324	GRAMNEXUS0000001096	VAL-1141 Sum Settling Plates.docm
1325	GRAMNEXUS0000001097	VAL-1155-SUM SAS.docm
1326	GRAMNEXUS0000001098	VAL-1160-SUM sas.docx
1327	GRAMNEXUS0000001099	VAL-1162-AD1 DE Additional Surface Testing for Grand River Protocol.pdf
1328	GRAMNEXUS0000001100	VAL-1162-SUM AD1 DE Additional Surface Testing for Grand River Final Report.pdf
1329	GRAMNEXUS0000001101	VAL-1173 - 2018 (1)(SAS).docm
1330	GRAMNEXUS0000001102	VAL-1173 - 2018 (SAS).docm
1331	GRAMNEXUS0000001103	VAL-1173 rev 01(SAS).docm
1332	GRAMNEXUS0000001104	VAL-1173-SUM(SAS).docm
1333	GRAMNEXUS0000001105	VAL-1199 ASB 01_19_18 SAS.docx
1334	GRAMNEXUS0000001106	VAL-1229 - 2018 (SAS).docm
1335	GRAMNEXUS0000001107	VAL-1229-SUM 9-24-18(SAS).docm
1336	GRAMNEXUS0000001108	VAL-1252 Summary Report (SAS).docx
1337	GRAMNEXUS0000001109	VAL-1252 Summary Report (SAS)bb fix.docx
1338	GRAMNEXUS0000001110	VAL-1343 WFI System URS (CAM)(SAS)(SCN).docx
1339	GRAMNEXUS0000001111	VAL-1343 WFI System URS (CAM)(SAS).docx
1340	GRAMNEXUS0000001112	VAL-1352 (URS for Clean Compressed Air) SAS.docm
1341	GRAMNEXUS0000001113	VAL-1352 (URS for Clean Compressed Air)(sas).docm
1342	GRAMNEXUS0000001114	VAL-1363-SUM(BS)(SAS).docm

1343	GRAMNEXUS0000001115	VAL-1383 SAS.docm
1344	GRAMNEXUS0000001116	VAL-1383-SUM(SAS).docm
1345	GRAMNEXUS0000001117	VAL-1393 Validation Template-Rev 01 SAS Particulate reader db(SAS).docm
1346	GRAMNEXUS0000001118	VAL-1393-SUM Validation Template-Rev 01(SAS).docm
1347	GRAMNEXUS0000001119	VAL-1394-SUM Validation Template-Rev 01(SAS).docm
1348	GRAMNEXUS0000001120	VAL-1476 DCR (Media Fill GP).docx
1349	GRAMNEXUS0000001121	VAL-1476-SUM(sas)(JLL).docm
1350	GRAMNEXUS0000001122	VAL-1617-SUM DCR.docx
1351	GRAMNEXUS0000001123	VAL-1644 Butterworth CCA PQ.docx
1352	GRAMNEXUS0000001124	VAL-1645 Butterworth Nitrogen PQ.docx
1353	GRAMNEXUS0000001125	VAL-1658 Micro ID IOPQ.docx
1354	GRAMNEXUS0000001126	VAL-1791_v01b Protocol.docx
1355	GRAMNEXUS0000001127	VAL-1800 Media Fill Protocol Template Rev 3(SAS).docx
1356	GRAMNEXUS0000001128	VAL-1812 DCR.docx
1357	GRAMNEXUS0000001129	VAL-1817 DCR.docx
1358	GRAMNEXUS0000001130	VAL-1817 Butterworth Isolator EMPQ.docx
1359	GRAMNEXUS0000001131	VAL-PPQ-0414 009-115B including split batch(RB)(SAS).docx
1360	GRAMNEXUS0000001132	WD Form.docm
1361	GRAMNEXUS0000001133	Weigh Dispense EMPQ(SAS).docx
1362	GRAMNEXUS0000001133.0001	Microsoft_Visio_Drawing.vsdx
1363	GRAMNEXUS0000001133.0002	Microsoft_Visio_Drawing1.vsdx
1364	GRAMNEXUS0000001133.0003	Microsoft_Visio_Drawing2.vsdx
1365	GRAMNEXUS0000001133.0004	Microsoft_Visio_Drawing3.vsdx
1366	GRAMNEXUS0000001133.0005	Microsoft_Visio_Drawing4.vsdx
1367	GRAMNEXUS0000001133.0006	Microsoft_Visio_Drawing5.vsdx
1368	GRAMNEXUS0000001133.0007	Microsoft_Visio_Drawing6.vsdx
1369	GRAMNEXUS0000001133.0008	Microsoft_Visio_Drawing7.vsdx
1370	GRAMNEXUS0000001134	Weigh Dispense EMPQ.docx
1371	GRAMNEXUS0000001134.0001	Microsoft_Visio_Drawing5.vsdx
1372	GRAMNEXUS0000001134.0002	Microsoft_Visio_Drawing.vsdx
1373	GRAMNEXUS0000001134.0003	Microsoft_Visio_Drawing1.vsdx
1374	GRAMNEXUS0000001134.0004	Microsoft_Visio_Drawing2.vsdx
1375	GRAMNEXUS0000001134.0005	Microsoft_Visio_Drawing3.vsdx
1376	GRAMNEXUS0000001134.0006	Microsoft_Visio_Drawing4.vsdx
1377	GRAMNEXUS0000001134.0007	Microsoft_Visio_Drawing6.vsdx
1378	GRAMNEXUS0000001134.0008	Microsoft_Visio_Drawing7.vsdx
1379	GRAMNEXUS0000001135	WFI NF Mono.pdf
1380	GRAMNEXUS0000001136	WFI NF Monograph.pdf
1381	GRAMNEXUS0000001137	~$-18-0926 EM SOP Rev. 21(SAS).docx
1382	GRAMNEXUS0000001138	~$igh Dispense EMPQ.docx
1383	GRAMNEXUS0000001139	~$RP-SOP-0074 Rev. 21(SAS).docx
1384	GRAMNEXUS0000001140	~WRL0001.tmp
1385	GRAMNEXUS0000001141	~WRL1186.tmp
1386	GRAMNEXUS0000001142	~WRL3264.tmp
1387	GRAMNEXUS0000001143	BD SabDex with Chloramphenicol.pdf
1388	GRAMNEXUS0000001144	CC 17-0019 Assessment QC.docx
1389	GRAMNEXUS0000001145	CC 17-0029 Assessment.docx
1390	GRAMNEXUS0000001146	CC Initiation for CHM-0004.docm
1391	GRAMNEXUS0000001147	CC-0028 Micro.docx
1392	GRAMNEXUS0000001148	CC-0037 Micro.docx
1393	GRAMNEXUS0000001149	CC-0043 Micro.docx
1394	GRAMNEXUS0000001150	CC-0045 Micro.docx
1395	GRAMNEXUS0000001151	cc-0055 docs.xlsx
1396	GRAMNEXUS0000001152	CC-0055 Micro.docx
1397	GRAMNEXUS0000001153	CC-0071 QC Micro assessment(SAS).docx
1398	GRAMNEXUS0000001154	CC-0072 Micro.docx
1399	GRAMNEXUS0000001155	CC-0073 Micro.docx
1400	GRAMNEXUS0000001156	CC-0105 Micro Assessment.docx
1401	GRAMNEXUS0000001157	CC-0107 Micro.docx
1402	GRAMNEXUS0000001158	CC-0115 Micro.docx
1403	GRAMNEXUS0000001159	CC-0125 Micro.docx
1404	GRAMNEXUS0000001160	CC-0146 Micro.docx
1405	GRAMNEXUS0000001161	CC-0151 Micro.docx
1406	GRAMNEXUS0000001162	CC-0155 Micro Assessment.docx

1407	GRAMNEXUS0000001163	CC-0155 Micro Assessment_KEL_CK_SAS.docx
1408	GRAMNEXUS0000001164	CC-0159 Micro.docx
1409	GRAMNEXUS0000001165	CC-0160 Micro.docx
1410	GRAMNEXUS0000001166	CC-0175 Scope (SAS).docx
1411	GRAMNEXUS0000001167	CC-0177 Micro assessment.docx
1412	GRAMNEXUS0000001168	CC-0177 Micro.docx
1413	GRAMNEXUS0000001169	CC-0184 Micro assessment.docx
1414	GRAMNEXUS0000001170	CC-0198 Micro assessment.docx
1415	GRAMNEXUS0000001171	CC-0237 Micro Assessment.docx
1416	GRAMNEXUS0000001172	CC-0248 Micro Assessment.docx
1417	GRAMNEXUS0000001173	CC-0252 Micro Assessment.docx
1418	GRAMNEXUS0000001174	CC-0253 Micro.docx
1419	GRAMNEXUS0000001175	CC-0255 Micro Assessment rev 1.docx
1420	GRAMNEXUS0000001176	CC-0255 Micro Assessment.docx
1421	GRAMNEXUS0000001177	CC-0263 Micro Assessment.docx
1422	GRAMNEXUS0000001178	CC-0271 Micro.docx
1423	GRAMNEXUS0000001179	CC-0278 Micro.docx
1424	GRAMNEXUS0000001180	CC-0281 Micro.docx
1425	GRAMNEXUS0000001181	CC-0285 Micro.docx
1426	GRAMNEXUS0000001182	CC-17-0015 micro assessment.docx
1427	GRAMNEXUS0000001183	CC-17-0015 micro assessment.pdf
1428	GRAMNEXUS0000001184	CC-17-0020 Implementation.docx
1429	GRAMNEXUS0000001185	CC-17-0020 Plan.docx
1430	GRAMNEXUS0000001186	CC-17-0034 micro assessment.docx
1431	GRAMNEXUS0000001187	CC-17-0043 micro assessment.docx
1432	GRAMNEXUS0000001188	CC-17-0054 micro assessment.docx
1433	GRAMNEXUS0000001189	CC-17-0055 micro assessment.docx
1434	GRAMNEXUS0000001190	CC-17-0056 micro assessment.docx
1435	GRAMNEXUS0000001191	CC-17-0057 micro assessment.docx
1436	GRAMNEXUS0000001192	CC-17-0058 micro assessment.docx
1437	GRAMNEXUS0000001193	CC-17-0060 micro assessment.docx
1438	GRAMNEXUS0000001194	CC-17-0061 micro assessment.docx
1439	GRAMNEXUS0000001195	CC-17-0063 micro assessment.docx
1440	GRAMNEXUS0000001196	CC-17-0065 micro assessment.docx
1441	GRAMNEXUS0000001197	CC-17-0071 micro assessment.docx
1442	GRAMNEXUS0000001198	CC-17-0080 micro assessment.docx
1443	GRAMNEXUS0000001199	CC-17-0090 micro assessment.docx
1444	GRAMNEXUS0000001200	CC-17-0109 micro assessment.docx
1445	GRAMNEXUS0000001201	CC-18-0011 micro assessment.docx
1446	GRAMNEXUS0000001202	CC-18-0011 micro assessment.pdf
1447	GRAMNEXUS0000001203	CC-18-0018 micro assessment.docx
1448	GRAMNEXUS0000001204	CC-18-0018 micro assessment.pdf
1449	GRAMNEXUS0000001205	ChangeControl cc-17-0006 sterility.docx
1450	GRAMNEXUS0000001206	ChangeControl Plan 17-0059.docx
1451	GRAMNEXUS0000001207	ChangeControl_170003.docx
1452	GRAMNEXUS0000001208	ChangeControl_Template-0051.docx
1453	GRAMNEXUS0000001209	ChangeControl_Template-0053 for endo.docx
1454	GRAMNEXUS0000001210	ChangeControl_Template-0055 implementation.docx
1455	GRAMNEXUS0000001211	CHM-0050 BB.pdf
1456	GRAMNEXUS0000001212	CHM-0050 Endo.pdf
1457	GRAMNEXUS0000001213	Compressed Air Testing CC -micro assessment.docx
1458	GRAMNEXUS0000001214	CORP-FRM-0273 APA Operator Qual.docx
1459	GRAMNEXUS0000001215	DCR-CORP-SOP-0556.docx
1460	GRAMNEXUS0000001216	Endotoxin Screen CC request.docm
1461	GRAMNEXUS0000001217	Nitrate CC.docm
1462	GRAMNEXUS0000001218	Scope for CC-0175 10-25-19(SAS).docx
1463	GRAMNEXUS0000001219	~$ 17-0019 Assessment QC.docx
1464	GRAMNEXUS0000001220	~$trate CC.docm
1465	GRAMNEXUS0000001221	006-150A Endo 1.docx
1466	GRAMNEXUS0000001222	006-150A Endo 2.docx
1467	GRAMNEXUS0000001223	006-150A Endo 3.docx
1468	GRAMNEXUS0000001224	006-150A Endo Dev.docx
1469	GRAMNEXUS0000001225	API-0023 lot ADEN131-1R BB.docx
1470	GRAMNEXUS0000001226	API-0023 lot ADEN131-1R endo.docx

1471	GRAMNEXUS0000001227	API-0030 CofA's.pdf
1472	GRAMNEXUS0000001228	API-0030 Endo 1.docx
1473	GRAMNEXUS0000001229	API-0030 Endo 2.docx
1474	GRAMNEXUS0000001230	API-0030 lot 4001-3-009-18 BB.docx
1475	GRAMNEXUS0000001231	API-0030 lot 4001-3-010-18 BB.docx
1476	GRAMNEXUS0000001232	Bioburden CofA Template.docx
1477	GRAMNEXUS0000001233	CHM-0007 endo val data.pdf
1478	GRAMNEXUS0000001234	CHM-0016 lot K48111957 BB.docx
1479	GRAMNEXUS0000001235	CHM-0016 lot K48111957 BB.pdf
1480	GRAMNEXUS0000001236	CofA example.docx
1481	GRAMNEXUS0000001237	Endotoxin CofA Template.docx
1482	GRAMNEXUS0000001238	010-117 lot A-17-008 BB.docx
1483	GRAMNEXUS0000001239	010-117 lot L-16-094 BB.docx
1484	GRAMNEXUS0000001240	010-117 lot L-16-096 BB.docx
1485	GRAMNEXUS0000001241	010-117A-B lot A-17-008 BB.pdf
1486	GRAMNEXUS0000001242	010-117A-B lot L-16-094 BB.pdf
1487	GRAMNEXUS0000001243	010-117A-B lot L-16-096 BB.pdf
1488	GRAMNEXUS0000001244	010-140A lot B-18-021 BB 2.docx
1489	GRAMNEXUS0000001245	010-140A lot B-18-021 BB2.pdf
1490	GRAMNEXUS0000001246	010-140A lot B-18-021 endo 3.docx
1491	GRAMNEXUS0000001247	010-140A lot B-18-021 Endo-3.pdf
1492	GRAMNEXUS0000001248	010-140A lot B-18-022 BB 3.docx
1493	GRAMNEXUS0000001249	010-140A lot B-18-022 BB3.pdf
1494	GRAMNEXUS0000001250	010-140A lot J-17-091 BB 1.docx
1495	GRAMNEXUS0000001251	010-140A lot J-17-091 BB1.pdf
1496	GRAMNEXUS0000001252	010-140A lot J-17-091 endo 1.docx
1497	GRAMNEXUS0000001253	010-140A lot J-17-091 Endo-1.pdf
1498	GRAMNEXUS0000001254	010-140A lot K-17-098 endo 2.docx
1499	GRAMNEXUS0000001255	010-140A lot K-17-098 Endo-2.pdf
1500	GRAMNEXUS0000001256	API-0008 lot 533310 BB.docx
1501	GRAMNEXUS0000001257	API-0008 lot S33310 BB.pdf
1502	GRAMNEXUS0000001258	API-0008 lot S87192 BB.docx
1503	GRAMNEXUS0000001259	API-0008 lot S87192 BB.pdf
1504	GRAMNEXUS0000001260	API-0008 lot T19863 BB.docx
1505	GRAMNEXUS0000001261	API-0008 lot T19863 BB.pdf
1506	GRAMNEXUS0000001262	API-0024 ZHPCy17001 BB.docx
1507	GRAMNEXUS0000001263	API-0024 ZHPCy17001 endo-1.docx
1508	GRAMNEXUS0000001264	API-0024 ZHPCy17003 BB.docx
1509	GRAMNEXUS0000001265	API-0024 ZHPCy17003 endo - 2.docx
1510	GRAMNEXUS0000001266	API-0024 ZHPCy17004 BB.docx
1511	GRAMNEXUS0000001267	API-0024 ZHPCy17004 BB.pdf
1512	GRAMNEXUS0000001268	API-0024 ZHPCy17004 endo - 3.docx
1513	GRAMNEXUS0000001269	CH14027 lot 0130-0696 BB.docx
1514	GRAMNEXUS0000001270	CH14027 lot 0130-0705 BB.docx
1515	GRAMNEXUS0000001271	CH14027 lot 0130-0705 BB.pdf
1516	GRAMNEXUS0000001272	CH14027 lot 0130-0711 BB.docx
1517	GRAMNEXUS0000001273	CH14027 lot 0130-0711BB.pdf
1518	GRAMNEXUS0000001274	CH14027 lot 0130-0712 BB.docx
1519	GRAMNEXUS0000001275	CH14027 lot 0130-0712BB.pdf
1520	GRAMNEXUS0000001276	012-119A I-17-088 BB.pdf
1521	GRAMNEXUS0000001277	012-119A I-17-089 BB.pdf
1522	GRAMNEXUS0000001278	012-119A I-17-090 BB.pdf
1523	GRAMNEXUS0000001279	012-119A lot I-17-088 BB.docx
1524	GRAMNEXUS0000001280	012-119A lot I-17-089 BB.docx
1525	GRAMNEXUS0000001281	012-119A lot I-17-090 BB.docx
1526	GRAMNEXUS0000001282	012-119A lot K-16-087.docx
1527	GRAMNEXUS0000001283	018-131A DEMDEV-JK08-04.pdf
1528	GRAMNEXUS0000001284	018-131A lot C-17-018 BB.docx
1529	GRAMNEXUS0000001285	018-131A lot C-17-018.pdf
1530	GRAMNEXUS0000001286	018-131A lot Client Batch DEMDEV-JK08-04 BB.docx
1531	GRAMNEXUS0000001287	018-136A GRAM lab batch BB.docx
1532	GRAMNEXUS0000001288	018-136A GRAM Lab Batch BB.pdf
1533	GRAMNEXUS0000001289	018-139A GRAM lab batch BB.docx
1534	GRAMNEXUS0000001290	018-139A Lab Batch BB.pdf

1535	GRAMNEXUS0000001291	API-0018 lot 1510001693 BB.docx
1536	GRAMNEXUS0000001292	API-0018 lot 1510001693.pdf
1537	GRAMNEXUS0000001293	API-0020 lot 4007200416 BB.docx
1538	GRAMNEXUS0000001294	API-0020 lot 4007200416 BB.pdf
1539	GRAMNEXUS0000001295	API-0022 lot 15100350 BB v02.docx
1540	GRAMNEXUS0000001296	API-0022 lot 15100350 BB v02.pdf
1541	GRAMNEXUS0000001297	API-0022 lot 151350 BB.docx
1542	GRAMNEXUS0000001298	API-0022 lot 151350 BB.pdf
1543	GRAMNEXUS0000001299	019-134A client batch 8216500001 BB.docx
1544	GRAMNEXUS0000001300	019-134A client batch 8216500001.pdf
1545	GRAMNEXUS0000001301	019-135A client batch 8219100001 BB.docx
1546	GRAMNEXUS0000001302	019-135A client batch 8219100001.pdf
1547	GRAMNEXUS0000001303	020-132A C-17-020 endo - 2.pdf
1548	GRAMNEXUS0000001304	020-132A C-17-020 endo V02 - 2.pdf
1549	GRAMNEXUS0000001305	020-132A Client Batch endo - 1.pdf
1550	GRAMNEXUS0000001306	020-132A Client Batch endo V02 - 1.pdf
1551	GRAMNEXUS0000001307	020-132A Endo C-17-020 V02-2.docx
1552	GRAMNEXUS0000001308	020-132A Endo C-17-020 V02.docx
1553	GRAMNEXUS0000001309	020-132A Endo C-17-020.docx
1554	GRAMNEXUS0000001310	020-132A Endo client batch V02-1.docx
1555	GRAMNEXUS0000001311	020-132A Endo client batch.docx
1556	GRAMNEXUS0000001312	020-132A Endo I-17-077 - 3.docx
1557	GRAMNEXUS0000001313	020-132A Endo I-17-077 V02 - 3.docx
1558	GRAMNEXUS0000001314	020-132A Endo I-17-078 routine.docx
1559	GRAMNEXUS0000001315	020-132A Endo I-17-078 V02 routine.docx
1560	GRAMNEXUS0000001316	020-132A Endo I-17-079 routine.docx
1561	GRAMNEXUS0000001317	020-132A Endo I-17-079 V02 routine.docx
1562	GRAMNEXUS0000001318	020-132A I-17-078 routine V02.pdf
1563	GRAMNEXUS0000001319	020-132A I-17-078 routine.pdf
1564	GRAMNEXUS0000001320	020-132A I-17-079 routine V02.pdf
1565	GRAMNEXUS0000001321	020-132A I-17-079 routine.pdf
1566	GRAMNEXUS0000001322	020-132A lot C-17-020 BB V02.docx
1567	GRAMNEXUS0000001323	020-132A lot C-17-020 BB V02.pdf
1568	GRAMNEXUS0000001324	020-132A lot C-17-020 BB.docx
1569	GRAMNEXUS0000001325	020-132A lot C-17-020 BB.pdf
1570	GRAMNEXUS0000001326	020-132A lot I-17-077 BB V02.docx
1571	GRAMNEXUS0000001327	020-132A lot I-17-077 BB V02.pdf
1572	GRAMNEXUS0000001328	020-132A lot I-17-077 BB.docx
1573	GRAMNEXUS0000001329	020-132A lot I-17-077 BB.pdf
1574	GRAMNEXUS0000001330	020-132A lot I-17-077 endo - 3.pdf
1575	GRAMNEXUS0000001331	020-132A lot I-17-077 endo V02- 3.pdf
1576	GRAMNEXUS0000001332	020-132A lot I-17-078 BB V02.docx
1577	GRAMNEXUS0000001333	020-132A lot I-17-078 BB V02.pdf
1578	GRAMNEXUS0000001334	020-132A lot I-17-078 BB.docx
1579	GRAMNEXUS0000001335	020-132A lot I-17-078 BB.pdf
1580	GRAMNEXUS0000001336	020-132A lot I-17-079 BB V02.docx
1581	GRAMNEXUS0000001337	020-132A lot I-17-079 BB V02.pdf
1582	GRAMNEXUS0000001338	020-132A lot I-17-079 BB.docx
1583	GRAMNEXUS0000001339	020-132A lot I-17-079 BB.pdf
1584	GRAMNEXUS0000001340	API-0019 1610001478 BB.pdf
1585	GRAMNEXUS0000001341	API-0019 1610001478 endo2.pdf
1586	GRAMNEXUS0000001342	API-0019 1610001478 V02 BB.pdf
1587	GRAMNEXUS0000001343	API-0019 1610001526 BB.pdf
1588	GRAMNEXUS0000001344	API-0019 1610001526 endo1.pdf
1589	GRAMNEXUS0000001345	API-0019 lot 1510000907 endo.docx
1590	GRAMNEXUS0000001346	API-0019 lot 1510000907 endo.pdf
1591	GRAMNEXUS0000001347	API-0019 lot 1610001478 BB V02.docx
1592	GRAMNEXUS0000001348	API-0019 lot 1610001478 BB.docx
1593	GRAMNEXUS0000001349	API-0019 lot 1610001478 endo.docx
1594	GRAMNEXUS0000001350	API-0019 lot 1610001526 BB.docx
1595	GRAMNEXUS0000001351	API-0019 lot 1610001526 endo.docx
1596	GRAMNEXUS0000001352	API-0019 lot 1610002217 BB.docx
1597	GRAMNEXUS0000001353	API-0019 lot 1610002217 BB.pdf
1598	GRAMNEXUS0000001354	020-148B lot I-18-095 BB.docx

1599	GRAMNEXUS0000001355	020-148B lot L-18-124 BB.docx
1600	GRAMNEXUS0000001356	020-148B lot L-18-125 BB.docx
1601	GRAMNEXUS0000001357	API-0026 lot 101-18-013 BB-1.pdf
1602	GRAMNEXUS0000001358	API-0026 lot 101-18-013 endo-1.docx
1603	GRAMNEXUS0000001359	API-0026 lot 101-18-013 endo-1.pdf
1604	GRAMNEXUS0000001360	API-0026 lot 101-18-13 BB-1.docx
1605	GRAMNEXUS0000001361	024-142A BB data.pdf
1606	GRAMNEXUS0000001362	024-142A Endo lot 122215B.docx
1607	GRAMNEXUS0000001363	024-142A Endo lot E-18-051 (2).docx
1608	GRAMNEXUS0000001364	024-142A Endo lot E-18-052 (3).docx
1609	GRAMNEXUS0000001365	024-142A IP Bioburden - 3 lots.pdf
1610	GRAMNEXUS0000001366	024-142A lot A-19-011 BB.docx
1611	GRAMNEXUS0000001367	024-142A lot A-19-012 BB.docx
1612	GRAMNEXUS0000001368	024-142A lot J-18-108 BB.docx
1613	GRAMNEXUS0000001369	09042018151302-0001.pdf
1614	GRAMNEXUS0000001370	API-0029 BB - 2 lots.pdf
1615	GRAMNEXUS0000001371	API-0029 BB data.pdf
1616	GRAMNEXUS0000001372	API-0029 Endo data.pdf
1617	GRAMNEXUS0000001373	API-0029 Endo-2.pdf
1618	GRAMNEXUS0000001374	Current Forecast (Shortage) - 02.18.20.pdf
1619	GRAMNEXUS0000001375	Expansion Schedule for GRAM Presentation.pptx
1620	GRAMNEXUS0000001376	023-157A Tech Transfer Plan 9.19.19 (SAS).docx
1621	GRAMNEXUS0000001376.0001	Microsoft_Visio_Drawing.vsdx
1622	GRAMNEXUS0000001377	17596528.PNG
1623	GRAMNEXUS0000001378	48D09BED.PNG
1624	GRAMNEXUS0000001379	87FEADEC.PNG
1625	GRAMNEXUS0000001380	Arginine COA.pdf
1626	GRAMNEXUS0000001381	contcop.PNG
1627	GRAMNEXUS0000001382	DA32D340.PNG
1628	GRAMNEXUS0000001383	L_1914.tmp.PNG
1629	GRAMNEXUS0000001384	L_1C3C.tmp.PNG
1630	GRAMNEXUS0000001385	L_362E.tmp.PNG
1631	GRAMNEXUS0000001386	L_4A20.tmp.PNG
1632	GRAMNEXUS0000001387	L_54EB.tmp.PNG
1633	GRAMNEXUS0000001388	L_67BD.tmp.PNG
1634	GRAMNEXUS0000001389	L_7AC1.tmp.PNG
1635	GRAMNEXUS0000001390	L_F7E3.tmp.PNG
1636	GRAMNEXUS0000001391	desktop.ini
1637	GRAMNEXUS0000001392	folder.ico
1638	GRAMNEXUS0000001393	2018 Copy of Increase Planning Worksheet - Sherri Scott.xlsx
1639	GRAMNEXUS0000001394	2018 Goals and Metrics.xlsx
1640	GRAMNEXUS0000001395	Cody training.xlsx
1641	GRAMNEXUS0000001396	Copy of 2018 - Sherri Scott.xlsx
1642	GRAMNEXUS0000001397	Fill Equipment Monitoring.docx
1643	GRAMNEXUS0000001398	Goals.xlsx
1644	GRAMNEXUS0000001399	Job Description - Shared QC Lab Technician (CCH)(RB)(AMP)(SAS).docx
1645	GRAMNEXUS0000001400	Micro Contractor.docx
1646	GRAMNEXUS0000001401	Micro I exp req.docx
1647	GRAMNEXUS0000001402	Micro job task list.xlsx
1648	GRAMNEXUS0000001403	Micro Tech Expansion 2.docx
1649	GRAMNEXUS0000001404	Micro Tech Expansion.docx
1650	GRAMNEXUS0000001405	Micro Tech Job Description revised.docx
1651	GRAMNEXUS0000001406	Microbiologist EIR new format.docx
1652	GRAMNEXUS0000001407	Microbiologist I Description revised.docx
1653	GRAMNEXUS0000001408	Microbiologist I exp.docx
1654	GRAMNEXUS0000001409	Microbiologist I new format.docx
1655	GRAMNEXUS0000001410	Microbiologist II Description revised.docx
1656	GRAMNEXUS0000001411	Microbiologist II expansion.docx
1657	GRAMNEXUS0000001412	Microbiologist II new format.docx
1658	GRAMNEXUS0000001413	Microbiologist III new format.docx
1659	GRAMNEXUS0000001414	Microbiology Intern new format.docx
1660	GRAMNEXUS0000001415	Microbiology Technician Expansion.docx
1661	GRAMNEXUS0000001416	Microbiology Technician new format 2nd shift.docx
1662	GRAMNEXUS0000001417	Microbiology Technician new format.docx

1663	GRAMNEXUS0000001418	Offer Letter - Weidenfeller.docx
1664	GRAMNEXUS0000001419	Position Request and Approval Form - Micro II 2019Q3.docx
1665	GRAMNEXUS0000001420	Position Request and Approval Form - Micro Tech 2019Q2 - 2nd shift.docx
1666	GRAMNEXUS0000001421	Position Request and Approval Form - Micro Tech 2019Q2.docx
1667	GRAMNEXUS0000001422	Position Request and Approval Form DP.docx
1668	GRAMNEXUS0000001423	Position Request and Approval Form JW.docx
1669	GRAMNEXUS0000001424	Position Request and Approval Form Sr Mic.docx
1670	GRAMNEXUS0000001425	Position Request and Approval Form Supervisor.docx
1671	GRAMNEXUS0000001426	Position Request and Approval Form.docx
1672	GRAMNEXUS0000001427	Position Request and Approval Micro I or II EIR.docx
1673	GRAMNEXUS0000001428	Senior Microbiologist job description.docx
1674	GRAMNEXUS0000001429	Senior Microbiologist new format.docx
1675	GRAMNEXUS0000001430	Sr Micro Position Justification Form.docx
1676	GRAMNEXUS0000001431	Supervisor Interview Questions.docx
1677	GRAMNEXUS0000001432	Supervisor new format.docx
1678	GRAMNEXUS0000001433	09202018085050-0001.pdf
1679	GRAMNEXUS0000001434	20181005065434237.pdf
1680	GRAMNEXUS0000001435	AJP counsel conduct.doc
1681	GRAMNEXUS0000001436	AJP Counsel time card.doc
1682	GRAMNEXUS0000001437	AJP Counsel.doc
1683	GRAMNEXUS0000001438	Discipline for AJP.docx
1684	GRAMNEXUS0000001439	GRAM Counseling.Disciplinary Form VJ (jaq edits).docx
1685	GRAMNEXUS0000001440	GRAM Counseling.Disciplinary Form VJ Written.docx
1686	GRAMNEXUS0000001441	GRAM Counseling.Disciplinary Form VJ.docx
1687	GRAMNEXUS0000001442	Increase Planning Worksheet - Sherri Scott.xlsx
1688	GRAMNEXUS0000001443	Cody offer.docx
1689	GRAMNEXUS0000001444	2018 Goals - SAS.docx
1690	GRAMNEXUS0000001445	CK attachment.docx
1691	GRAMNEXUS0000001446	Core Competency Continuum.pdf
1692	GRAMNEXUS0000001447	Performance Review Template (CCH).docx
1693	GRAMNEXUS0000001448	Amanda 2016 Review DRAFT (SAS).docx
1694	GRAMNEXUS0000001449	Susana 2016 Review FINAL.docx
1695	GRAMNEXUS0000001450	2017 Performance Assessment SV.docx
1696	GRAMNEXUS0000001451	Johnson - 2017 Performance Assessment (DRAFT).docx
1697	GRAMNEXUS0000001452	Koetje - 2017 Performance Assessment (DRAFT).docx
1698	GRAMNEXUS0000001453	Mercado - 2017 Performance Assessment (DRAFT).docx
1699	GRAMNEXUS0000001454	Plavcic - 2017 Performance Assessment (DRAFT).docx
1700	GRAMNEXUS0000001455	villagomez - 2017 Performance Assessment (DRAFT).docx
1701	GRAMNEXUS0000001456	Walco-Ybarra - 2017 Performance Assessment (DRAFT).docx
1702	GRAMNEXUS0000001457	Weidenfeller - 2017 Performance Assessment (DRAFT).docx
1703	GRAMNEXUS0000001458	2018 Performance Assessment - CK.docx
1704	GRAMNEXUS0000001459	2018 Performance Assessment - Template.docx
1705	GRAMNEXUS0000001460	2018 Performance Assessment - CLK.docx
1706	GRAMNEXUS0000001461	2018 Performance Assessment - DE.docx
1707	GRAMNEXUS0000001462	2018 Performance Assessment - DP.docx
1708	GRAMNEXUS0000001463	2018 Performance Assessment - EWY.docx
1709	GRAMNEXUS0000001464	2018 Performance Assessment - JW.docx
1710	GRAMNEXUS0000001465	2018 Performance Assessment - SV.docx
1711	GRAMNEXUS0000001466	2018 Performance Assessment - VJ.docx
1712	GRAMNEXUS0000001467	2018 Self-Assessment Review DP.docx
1713	GRAMNEXUS0000001468	2018 Self-Assessment JW.docx
1714	GRAMNEXUS0000001469	[redacted] Self-Assessment 2018.docx
1715	GRAMNEXUS0000001470	DE Self-Assessment Form.docx
1716	GRAMNEXUS0000001471	Self Assessment 2018 SV.docx
1717	GRAMNEXUS0000001472	Self-Assessment Form 2018 CLK.docx
1718	GRAMNEXUS0000001473	Self-Assessment Form 2018 EWY.docx
1719	GRAMNEXUS0000001474	Self-Assessment Form 2018 VJ.docx
1720	GRAMNEXUS0000001475	Scott - 2017 Performance Assessment (DRAFT).docx
1721	GRAMNEXUS0000001476	Self-Assessment Form SAS 2017.docx
1722	GRAMNEXUS0000001477	Self-Assessment Form SAS 2018.docx
1723	GRAMNEXUS0000001478	Self-Assessment Form SAS.docx
1724	GRAMNEXUS0000001479	EIR Dec 2018 unfavorable memo.doc
1725	GRAMNEXUS0000001480	EIR Jan 2019 unfavorable memo.doc
1726	GRAMNEXUS0000001481	EIR June 2017 unfavorable memo.doc

1727	GRAMNEXUS0000001482	EIR Nov 2017 unfavorable memo.doc
1728	GRAMNEXUS0000001483	EIR Sep 2017 unfavorable memo.doc
1729	GRAMNEXUS0000001484	EIR Sep 2017.pdf
1730	GRAMNEXUS0000001485	EIR Sep 2019 unfavorable memo.doc
1731	GRAMNEXUS0000001486	Feb 2018 EIR.docx
1732	GRAMNEXUS0000001486.0001	Microsoft_Excel_Worksheet1.xlsx
1733	GRAMNEXUS0000001487	Feb 2018 isolates.docx
1734	GRAMNEXUS0000001488	July 2017 EIR's by type.docx
1735	GRAMNEXUS0000001489	June 2017 EIR by type.docx
1736	GRAMNEXUS0000001489.0001	Microsoft_Excel_Worksheet1.xlsx
1737	GRAMNEXUS0000001490	June 2017 Isolates.docx
1738	GRAMNEXUS0000001491	March 2018 EIR by type.docx
1739	GRAMNEXUS0000001492	March 2018 Isolates.docx
1740	GRAMNEXUS0000001493	May 2017 KPI EIR.docx
1741	GRAMNEXUS0000001493.0001	oleObject1
1742	GRAMNEXUS0000001494	May 2017 KPI EM Isolates.docx
1743	GRAMNEXUS0000001495	Oct 2017 EIR.docx
1744	GRAMNEXUS0000001496	Oct 2017 Isolates.docx
1745	GRAMNEXUS0000001497	PM June 2017.doc
1746	GRAMNEXUS0000001498	Q4 EM Treding 2016 for QMR.xlsx
1747	GRAMNEXUS0000001499	Sept 2017 EIR.docx
1748	GRAMNEXUS0000001500	Sept 2017 Isolates.docx
1749	GRAMNEXUS0000001501	Annual Summary Report 2019(SAS)(JW)1.docx
1750	GRAMNEXUS0000001502	Annual Summary Report 2019(SAS).docx
1751	GRAMNEXUS0000001503	BTR_FIRST_QC_LYT_001-1308.pdf
1752	GRAMNEXUS0000001504	BTR_FIRST_QC_LYT_001-1314.pdf
1753	GRAMNEXUS0000001505	BTR_FIRST_QC_LYT_001-1321.pdf
1754	GRAMNEXUS0000001506	BTR_FIRST_QC_LYT_001-1323.pdf
1755	GRAMNEXUS0000001507	BTR_FIRST_QC_LYT_001-1324.pdf
1756	GRAMNEXUS0000001508	BTR_FIRST_QC_LYT_001-1325.pdf
1757	GRAMNEXUS0000001509	BTR_FIRST_QC_LYT_001-1326-1.pdf
1758	GRAMNEXUS0000001510	BTR_FIRST_QC_LYT_001-1328.pdf
1759	GRAMNEXUS0000001511	BTR_FIRST_QC_LYT_001-1329.pdf
1760	GRAMNEXUS0000001512	BTR_FIRST_QC_LYT_001-1330.pdf
1761	GRAMNEXUS0000001513	BTR_FIRST_QC_LYT_001-1331.pdf
1762	GRAMNEXUS0000001514	BTR_FIRST_QC_LYT_001-1332.pdf
1763	GRAMNEXUS0000001515	BTR_FIRST_QC_LYT_001-1333.pdf
1764	GRAMNEXUS0000001516	BTR_FIRST_QC_LYT_001-1334.pdf
1765	GRAMNEXUS0000001517	BTR_FIRST_QC_LYT_001-1335.pdf
1766	GRAMNEXUS0000001518	BTR_FIRST_QC_LYT_001-1339.pdf
1767	GRAMNEXUS0000001519	BTR_FIRST_QC_LYT_001-1340.pdf
1768	GRAMNEXUS0000001520	BTR_FIRST_QC_LYT_001-1341.pdf
1769	GRAMNEXUS0000001521	BTR_FIRST_QC_LYT_001-1342.pdf
1770	GRAMNEXUS0000001522	BTR_FIRST_QC_LYT_001-1344.pdf
1771	GRAMNEXUS0000001523	BTR_FIRST_QC_LYT_001-1345.pdf
1772	GRAMNEXUS0000001524	BTR_FIRST_QC_LYT_001-1346.pdf
1773	GRAMNEXUS0000001525	BTR_FIRST_QC_LYT_001-1347.pdf
1774	GRAMNEXUS0000001526	BTR_FIRST_QC_LYT_001-1348.pdf
1775	GRAMNEXUS0000001527	BTR_FIRST_QC_LYT_001-1350.pdf
1776	GRAMNEXUS0000001528	GRAM-TM-0004 Train FP1.docx
1777	GRAMNEXUS0000001529	GRAM-TM-0004 Train FP2.docx
1778	GRAMNEXUS0000001530	GRAM-TM-0004 Train FP3.docx
1779	GRAMNEXUS0000001531	GRAM-TM-0004 Train FP4.docx
1780	GRAMNEXUS0000001532	GRAM-TM-0004 Train RM 1.docx
1781	GRAMNEXUS0000001533	GRAM-TM-0004 Train RM 2.docx
1782	GRAMNEXUS0000001534	GRAM-TM-0004 Train RM 3.docx
1783	GRAMNEXUS0000001535	GRAM-TM-0004 Train RM 4.docx
1784	GRAMNEXUS0000001536	GRAM-TM-0016 training - standard prep.docx
1785	GRAMNEXUS0000001537	Training Outline GRAM-TM-0004.docx
1786	GRAMNEXUS0000001538	Training Outline GRAM-TM-0016.docx
1787	GRAMNEXUS0000001539	desktop.ini
1788	GRAMNEXUS0000001540	Desktop.lnk
1789	GRAMNEXUS0000001541	Downloads.lnk
1790	GRAMNEXUS0000001542	Favorites - Shortcut.lnk

1791	GRAMNEXUS0000001543	OneDrive.lnk
1792	GRAMNEXUS0000001544	desktop.ini
1793	GRAMNEXUS0000001545	1211 TDS SporKlenz RTU.pdf
1794	GRAMNEXUS0000001546	AI-0362.doc
1795	GRAMNEXUS0000001547	API-0017 VAL-1074_Report (SAS).docx
1796	GRAMNEXUS0000001548	Bioburden Re-Valdiation Letter to Clients(SAS).docx
1797	GRAMNEXUS0000001549	CAPA CA Log working.xlsx
1798	GRAMNEXUS0000001550	CHM-0015 VAL-1071_Report (SAS) changed.docx
1799	GRAMNEXUS0000001551	CHM-0015 VAL-1071_Report (SAS).docx
1800	GRAMNEXUS0000001552	Cisco Webex Meetings.lnk
1801	GRAMNEXUS0000001553	Cody Resume.docx
1802	GRAMNEXUS0000001554	Copy of GRAM Expense Report_2013.xlsx
1803	GRAMNEXUS0000001555	Copy of Ion Lab Equipment and Personnel for Expansion.xlsx
1804	GRAMNEXUS0000001556	Current CAPAs.xlsx
1805	GRAMNEXUS0000001557	DCR for CORP-SOP-0051.docx
1806	GRAMNEXUS0000001558	endo doc changes.docx
1807	GRAMNEXUS0000001559	Endotoxin Validation List (SAS).docx
1808	GRAMNEXUS0000001560	GoToAssist Customer.lnk
1809	GRAMNEXUS0000001561	GRAM Bios.docx
1810	GRAMNEXUS0000001562	ID Trending.xlsx
1811	GRAMNEXUS0000001563	INTCAPA and Audit Commitments Log working.xlsx
1812	GRAMNEXUS0000001564	Microsoft Teams.lnk
1813	GRAMNEXUS0000001565	MRI order.pdf
1814	GRAMNEXUS0000001566	MSDS Online.url
1815	GRAMNEXUS0000001567	My CAPAs for review.xlsx
1816	GRAMNEXUS0000001568	PA-150012 NEW NAMES.xlsx
1817	GRAMNEXUS0000001569	Polycom RealPresence Desktop.lnk
1818	GRAMNEXUS0000001570	Purchase Order Microworks.xlsx
1819	GRAMNEXUS0000001571	ActivatorClientClassLibrary.dll
1820	GRAMNEXUS0000001572	appIcon32.ico
1821	GRAMNEXUS0000001573	Aspose.Pdf.Kit.dll
1822	GRAMNEXUS0000001574	Aspose.Pdf.Kit.xml
1823	GRAMNEXUS0000001575	DicomNet.Common.SCPVerification.xml
1824	GRAMNEXUS0000001576	Reviewer.xml
1825	GRAMNEXUS0000001577	DataDictionary.ImplicitVR.xml
1826	GRAMNEXUS0000001578	DicomNet.Config.xml
1827	GRAMNEXUS0000001579	DicomNet.Logger.LogLevels.xml
1828	GRAMNEXUS0000001580	MAS.Oem.config
1829	GRAMNEXUS0000001581	Reviewer.Modality.CR.config
1830	GRAMNEXUS0000001582	Reviewer.Modality.CT.config
1831	GRAMNEXUS0000001583	Reviewer.Modality.Default.config
1832	GRAMNEXUS0000001584	Reviewer.Modality.DX.config
1833	GRAMNEXUS0000001585	Reviewer.Modality.IO.config
1834	GRAMNEXUS0000001586	Reviewer.Modality.MG.config
1835	GRAMNEXUS0000001587	Reviewer.Modality.MR.config
1836	GRAMNEXUS0000001588	Reviewer.Modality.NM.config
1837	GRAMNEXUS0000001589	Reviewer.Modality.OP.config
1838	GRAMNEXUS0000001590	Reviewer.Modality.OT.config
1839	GRAMNEXUS0000001591	Reviewer.Modality.PT.config
1840	GRAMNEXUS0000001592	Reviewer.Modality.RF.config
1841	GRAMNEXUS0000001593	Reviewer.Modality.RG.config
1842	GRAMNEXUS0000001594	Reviewer.Modality.SC.config
1843	GRAMNEXUS0000001595	Reviewer.Modality.US.config
1844	GRAMNEXUS0000001596	Reviewer.Modality.XA.config
1845	GRAMNEXUS0000001597	Reviewer.Modality.XC.config
1846	GRAMNEXUS0000001598	Reviewer.OverlayTag.CR.config
1847	GRAMNEXUS0000001599	Reviewer.OverlayTag.CT.config
1848	GRAMNEXUS0000001600	Reviewer.OverlayTag.Default.config
1849	GRAMNEXUS0000001601	Reviewer.OverlayTag.DX.config
1850	GRAMNEXUS0000001602	Reviewer.OverlayTag.IO.config
1851	GRAMNEXUS0000001603	Reviewer.OverlayTag.MG.config
1852	GRAMNEXUS0000001604	Reviewer.OverlayTag.MR.config
1853	GRAMNEXUS0000001605	Reviewer.OverlayTag.NM.config
1854	GRAMNEXUS0000001606	Reviewer.OverlayTag.OP.config

1855	GRAMNEXUS0000001607	Reviewer.OverlayTag.OT.config
1856	GRAMNEXUS0000001608	Reviewer.OverlayTag.PT.config
1857	GRAMNEXUS0000001609	Reviewer.OverlayTag.RF.config
1858	GRAMNEXUS0000001610	Reviewer.OverlayTag.RG.config
1859	GRAMNEXUS0000001611	Reviewer.OverlayTag.SC.config
1860	GRAMNEXUS0000001612	Reviewer.OverlayTag.US.config
1861	GRAMNEXUS0000001613	Reviewer.OverlayTag.XA.config
1862	GRAMNEXUS0000001614	Reviewer.OverlayTag.XC.config
1863	GRAMNEXUS0000001615	Reviewer.Application.config
1864	GRAMNEXUS0000001616	Reviewer.Display.config
1865	GRAMNEXUS0000001617	Reviewer.Oem.config
1866	GRAMNEXUS0000001618	Reviewer.StudyExplorer.config
1867	GRAMNEXUS0000001619	Reviewer.User.config
1868	GRAMNEXUS0000001620	design.std
1869	GRAMNEXUS0000001621	oemLogo.png
1870	GRAMNEXUS0000001622	Rev Quik Steps.pdf
1871	GRAMNEXUS0000001623	Reviewer EMR User Guide.pdf
1872	GRAMNEXUS0000001624	Thumbs.db
1873	GRAMNEXUS0000001625	DicomNet.Common.CLib.dll
1874	GRAMNEXUS0000001626	DicomNet.Common.DcmJpegAsm.dll
1875	GRAMNEXUS0000001627	DicomNet.Common.DCommon.dll
1876	GRAMNEXUS0000001628	DicomNet.Common.DicomStreams.DcmJpeg.dll
1877	GRAMNEXUS0000001629	DicomNet.Common.DicomStreams.dll
1878	GRAMNEXUS0000001630	DicomNet.Common.DicomStreams.OpenJpeg.dll
1879	GRAMNEXUS0000001631	DicomNet.Common.Lib.dll
1880	GRAMNEXUS0000001632	DicomNet.Common.Media.dll
1881	GRAMNEXUS0000001633	DicomNet.Common.SCU.dll
1882	GRAMNEXUS0000001634	DicomNet.Config.Lib.dll
1883	GRAMNEXUS0000001635	DicomNet.Display.CLib.dll
1884	GRAMNEXUS0000001636	DicomNet.Display.dll
1885	GRAMNEXUS0000001637	DicomNet.Logger.dll
1886	GRAMNEXUS0000001638	DotNetMagic2005.dll
1887	GRAMNEXUS0000001639	openjp2.dll
1888	GRAMNEXUS0000001640	Reviewer.Common.dll
1889	GRAMNEXUS0000001641	Reviewer.DataStructure.dll
1890	GRAMNEXUS0000001642	Reviewer.exe
1891	GRAMNEXUS0000001643	Sorna.Crypto.dll
1892	GRAMNEXUS0000001644	Sorna.License.exml
1893	GRAMNEXUS0000001645	sqlite3.dll
1894	GRAMNEXUS0000001646	SQLiteWrapper.dll
1895	GRAMNEXUS0000001647	Autorun.inf
1896	GRAMNEXUS0000001648	DICOMDIR
1897	GRAMNEXUS0000001649	Launch.exe
1898	GRAMNEXUS0000001650	Launch.ico
1899	GRAMNEXUS0000001651	copy.html
1900	GRAMNEXUS0000001652	data.xml
1901	GRAMNEXUS0000001653	logo.JPG
1902	GRAMNEXUS0000001654	style.css
1903	GRAMNEXUS0000001655	IN000001
1904	GRAMNEXUS0000001656	IN000002
1905	GRAMNEXUS0000001657	IN000001
1906	GRAMNEXUS0000001658	IN000002
1907	GRAMNEXUS0000001659	IN000003
1908	GRAMNEXUS0000001660	IN000004
1909	GRAMNEXUS0000001661	IN000005
1910	GRAMNEXUS0000001662	IN000006
1911	GRAMNEXUS0000001663	IN000007
1912	GRAMNEXUS0000001664	IN000008
1913	GRAMNEXUS0000001665	IN000009
1914	GRAMNEXUS0000001666	IN000010
1915	GRAMNEXUS0000001667	IN000011
1916	GRAMNEXUS0000001668	IN000012
1917	GRAMNEXUS0000001669	IN000013
1918	GRAMNEXUS0000001670	IN000014

1919	GRAMNEXUS0000001671	IN000015
1920	GRAMNEXUS0000001672	IN000016
1921	GRAMNEXUS0000001673	IN000017
1922	GRAMNEXUS0000001674	IN000018
1923	GRAMNEXUS0000001675	IN000019
1924	GRAMNEXUS0000001676	IN000020
1925	GRAMNEXUS0000001677	IN000021
1926	GRAMNEXUS0000001678	IN000022
1927	GRAMNEXUS0000001679	IN000023
1928	GRAMNEXUS0000001680	IN000024
1929	GRAMNEXUS0000001681	IN000025
1930	GRAMNEXUS0000001682	IN000026
1931	GRAMNEXUS0000001683	IN000027
1932	GRAMNEXUS0000001684	IN000028
1933	GRAMNEXUS0000001685	IN000029
1934	GRAMNEXUS0000001686	IN000030
1935	GRAMNEXUS0000001687	IN000031
1936	GRAMNEXUS0000001688	IN000032
1937	GRAMNEXUS0000001689	IN000033
1938	GRAMNEXUS0000001690	IN000034
1939	GRAMNEXUS0000001691	IN000035
1940	GRAMNEXUS0000001692	IN000036
1941	GRAMNEXUS0000001693	IN000037
1942	GRAMNEXUS0000001694	IN000038
1943	GRAMNEXUS0000001695	IN000039
1944	GRAMNEXUS0000001696	IN000040
1945	GRAMNEXUS0000001697	IN000041
1946	GRAMNEXUS0000001698	IN000042
1947	GRAMNEXUS0000001699	IN000043
1948	GRAMNEXUS0000001700	IN000044
1949	GRAMNEXUS0000001701	IN000045
1950	GRAMNEXUS0000001702	IN000046
1951	GRAMNEXUS0000001703	IN000047
1952	GRAMNEXUS0000001704	IN000048
1953	GRAMNEXUS0000001705	IN000049
1954	GRAMNEXUS0000001706	IN000050
1955	GRAMNEXUS0000001707	IN000051
1956	GRAMNEXUS0000001708	IN000052
1957	GRAMNEXUS0000001709	IN000053
1958	GRAMNEXUS0000001710	IN000054
1959	GRAMNEXUS0000001711	IN000055
1960	GRAMNEXUS0000001712	IN000056
1961	GRAMNEXUS0000001713	IN000057
1962	GRAMNEXUS0000001714	IN000058
1963	GRAMNEXUS0000001715	IN000059
1964	GRAMNEXUS0000001716	IN000060
1965	GRAMNEXUS0000001717	IN000061
1966	GRAMNEXUS0000001718	IN000062
1967	GRAMNEXUS0000001719	IN000063
1968	GRAMNEXUS0000001720	IN000064
1969	GRAMNEXUS0000001721	IN000065
1970	GRAMNEXUS0000001722	IN000066
1971	GRAMNEXUS0000001723	IN000067
1972	GRAMNEXUS0000001724	IN000068
1973	GRAMNEXUS0000001725	IN000069
1974	GRAMNEXUS0000001726	IN000070
1975	GRAMNEXUS0000001727	IN000071
1976	GRAMNEXUS0000001728	IN000072
1977	GRAMNEXUS0000001729	IN000073
1978	GRAMNEXUS0000001730	IN000074
1979	GRAMNEXUS0000001731	IN000075
1980	GRAMNEXUS0000001732	IN000076
1981	GRAMNEXUS0000001733	IN000077
1982	GRAMNEXUS0000001734	IN000078

1983	GRAMNEXUS0000001735	IN000079
1984	GRAMNEXUS0000001736	IN000080
1985	GRAMNEXUS0000001737	IN000081
1986	GRAMNEXUS0000001738	IN000082
1987	GRAMNEXUS0000001739	IN000083
1988	GRAMNEXUS0000001740	IN000084
1989	GRAMNEXUS0000001741	IN000085
1990	GRAMNEXUS0000001742	IN000086
1991	GRAMNEXUS0000001743	IN000087
1992	GRAMNEXUS0000001744	IN000088
1993	GRAMNEXUS0000001745	IN000089
1994	GRAMNEXUS0000001746	IN000090
1995	GRAMNEXUS0000001747	IN000091
1996	GRAMNEXUS0000001748	IN000092
1997	GRAMNEXUS0000001749	IN000093
1998	GRAMNEXUS0000001750	IN000094
1999	GRAMNEXUS0000001751	IN000095
2000	GRAMNEXUS0000001752	IN000096
2001	GRAMNEXUS0000001753	IN000097
2002	GRAMNEXUS0000001754	IN000098
2003	GRAMNEXUS0000001755	IN000099
2004	GRAMNEXUS0000001756	IN000100
2005	GRAMNEXUS0000001757	IN000101
2006	GRAMNEXUS0000001758	IN000102
2007	GRAMNEXUS0000001759	IN000103
2008	GRAMNEXUS0000001760	IN000104
2009	GRAMNEXUS0000001761	IN000105
2010	GRAMNEXUS0000001762	IN000106
2011	GRAMNEXUS0000001763	IN000107
2012	GRAMNEXUS0000001764	IN000108
2013	GRAMNEXUS0000001765	IN000109
2014	GRAMNEXUS0000001766	IN000110
2015	GRAMNEXUS0000001767	IN000111
2016	GRAMNEXUS0000001768	IN000112
2017	GRAMNEXUS0000001769	IN000113
2018	GRAMNEXUS0000001770	IN000114
2019	GRAMNEXUS0000001771	IN000115
2020	GRAMNEXUS0000001772	IN000116
2021	GRAMNEXUS0000001773	IN000117
2022	GRAMNEXUS0000001774	IN000118
2023	GRAMNEXUS0000001775	IN000119
2024	GRAMNEXUS0000001776	IN000120
2025	GRAMNEXUS0000001777	IN000121
2026	GRAMNEXUS0000001778	IN000122
2027	GRAMNEXUS0000001779	IN000123
2028	GRAMNEXUS0000001780	IN000124
2029	GRAMNEXUS0000001781	IN000125
2030	GRAMNEXUS0000001782	IN000126
2031	GRAMNEXUS0000001783	IN000127
2032	GRAMNEXUS0000001784	IN000128
2033	GRAMNEXUS0000001785	IN000129
2034	GRAMNEXUS0000001786	IN000130
2035	GRAMNEXUS0000001787	IN000131
2036	GRAMNEXUS0000001788	IN000132
2037	GRAMNEXUS0000001789	IN000133
2038	GRAMNEXUS0000001790	IN000134
2039	GRAMNEXUS0000001791	IN000135
2040	GRAMNEXUS0000001792	IN000136
2041	GRAMNEXUS0000001793	IN000137
2042	GRAMNEXUS0000001794	IN000138
2043	GRAMNEXUS0000001795	IN000139
2044	GRAMNEXUS0000001796	IN000140
2045	GRAMNEXUS0000001797	IN000141
2046	GRAMNEXUS0000001798	IN000142

2047	GRAMNEXUS0000001799	IN000143
2048	GRAMNEXUS0000001800	IN000144
2049	GRAMNEXUS0000001801	IN000145
2050	GRAMNEXUS0000001802	IN000146
2051	GRAMNEXUS0000001803	IN000147
2052	GRAMNEXUS0000001804	IN000148
2053	GRAMNEXUS0000001805	IN000149
2054	GRAMNEXUS0000001806	IN000150
2055	GRAMNEXUS0000001807	IN000151
2056	GRAMNEXUS0000001808	IN000152
2057	GRAMNEXUS0000001809	IN000153
2058	GRAMNEXUS0000001810	IN000154
2059	GRAMNEXUS0000001811	IN000155
2060	GRAMNEXUS0000001812	IN000156
2061	GRAMNEXUS0000001813	IN000157
2062	GRAMNEXUS0000001814	IN000158
2063	GRAMNEXUS0000001815	IN000159
2064	GRAMNEXUS0000001816	IN000160
2065	GRAMNEXUS0000001817	IN000161
2066	GRAMNEXUS0000001818	IN000162
2067	GRAMNEXUS0000001819	IN000163
2068	GRAMNEXUS0000001820	IN000164
2069	GRAMNEXUS0000001821	IN000165
2070	GRAMNEXUS0000001822	IN000166
2071	GRAMNEXUS0000001823	IN000167
2072	GRAMNEXUS0000001824	IN000168
2073	GRAMNEXUS0000001825	IN000169
2074	GRAMNEXUS0000001826	IN000170
2075	GRAMNEXUS0000001827	IN000171
2076	GRAMNEXUS0000001828	IN000172
2077	GRAMNEXUS0000001829	IN000173
2078	GRAMNEXUS0000001830	IN000174
2079	GRAMNEXUS0000001831	IN000175
2080	GRAMNEXUS0000001832	IN000176
2081	GRAMNEXUS0000001833	IN000177
2082	GRAMNEXUS0000001834	IN000178
2083	GRAMNEXUS0000001835	IN000179
2084	GRAMNEXUS0000001836	IN000180
2085	GRAMNEXUS0000001837	IN000181
2086	GRAMNEXUS0000001838	IN000182
2087	GRAMNEXUS0000001839	IN000183
2088	GRAMNEXUS0000001840	IN000184
2089	GRAMNEXUS0000001841	IN000185
2090	GRAMNEXUS0000001842	IN000186
2091	GRAMNEXUS0000001843	IN000187
2092	GRAMNEXUS0000001844	IN000188
2093	GRAMNEXUS0000001845	IN000189
2094	GRAMNEXUS0000001846	IN000190
2095	GRAMNEXUS0000001847	IN000191
2096	GRAMNEXUS0000001848	IN000192
2097	GRAMNEXUS0000001849	IN000193
2098	GRAMNEXUS0000001850	IN000194
2099	GRAMNEXUS0000001851	IN000195
2100	GRAMNEXUS0000001852	IN000196
2101	GRAMNEXUS0000001853	IN000197
2102	GRAMNEXUS0000001854	IN000198
2103	GRAMNEXUS0000001855	IN000199
2104	GRAMNEXUS0000001856	IN000200
2105	GRAMNEXUS0000001857	IN000201
2106	GRAMNEXUS0000001858	IN000202
2107	GRAMNEXUS0000001859	IN000203
2108	GRAMNEXUS0000001860	IN000204
2109	GRAMNEXUS0000001861	IN000205
2110	GRAMNEXUS0000001862	IN000206

2111	GRAMNEXUS0000001863	IN000207
2112	GRAMNEXUS0000001864	IN000208
2113	GRAMNEXUS0000001865	IN000209
2114	GRAMNEXUS0000001866	IN000210
2115	GRAMNEXUS0000001867	IN000211
2116	GRAMNEXUS0000001868	IN000212
2117	GRAMNEXUS0000001869	IN000213
2118	GRAMNEXUS0000001870	IN000214
2119	GRAMNEXUS0000001871	IN000001
2120	GRAMNEXUS0000001872	IN000001
2121	GRAMNEXUS0000001873	IN000002
2122	GRAMNEXUS0000001874	IN000003
2123	GRAMNEXUS0000001875	IN000004
2124	GRAMNEXUS0000001876	IN000005
2125	GRAMNEXUS0000001877	IN000006
2126	GRAMNEXUS0000001878	IN000007
2127	GRAMNEXUS0000001879	IN000008
2128	GRAMNEXUS0000001880	IN000009
2129	GRAMNEXUS0000001881	IN000010
2130	GRAMNEXUS0000001882	IN000011
2131	GRAMNEXUS0000001883	IN000012
2132	GRAMNEXUS0000001884	IN000013
2133	GRAMNEXUS0000001885	IN000014
2134	GRAMNEXUS0000001886	IN000015
2135	GRAMNEXUS0000001887	IN000016
2136	GRAMNEXUS0000001888	IN000017
2137	GRAMNEXUS0000001889	IN000018
2138	GRAMNEXUS0000001890	IN000019
2139	GRAMNEXUS0000001891	IN000020
2140	GRAMNEXUS0000001892	IN000021
2141	GRAMNEXUS0000001893	IN000022
2142	GRAMNEXUS0000001894	IN000023
2143	GRAMNEXUS0000001895	IN000024
2144	GRAMNEXUS0000001896	IN000025
2145	GRAMNEXUS0000001897	IN000026
2146	GRAMNEXUS0000001898	IN000027
2147	GRAMNEXUS0000001899	IN000028
2148	GRAMNEXUS0000001900	IN000029
2149	GRAMNEXUS0000001901	IN000030
2150	GRAMNEXUS0000001902	IN000031
2151	GRAMNEXUS0000001903	IN000032
2152	GRAMNEXUS0000001904	IN000033
2153	GRAMNEXUS0000001905	IN000034
2154	GRAMNEXUS0000001906	IN000035
2155	GRAMNEXUS0000001907	IN000036
2156	GRAMNEXUS0000001908	IN000037
2157	GRAMNEXUS0000001909	IN000038
2158	GRAMNEXUS0000001910	IN000039
2159	GRAMNEXUS0000001911	IN000040
2160	GRAMNEXUS0000001912	IN000041
2161	GRAMNEXUS0000001913	IN000042
2162	GRAMNEXUS0000001914	IN000043
2163	GRAMNEXUS0000001915	IN000044
2164	GRAMNEXUS0000001916	IN000045
2165	GRAMNEXUS0000001917	IN000046
2166	GRAMNEXUS0000001918	IN000047
2167	GRAMNEXUS0000001919	IN000048
2168	GRAMNEXUS0000001920	IN000049
2169	GRAMNEXUS0000001921	IN000050
2170	GRAMNEXUS0000001922	IN000051
2171	GRAMNEXUS0000001923	IN000052
2172	GRAMNEXUS0000001924	IN000053
2173	GRAMNEXUS0000001925	IN000054
2174	GRAMNEXUS0000001926	IN000055

2175	GRAMNEXUS0000001927	IN000056
2176	GRAMNEXUS0000001928	IN000057
2177	GRAMNEXUS0000001929	IN000058
2178	GRAMNEXUS0000001930	IN000059
2179	GRAMNEXUS0000001931	IN000060
2180	GRAMNEXUS0000001932	IN000061
2181	GRAMNEXUS0000001933	IN000062
2182	GRAMNEXUS0000001934	IN000063
2183	GRAMNEXUS0000001935	IN000064
2184	GRAMNEXUS0000001936	IN000065
2185	GRAMNEXUS0000001937	IN000066
2186	GRAMNEXUS0000001938	IN000067
2187	GRAMNEXUS0000001939	IN000068
2188	GRAMNEXUS0000001940	IN000069
2189	GRAMNEXUS0000001941	IN000070
2190	GRAMNEXUS0000001942	IN000071
2191	GRAMNEXUS0000001943	IN000072
2192	GRAMNEXUS0000001944	IN000073
2193	GRAMNEXUS0000001945	IN000074
2194	GRAMNEXUS0000001946	IN000075
2195	GRAMNEXUS0000001947	IN000076
2196	GRAMNEXUS0000001948	IN000077
2197	GRAMNEXUS0000001949	IN000078
2198	GRAMNEXUS0000001950	IN000079
2199	GRAMNEXUS0000001951	IN000080
2200	GRAMNEXUS0000001952	IN000081
2201	GRAMNEXUS0000001953	IN000082
2202	GRAMNEXUS0000001954	IN000083
2203	GRAMNEXUS0000001955	IN000084
2204	GRAMNEXUS0000001956	IN000085
2205	GRAMNEXUS0000001957	IN000086
2206	GRAMNEXUS0000001958	IN000087
2207	GRAMNEXUS0000001959	IN000088
2208	GRAMNEXUS0000001960	IN000089
2209	GRAMNEXUS0000001961	IN000090
2210	GRAMNEXUS0000001962	IN000091
2211	GRAMNEXUS0000001963	IN000092
2212	GRAMNEXUS0000001964	IN000093
2213	GRAMNEXUS0000001965	IN000094
2214	GRAMNEXUS0000001966	IN000095
2215	GRAMNEXUS0000001967	IN000096
2216	GRAMNEXUS0000001968	IN000097
2217	GRAMNEXUS0000001969	IN000098
2218	GRAMNEXUS0000001970	IN000099
2219	GRAMNEXUS0000001971	IN000100
2220	GRAMNEXUS0000001972	IN000101
2221	GRAMNEXUS0000001973	IN000102
2222	GRAMNEXUS0000001974	IN000103
2223	GRAMNEXUS0000001975	IN000104
2224	GRAMNEXUS0000001976	IN000105
2225	GRAMNEXUS0000001977	IN000106
2226	GRAMNEXUS0000001978	IN000107
2227	GRAMNEXUS0000001979	IN000108
2228	GRAMNEXUS0000001980	IN000109
2229	GRAMNEXUS0000001981	IN000110
2230	GRAMNEXUS0000001982	IN000111
2231	GRAMNEXUS0000001983	IN000112
2232	GRAMNEXUS0000001984	IN000113
2233	GRAMNEXUS0000001985	IN000114
2234	GRAMNEXUS0000001986	IN000115
2235	GRAMNEXUS0000001987	IN000116
2236	GRAMNEXUS0000001988	IN000117
2237	GRAMNEXUS0000001989	IN000118
2238	GRAMNEXUS0000001990	IN000119

2239	GRAMNEXUS0000001991	IN000120
2240	GRAMNEXUS0000001992	IN000121
2241	GRAMNEXUS0000001993	IN000122
2242	GRAMNEXUS0000001994	IN000123
2243	GRAMNEXUS0000001995	IN000124
2244	GRAMNEXUS0000001996	IN000125
2245	GRAMNEXUS0000001997	IN000126
2246	GRAMNEXUS0000001998	IN000127
2247	GRAMNEXUS0000001999	IN000128
2248	GRAMNEXUS0000002000	IN000129
2249	GRAMNEXUS0000002001	IN000130
2250	GRAMNEXUS0000002002	IN000131
2251	GRAMNEXUS0000002003	IN000132
2252	GRAMNEXUS0000002004	IN000133
2253	GRAMNEXUS0000002005	IN000134
2254	GRAMNEXUS0000002006	IN000135
2255	GRAMNEXUS0000002007	IN000136
2256	GRAMNEXUS0000002008	IN000137
2257	GRAMNEXUS0000002009	IN000138
2258	GRAMNEXUS0000002010	IN000139
2259	GRAMNEXUS0000002011	IN000140
2260	GRAMNEXUS0000002012	IN000141
2261	GRAMNEXUS0000002013	IN000142
2262	GRAMNEXUS0000002014	IN000143
2263	GRAMNEXUS0000002015	IN000144
2264	GRAMNEXUS0000002016	IN000145
2265	GRAMNEXUS0000002017	IN000146
2266	GRAMNEXUS0000002018	IN000147
2267	GRAMNEXUS0000002019	IN000148
2268	GRAMNEXUS0000002020	IN000149
2269	GRAMNEXUS0000002021	IN000150
2270	GRAMNEXUS0000002022	IN000151
2271	GRAMNEXUS0000002023	IN000152
2272	GRAMNEXUS0000002024	IN000153
2273	GRAMNEXUS0000002025	IN000154
2274	GRAMNEXUS0000002026	IN000155
2275	GRAMNEXUS0000002027	IN000156
2276	GRAMNEXUS0000002028	IN000157
2277	GRAMNEXUS0000002029	IN000158
2278	GRAMNEXUS0000002030	IN000159
2279	GRAMNEXUS0000002031	IN000160
2280	GRAMNEXUS0000002032	IN000161
2281	GRAMNEXUS0000002033	IN000162
2282	GRAMNEXUS0000002034	IN000163
2283	GRAMNEXUS0000002035	IN000164
2284	GRAMNEXUS0000002036	IN000165
2285	GRAMNEXUS0000002037	IN000166
2286	GRAMNEXUS0000002038	IN000167
2287	GRAMNEXUS0000002039	IN000168
2288	GRAMNEXUS0000002040	IN000169
2289	GRAMNEXUS0000002041	IN000170
2290	GRAMNEXUS0000002042	IN000171
2291	GRAMNEXUS0000002043	IN000172
2292	GRAMNEXUS0000002044	IN000173
2293	GRAMNEXUS0000002045	IN000174
2294	GRAMNEXUS0000002046	IN000175
2295	GRAMNEXUS0000002047	IN000176
2296	GRAMNEXUS0000002048	IN000177
2297	GRAMNEXUS0000002049	IN000178
2298	GRAMNEXUS0000002050	IN000179
2299	GRAMNEXUS0000002051	IN000180
2300	GRAMNEXUS0000002052	IN000181
2301	GRAMNEXUS0000002053	IN000182
2302	GRAMNEXUS0000002054	IN000183

2303	GRAMNEXUS0000002055	IN000184
2304	GRAMNEXUS0000002056	IN000185
2305	GRAMNEXUS0000002057	IN000186
2306	GRAMNEXUS0000002058	IN000187
2307	GRAMNEXUS0000002059	IN000188
2308	GRAMNEXUS0000002060	IN000189
2309	GRAMNEXUS0000002061	IN000190
2310	GRAMNEXUS0000002062	IN000191
2311	GRAMNEXUS0000002063	IN000192
2312	GRAMNEXUS0000002064	IN000193
2313	GRAMNEXUS0000002065	IN000194
2314	GRAMNEXUS0000002066	IN000195
2315	GRAMNEXUS0000002067	IN000196
2316	GRAMNEXUS0000002068	IN000001
2317	GRAMNEXUS0000002069	IN000002
2318	GRAMNEXUS0000002070	IN000003
2319	GRAMNEXUS0000002071	IN000004
2320	GRAMNEXUS0000002072	IN000005
2321	GRAMNEXUS0000002073	IN000006
2322	GRAMNEXUS0000002074	IN000007
2323	GRAMNEXUS0000002075	IN000008
2324	GRAMNEXUS0000002076	IN000009
2325	GRAMNEXUS0000002077	IN000010
2326	GRAMNEXUS0000002078	IN000011
2327	GRAMNEXUS0000002079	IN000012
2328	GRAMNEXUS0000002080	IN000013
2329	GRAMNEXUS0000002081	IN000014
2330	GRAMNEXUS0000002082	IN000015
2331	GRAMNEXUS0000002083	IN000016
2332	GRAMNEXUS0000002084	IN000017
2333	GRAMNEXUS0000002085	IN000018
2334	GRAMNEXUS0000002086	IN000019
2335	GRAMNEXUS0000002087	IN000020
2336	GRAMNEXUS0000002088	IN000021
2337	GRAMNEXUS0000002089	IN000022
2338	GRAMNEXUS0000002090	IN000023
2339	GRAMNEXUS0000002091	IN000024
2340	GRAMNEXUS0000002092	IN000025
2341	GRAMNEXUS0000002093	IN000026
2342	GRAMNEXUS0000002094	IN000027
2343	GRAMNEXUS0000002095	IN000028
2344	GRAMNEXUS0000002096	IN000029
2345	GRAMNEXUS0000002097	IN000030
2346	GRAMNEXUS0000002098	IN000031
2347	GRAMNEXUS0000002099	IN000032
2348	GRAMNEXUS0000002100	IN000033
2349	GRAMNEXUS0000002101	IN000034
2350	GRAMNEXUS0000002102	IN000035
2351	GRAMNEXUS0000002103	IN000036
2352	GRAMNEXUS0000002104	IN000037
2353	GRAMNEXUS0000002105	IN000038
2354	GRAMNEXUS0000002106	IN000039
2355	GRAMNEXUS0000002107	IN000040
2356	GRAMNEXUS0000002108	IN000041
2357	GRAMNEXUS0000002109	IN000042
2358	GRAMNEXUS0000002110	IN000043
2359	GRAMNEXUS0000002111	IN000044
2360	GRAMNEXUS0000002112	IN000045
2361	GRAMNEXUS0000002113	IN000046
2362	GRAMNEXUS0000002114	IN000047
2363	GRAMNEXUS0000002115	IN000048
2364	GRAMNEXUS0000002116	IN000049
2365	GRAMNEXUS0000002117	IN000050
2366	GRAMNEXUS0000002118	IN000051

2367	GRAMNEXUS0000002119	IN000052
2368	GRAMNEXUS0000002120	IN000053
2369	GRAMNEXUS0000002121	IN000054
2370	GRAMNEXUS0000002122	IN000055
2371	GRAMNEXUS0000002123	IN000056
2372	GRAMNEXUS0000002124	IN000057
2373	GRAMNEXUS0000002125	IN000058
2374	GRAMNEXUS0000002126	IN000059
2375	GRAMNEXUS0000002127	IN000060
2376	GRAMNEXUS0000002128	IN000061
2377	GRAMNEXUS0000002129	IN000062
2378	GRAMNEXUS0000002130	IN000063
2379	GRAMNEXUS0000002131	IN000064
2380	GRAMNEXUS0000002132	IN000065
2381	GRAMNEXUS0000002133	IN000066
2382	GRAMNEXUS0000002134	IN000067
2383	GRAMNEXUS0000002135	IN000068
2384	GRAMNEXUS0000002136	IN000069
2385	GRAMNEXUS0000002137	IN000070
2386	GRAMNEXUS0000002138	IN000071
2387	GRAMNEXUS0000002139	IN000072
2388	GRAMNEXUS0000002140	IN000073
2389	GRAMNEXUS0000002141	IN000074
2390	GRAMNEXUS0000002142	IN000075
2391	GRAMNEXUS0000002143	IN000076
2392	GRAMNEXUS0000002144	IN000077
2393	GRAMNEXUS0000002145	IN000078
2394	GRAMNEXUS0000002146	IN000079
2395	GRAMNEXUS0000002147	IN000080
2396	GRAMNEXUS0000002148	IN000081
2397	GRAMNEXUS0000002149	IN000082
2398	GRAMNEXUS0000002150	IN000083
2399	GRAMNEXUS0000002151	IN000084
2400	GRAMNEXUS0000002152	IN000085
2401	GRAMNEXUS0000002153	IN000086
2402	GRAMNEXUS0000002154	IN000087
2403	GRAMNEXUS0000002155	IN000088
2404	GRAMNEXUS0000002156	IN000089
2405	GRAMNEXUS0000002157	IN000090
2406	GRAMNEXUS0000002158	IN000091
2407	GRAMNEXUS0000002159	IN000092
2408	GRAMNEXUS0000002160	IN000093
2409	GRAMNEXUS0000002161	IN000094
2410	GRAMNEXUS0000002162	IN000095
2411	GRAMNEXUS0000002163	IN000096
2412	GRAMNEXUS0000002164	IN000097
2413	GRAMNEXUS0000002165	IN000098
2414	GRAMNEXUS0000002166	IN000099
2415	GRAMNEXUS0000002167	IN000100
2416	GRAMNEXUS0000002168	IN000101
2417	GRAMNEXUS0000002169	IN000102
2418	GRAMNEXUS0000002170	IN000103
2419	GRAMNEXUS0000002171	IN000104
2420	GRAMNEXUS0000002172	IN000105
2421	GRAMNEXUS0000002173	IN000106
2422	GRAMNEXUS0000002174	IN000107
2423	GRAMNEXUS0000002175	IN000108
2424	GRAMNEXUS0000002176	IN000109
2425	GRAMNEXUS0000002177	IN000110
2426	GRAMNEXUS0000002178	IN000111
2427	GRAMNEXUS0000002179	IN000112
2428	GRAMNEXUS0000002180	IN000113
2429	GRAMNEXUS0000002181	IN000114
2430	GRAMNEXUS0000002182	IN000115

2431	GRAMNEXUS0000002183	IN000116
2432	GRAMNEXUS0000002184	IN000117
2433	GRAMNEXUS0000002185	IN000118
2434	GRAMNEXUS0000002186	IN000119
2435	GRAMNEXUS0000002187	IN000120
2436	GRAMNEXUS0000002188	IN000121
2437	GRAMNEXUS0000002189	IN000122
2438	GRAMNEXUS0000002190	IN000123
2439	GRAMNEXUS0000002191	IN000124
2440	GRAMNEXUS0000002192	IN000125
2441	GRAMNEXUS0000002193	IN000126
2442	GRAMNEXUS0000002194	IN000127
2443	GRAMNEXUS0000002195	IN000128
2444	GRAMNEXUS0000002196	IN000129
2445	GRAMNEXUS0000002197	IN000130
2446	GRAMNEXUS0000002198	IN000131
2447	GRAMNEXUS0000002199	IN000132
2448	GRAMNEXUS0000002200	IN000133
2449	GRAMNEXUS0000002201	IN000134
2450	GRAMNEXUS0000002202	IN000135
2451	GRAMNEXUS0000002203	IN000136
2452	GRAMNEXUS0000002204	IN000137
2453	GRAMNEXUS0000002205	IN000138
2454	GRAMNEXUS0000002206	IN000139
2455	GRAMNEXUS0000002207	IN000140
2456	GRAMNEXUS0000002208	IN000141
2457	GRAMNEXUS0000002209	IN000142
2458	GRAMNEXUS0000002210	IN000143
2459	GRAMNEXUS0000002211	IN000144
2460	GRAMNEXUS0000002212	IN000145
2461	GRAMNEXUS0000002213	IN000146
2462	GRAMNEXUS0000002214	IN000147
2463	GRAMNEXUS0000002215	IN000148
2464	GRAMNEXUS0000002216	IN000149
2465	GRAMNEXUS0000002217	IN000150
2466	GRAMNEXUS0000002218	IN000151
2467	GRAMNEXUS0000002219	IN000152
2468	GRAMNEXUS0000002220	IN000153
2469	GRAMNEXUS0000002221	IN000154
2470	GRAMNEXUS0000002222	IN000155
2471	GRAMNEXUS0000002223	IN000156
2472	GRAMNEXUS0000002224	IN000157
2473	GRAMNEXUS0000002225	IN000158
2474	GRAMNEXUS0000002226	IN000159
2475	GRAMNEXUS0000002227	IN000160
2476	GRAMNEXUS0000002228	IN000161
2477	GRAMNEXUS0000002229	IN000162
2478	GRAMNEXUS0000002230	IN000163
2479	GRAMNEXUS0000002231	IN000164
2480	GRAMNEXUS0000002232	IN000165
2481	GRAMNEXUS0000002233	IN000166
2482	GRAMNEXUS0000002234	IN000167
2483	GRAMNEXUS0000002235	IN000168
2484	GRAMNEXUS0000002236	IN000169
2485	GRAMNEXUS0000002237	IN000170
2486	GRAMNEXUS0000002238	IN000171
2487	GRAMNEXUS0000002239	IN000172
2488	GRAMNEXUS0000002240	IN000173
2489	GRAMNEXUS0000002241	IN000174
2490	GRAMNEXUS0000002242	IN000175
2491	GRAMNEXUS0000002243	IN000176
2492	GRAMNEXUS0000002244	IN000177
2493	GRAMNEXUS0000002245	IN000178
2494	GRAMNEXUS0000002246	IN000179

2495	GRAMNEXUS0000002247	IN000180
2496	GRAMNEXUS0000002248	IN000181
2497	GRAMNEXUS0000002249	IN000182
2498	GRAMNEXUS0000002250	IN000183
2499	GRAMNEXUS0000002251	IN000184
2500	GRAMNEXUS0000002252	IN000185
2501	GRAMNEXUS0000002253	IN000186
2502	GRAMNEXUS0000002254	IN000187
2503	GRAMNEXUS0000002255	IN000188
2504	GRAMNEXUS0000002256	IN000189
2505	GRAMNEXUS0000002257	IN000190
2506	GRAMNEXUS0000002258	IN000191
2507	GRAMNEXUS0000002259	IN000192
2508	GRAMNEXUS0000002260	IN000193
2509	GRAMNEXUS0000002261	IN000194
2510	GRAMNEXUS0000002262	IN000195
2511	GRAMNEXUS0000002263	IN000001
2512	GRAMNEXUS0000002264	IN000002
2513	GRAMNEXUS0000002265	IN000003
2514	GRAMNEXUS0000002266	IN000004
2515	GRAMNEXUS0000002267	IN000005
2516	GRAMNEXUS0000002268	IN000006
2517	GRAMNEXUS0000002269	IN000007
2518	GRAMNEXUS0000002270	IN000008
2519	GRAMNEXUS0000002271	IN000009
2520	GRAMNEXUS0000002272	IN000010
2521	GRAMNEXUS0000002273	IN000011
2522	GRAMNEXUS0000002274	IN000012
2523	GRAMNEXUS0000002275	IN000013
2524	GRAMNEXUS0000002276	IN000014
2525	GRAMNEXUS0000002277	IN000015
2526	GRAMNEXUS0000002278	IN000016
2527	GRAMNEXUS0000002279	IN000017
2528	GRAMNEXUS0000002280	IN000018
2529	GRAMNEXUS0000002281	IN000019
2530	GRAMNEXUS0000002282	IN000020
2531	GRAMNEXUS0000002283	IN000021
2532	GRAMNEXUS0000002284	IN000022
2533	GRAMNEXUS0000002285	IN000023
2534	GRAMNEXUS0000002286	IN000024
2535	GRAMNEXUS0000002287	IN000025
2536	GRAMNEXUS0000002288	IN000026
2537	GRAMNEXUS0000002289	IN000027
2538	GRAMNEXUS0000002290	IN000028
2539	GRAMNEXUS0000002291	IN000029
2540	GRAMNEXUS0000002292	IN000030
2541	GRAMNEXUS0000002293	IN000031
2542	GRAMNEXUS0000002294	IN000032
2543	GRAMNEXUS0000002295	IN000033
2544	GRAMNEXUS0000002296	IN000034
2545	GRAMNEXUS0000002297	IN000035
2546	GRAMNEXUS0000002298	IN000036
2547	GRAMNEXUS0000002299	IN000037
2548	GRAMNEXUS0000002300	IN000038
2549	GRAMNEXUS0000002301	IN000039
2550	GRAMNEXUS0000002302	IN000040
2551	GRAMNEXUS0000002303	IN000041
2552	GRAMNEXUS0000002304	IN000042
2553	GRAMNEXUS0000002305	IN000043
2554	GRAMNEXUS0000002306	IN000044
2555	GRAMNEXUS0000002307	IN000045
2556	GRAMNEXUS0000002308	IN000046
2557	GRAMNEXUS0000002309	IN000047
2558	GRAMNEXUS0000002310	IN000048

2559	GRAMNEXUS0000002311	IN000049
2560	GRAMNEXUS0000002312	IN000050
2561	GRAMNEXUS0000002313	IN000051
2562	GRAMNEXUS0000002314	IN000052
2563	GRAMNEXUS0000002315	IN000053
2564	GRAMNEXUS0000002316	IN000054
2565	GRAMNEXUS0000002317	IN000055
2566	GRAMNEXUS0000002318	IN000056
2567	GRAMNEXUS0000002319	IN000057
2568	GRAMNEXUS0000002320	IN000058
2569	GRAMNEXUS0000002321	IN000059
2570	GRAMNEXUS0000002322	IN000060
2571	GRAMNEXUS0000002323	IN000061
2572	GRAMNEXUS0000002324	IN000062
2573	GRAMNEXUS0000002325	IN000063
2574	GRAMNEXUS0000002326	IN000064
2575	GRAMNEXUS0000002327	IN000065
2576	GRAMNEXUS0000002328	IN000066
2577	GRAMNEXUS0000002329	IN000067
2578	GRAMNEXUS0000002330	IN000068
2579	GRAMNEXUS0000002331	IN000069
2580	GRAMNEXUS0000002332	IN000070
2581	GRAMNEXUS0000002333	IN000071
2582	GRAMNEXUS0000002334	IN000072
2583	GRAMNEXUS0000002335	IN000073
2584	GRAMNEXUS0000002336	IN000074
2585	GRAMNEXUS0000002337	IN000075
2586	GRAMNEXUS0000002338	IN000076
2587	GRAMNEXUS0000002339	IN000077
2588	GRAMNEXUS0000002340	IN000078
2589	GRAMNEXUS0000002341	IN000079
2590	GRAMNEXUS0000002342	IN000080
2591	GRAMNEXUS0000002343	IN000081
2592	GRAMNEXUS0000002344	IN000082
2593	GRAMNEXUS0000002345	IN000083
2594	GRAMNEXUS0000002346	IN000084
2595	GRAMNEXUS0000002347	IN000085
2596	GRAMNEXUS0000002348	IN000086
2597	GRAMNEXUS0000002349	IN000087
2598	GRAMNEXUS0000002350	IN000088
2599	GRAMNEXUS0000002351	IN000089
2600	GRAMNEXUS0000002352	IN000090
2601	GRAMNEXUS0000002353	IN000091
2602	GRAMNEXUS0000002354	IN000092
2603	GRAMNEXUS0000002355	IN000093
2604	GRAMNEXUS0000002356	IN000094
2605	GRAMNEXUS0000002357	IN000095
2606	GRAMNEXUS0000002358	IN000096
2607	GRAMNEXUS0000002359	IN000097
2608	GRAMNEXUS0000002360	IN000098
2609	GRAMNEXUS0000002361	IN000099
2610	GRAMNEXUS0000002362	IN000100
2611	GRAMNEXUS0000002363	IN000101
2612	GRAMNEXUS0000002364	IN000102
2613	GRAMNEXUS0000002365	IN000103
2614	GRAMNEXUS0000002366	IN000104
2615	GRAMNEXUS0000002367	IN000105
2616	GRAMNEXUS0000002368	IN000106
2617	GRAMNEXUS0000002369	IN000107
2618	GRAMNEXUS0000002370	IN000108
2619	GRAMNEXUS0000002371	IN000109
2620	GRAMNEXUS0000002372	IN000110
2621	GRAMNEXUS0000002373	IN000111
2622	GRAMNEXUS0000002374	IN000112

2623	GRAMNEXUS0000002375	IN000113
2624	GRAMNEXUS0000002376	IN000114
2625	GRAMNEXUS0000002377	IN000115
2626	GRAMNEXUS0000002378	IN000116
2627	GRAMNEXUS0000002379	IN000117
2628	GRAMNEXUS0000002380	IN000118
2629	GRAMNEXUS0000002381	IN000119
2630	GRAMNEXUS0000002382	IN000120
2631	GRAMNEXUS0000002383	IN000121
2632	GRAMNEXUS0000002384	IN000122
2633	GRAMNEXUS0000002385	IN000123
2634	GRAMNEXUS0000002386	IN000124
2635	GRAMNEXUS0000002387	IN000125
2636	GRAMNEXUS0000002388	IN000126
2637	GRAMNEXUS0000002389	IN000127
2638	GRAMNEXUS0000002390	IN000128
2639	GRAMNEXUS0000002391	IN000129
2640	GRAMNEXUS0000002392	IN000130
2641	GRAMNEXUS0000002393	IN000131
2642	GRAMNEXUS0000002394	IN000132
2643	GRAMNEXUS0000002395	IN000133
2644	GRAMNEXUS0000002396	IN000134
2645	GRAMNEXUS0000002397	IN000135
2646	GRAMNEXUS0000002398	IN000136
2647	GRAMNEXUS0000002399	IN000137
2648	GRAMNEXUS0000002400	IN000138
2649	GRAMNEXUS0000002401	IN000139
2650	GRAMNEXUS0000002402	IN000140
2651	GRAMNEXUS0000002403	IN000141
2652	GRAMNEXUS0000002404	IN000142
2653	GRAMNEXUS0000002405	IN000143
2654	GRAMNEXUS0000002406	IN000144
2655	GRAMNEXUS0000002407	IN000145
2656	GRAMNEXUS0000002408	IN000146
2657	GRAMNEXUS0000002409	IN000147
2658	GRAMNEXUS0000002410	IN000148
2659	GRAMNEXUS0000002411	IN000149
2660	GRAMNEXUS0000002412	IN000150
2661	GRAMNEXUS0000002413	IN000151
2662	GRAMNEXUS0000002414	IN000152
2663	GRAMNEXUS0000002415	IN000153
2664	GRAMNEXUS0000002416	IN000154
2665	GRAMNEXUS0000002417	IN000155
2666	GRAMNEXUS0000002418	IN000156
2667	GRAMNEXUS0000002419	IN000157
2668	GRAMNEXUS0000002420	IN000158
2669	GRAMNEXUS0000002421	IN000159
2670	GRAMNEXUS0000002422	IN000160
2671	GRAMNEXUS0000002423	IN000161
2672	GRAMNEXUS0000002424	IN000162
2673	GRAMNEXUS0000002425	IN000163
2674	GRAMNEXUS0000002426	IN000164
2675	GRAMNEXUS0000002427	IN000165
2676	GRAMNEXUS0000002428	IN000166
2677	GRAMNEXUS0000002429	IN000167
2678	GRAMNEXUS0000002430	IN000168
2679	GRAMNEXUS0000002431	IN000169
2680	GRAMNEXUS0000002432	IN000170
2681	GRAMNEXUS0000002433	IN000171
2682	GRAMNEXUS0000002434	IN000172
2683	GRAMNEXUS0000002435	IN000173
2684	GRAMNEXUS0000002436	IN000174
2685	GRAMNEXUS0000002437	IN000175
2686	GRAMNEXUS0000002438	IN000176

2687	GRAMNEXUS0000002439	IN000177
2688	GRAMNEXUS0000002440	IN000178
2689	GRAMNEXUS0000002441	IN000179
2690	GRAMNEXUS0000002442	IN000180
2691	GRAMNEXUS0000002443	IN000181
2692	GRAMNEXUS0000002444	IN000182
2693	GRAMNEXUS0000002445	IN000183
2694	GRAMNEXUS0000002446	IN000184
2695	GRAMNEXUS0000002447	IN000185
2696	GRAMNEXUS0000002448	IN000186
2697	GRAMNEXUS0000002449	IN000187
2698	GRAMNEXUS0000002450	IN000188
2699	GRAMNEXUS0000002451	IN000189
2700	GRAMNEXUS0000002452	IN000190
2701	GRAMNEXUS0000002453	IN000191
2702	GRAMNEXUS0000002454	IN000192
2703	GRAMNEXUS0000002455	IN000193
2704	GRAMNEXUS0000002456	IN000194
2705	GRAMNEXUS0000002457	IN000195
2706	GRAMNEXUS0000002458	IN000196
2707	GRAMNEXUS0000002459	IN000197
2708	GRAMNEXUS0000002460	IN000198
2709	GRAMNEXUS0000002461	IN000199
2710	GRAMNEXUS0000002462	IN000200
2711	GRAMNEXUS0000002463	IN000201
2712	GRAMNEXUS0000002464	IN000202
2713	GRAMNEXUS0000002465	IN000203
2714	GRAMNEXUS0000002466	IN000204
2715	GRAMNEXUS0000002467	IN000205
2716	GRAMNEXUS0000002468	IN000206
2717	GRAMNEXUS0000002469	IN000207
2718	GRAMNEXUS0000002470	IN000208
2719	GRAMNEXUS0000002471	IN000209
2720	GRAMNEXUS0000002472	IN000210
2721	GRAMNEXUS0000002473	IN000211
2722	GRAMNEXUS0000002474	IN000212
2723	GRAMNEXUS0000002475	IN000213
2724	GRAMNEXUS0000002476	IN000214
2725	GRAMNEXUS0000002477	IN000215
2726	GRAMNEXUS0000002478	IN000216
2727	GRAMNEXUS0000002479	IN000217
2728	GRAMNEXUS0000002480	IN000218
2729	GRAMNEXUS0000002481	IN000219
2730	GRAMNEXUS0000002482	IN000220
2731	GRAMNEXUS0000002483	IN000221
2732	GRAMNEXUS0000002484	IN000222
2733	GRAMNEXUS0000002485	IN000223
2734	GRAMNEXUS0000002486	IN000224
2735	GRAMNEXUS0000002487	IN000225
2736	GRAMNEXUS0000002488	IN000226
2737	GRAMNEXUS0000002489	IN000227
2738	GRAMNEXUS0000002490	IN000228
2739	GRAMNEXUS0000002491	IN000229
2740	GRAMNEXUS0000002492	IN000230
2741	GRAMNEXUS0000002493	IN000231
2742	GRAMNEXUS0000002494	IN000232
2743	GRAMNEXUS0000002495	IN000233
2744	GRAMNEXUS0000002496	IN000001
2745	GRAMNEXUS0000002497	reviewer.bat
2746	GRAMNEXUS0000002498	reviewer.exe
2747	GRAMNEXUS0000002499	studies.exe
2748	GRAMNEXUS0000002500	merge.txt
2749	GRAMNEXUS0000002501	SP_Sorna.tdd
2750	GRAMNEXUS0000002502	RingCentral Meetings.lnk

2751	GRAMNEXUS0000002503	RM Endo DR.docx
2752	GRAMNEXUS0000002504	SCOTT L XRAY.docx
2753	GRAMNEXUS0000002505	SCOTT MRI ORDER.docx
2754	GRAMNEXUS0000002506	SCOTT SCOLLIO XRAY.docx
2755	GRAMNEXUS0000002507	Sterility - Endo LIRs.xlsx
2756	GRAMNEXUS0000002508	Syringe Media Study.xlsx
2757	GRAMNEXUS0000002509	u223_457679.pdf
2758	GRAMNEXUS0000002510	VAL-1141 Sum.docm
2759	GRAMNEXUS0000002511	Validation Summary Template.docm
2760	GRAMNEXUS0000002512	Virtue_Cider_40.9_mile_route.fit
2761	GRAMNEXUS0000002513	~$cro Tech Job Description revised.docx
2762	GRAMNEXUS0000002514	~WRL0003.tmp
2763	GRAMNEXUS0000002515	~WRL0005.tmp
2764	GRAMNEXUS0000002516	~WRL3311.tmp
2765	GRAMNEXUS0000002517	My MasterControl.url
2766	GRAMNEXUS0000002518	211.png
2767	GRAMNEXUS0000002519	basement.jpg
2768	GRAMNEXUS0000002520	broken floof.jpg
2769	GRAMNEXUS0000002521	cleanroom.jpg
2770	GRAMNEXUS0000002522	cleanroom.png
2771	GRAMNEXUS0000002523	Colony_morphology_svg.png
2772	GRAMNEXUS0000002524	doggos.jpg
2773	GRAMNEXUS0000002525	dogs.jpg
2774	GRAMNEXUS0000002526	ID2.jpg
2775	GRAMNEXUS0000002527	id3.jpg
2776	GRAMNEXUS0000002528	IDs.jpg
2777	GRAMNEXUS0000002529	IMG_4723.JPG
2778	GRAMNEXUS0000002530	Lab PPE.jpg
2779	GRAMNEXUS0000002531	lab sketch.jpg
2780	GRAMNEXUS0000002532	microbes.jpg
2781	GRAMNEXUS0000002533	middle.jpg
2782	GRAMNEXUS0000002534	mold.png
2783	GRAMNEXUS0000002535	pinky.jpg
2784	GRAMNEXUS0000002536	pointer.jpg
2785	GRAMNEXUS0000002537	qc lab.PNG
2786	GRAMNEXUS0000002538	receipt1.jpg
2787	GRAMNEXUS0000002539	receipt2.jpg
2788	GRAMNEXUS0000002540	receipt3.jpg
2789	GRAMNEXUS0000002541	ring.jpg
2790	GRAMNEXUS0000002542	stan.jpg
2791	GRAMNEXUS0000002543	tacomemedidsomeonesay.jpg
2792	GRAMNEXUS0000002544	thumb.jpg
2793	GRAMNEXUS0000002545	Trends.PNG
2794	GRAMNEXUS0000002546	VW.jpg
2795	GRAMNEXUS0000002547	mapi15---{S-1-5-21-558651068-1390397249-3264284442-2120}-.searchconnector-ms
2796	GRAMNEXUS0000002548	Sticky Notes (Windows Sticky Notes).searchconnector-ms
2797	GRAMNEXUS0000002549	'$4A612DEE.jpg
2798	GRAMNEXUS0000002550	'$BDE18270.doc
2799	GRAMNEXUS0000002551	'$D02E3D0B.xls
2800	GRAMNEXUS0000002552	'$FF14F4D0.pptx
2801	GRAMNEXUS0000002553	GRAM SOP Administration of the Vitek 2 Compact System.docx
2802	GRAMNEXUS0000002554	VITEK 2 COMPACT URS VAL-00270 (GrandRiver) _Sequence Signed.pdf
2803	GRAMNEXUS0000002555	VITEK 2 Compact IOPQ _VAL-00273_(Grand River)_25Mar2010_Sequence Signed.pdf
2804	GRAMNEXUS0000002556	GRAM Vitek 2 Compact Identification Result Form (1).docx
2805	GRAMNEXUS0000002557	GRAM Vitek 2 Compact Analyst Qualification Form (1).docx
2806	GRAMNEXUS0000002558	GRAM Vitek 2 Compact QC Card Release Form.docx
2807	GRAMNEXUS0000002559	CORP-0558 GRAM Operation and Maintenance of the Vitek 2 Compact System.docx
2808	GRAMNEXUS0000002560	VITEK 2 Compact Validation Summary Report (GrandRiver).pdf
2809	GRAMNEXUS0000002561	VITEK 2 Compact 30 Schedule (GR).pdf
2810	GRAMNEXUS0000002562	VITEK 2 System Validation Plan VAL-00272 (GrandRiver) _Sequence Signed 23Mar20.pdf
2811	GRAMNEXUS0000002563	VAL-1383-SUM(SAS).docm
2812	GRAMNEXUS0000002564	Template-0044.docm
2813	GRAMNEXUS0000002565	EIR-180001.docx
2814	GRAMNEXUS0000002565.0001	Microsoft_Visio_Drawing1.vsdx

2815	GRAMNEXUS0000002566	EIR-170090.docx
2816	GRAMNEXUS0000002566.0001	Microsoft_Visio_Drawing1.vsdx
2817	GRAMNEXUS0000002567	EIR-170089.docx
2818	GRAMNEXUS0000002567.0001	Microsoft_Visio_Drawing1.vsdx
2819	GRAMNEXUS0000002568	EIR-170086.docx
2820	GRAMNEXUS0000002568.0001	Microsoft_Visio_Drawing1.vsdx
2821	GRAMNEXUS0000002569	EIR-170082.docx
2822	GRAMNEXUS0000002569.0001	Microsoft_Visio_Drawing1.vsdx
2823	GRAMNEXUS0000002570	EIR-170084.docx
2824	GRAMNEXUS0000002570.0001	Microsoft_Visio_Drawing1.vsdx
2825	GRAMNEXUS0000002571	EIR-170085.docx
2826	GRAMNEXUS0000002572	EIR-170081.docx
2827	GRAMNEXUS0000002573	EIR-170079.docx
2828	GRAMNEXUS0000002573.0001	Microsoft_Visio_Drawing1.vsdx
2829	GRAMNEXUS0000002574	EIR-170074.docx
2830	GRAMNEXUS0000002574.0001	Microsoft_Visio_Drawing1.vsdx
2831	GRAMNEXUS0000002575	CORP-LOG-0005 - Equipment Tracking Log.xlsx
2832	GRAMNEXUS0000002576	CORP-LOG-0070 - Master Calibration List.xlsx
2833	GRAMNEXUS0000002577	PPO (4A)SBC (11.13).pdf
2834	GRAMNEXUS0000002578	I-16-068 CofA Ver02.pdf
2835	GRAMNEXUS0000002579	Compressed Gas Trending 2016.xlsx
2836	GRAMNEXUS0000002580	Water Trending Q4 2016.xlsx
2837	GRAMNEXUS0000002581	LIR Extension Template.docx
2838	GRAMNEXUS0000002582	DR-170039.docx
2839	GRAMNEXUS0000002583	EIR-160076.docx
2840	GRAMNEXUS0000002584	EIR-160077.docx
2841	GRAMNEXUS0000002585	EIR-160078.docx
2842	GRAMNEXUS0000002586	EIR-160084.docx
2843	GRAMNEXUS0000002587	EIR-160085.docx
2844	GRAMNEXUS0000002588	EIR-160088.docx
2845	GRAMNEXUS0000002589	EIR-170002.docx
2846	GRAMNEXUS0000002590	EIR-170003.docx
2847	GRAMNEXUS0000002591	EIR-170004.docx
2848	GRAMNEXUS0000002592	EIR-170005.docx
2849	GRAMNEXUS0000002593	EIR-170006.docx
2850	GRAMNEXUS0000002594	EIR-170007.docx
2851	GRAMNEXUS0000002595	EIR-170008.docx
2852	GRAMNEXUS0000002596	EIR-170009.docx
2853	GRAMNEXUS0000002597	EIR-170010.docx
2854	GRAMNEXUS0000002598	EIR-170011.docx
2855	GRAMNEXUS0000002599	EIR-170012.docx
2856	GRAMNEXUS0000002600	EIR-170013.docx
2857	GRAMNEXUS0000002601	EIR-170014.docx
2858	GRAMNEXUS0000002602	EIR-170015.docx
2859	GRAMNEXUS0000002602.0001	Microsoft_Visio_Drawing1.vsdx
2860	GRAMNEXUS0000002603	EIR-170016.docx
2861	GRAMNEXUS0000002604	EIR-170019.docx
2862	GRAMNEXUS0000002605	EIR-170021 SWBv1(SAS).docx
2863	GRAMNEXUS0000002606	EIR-170021.docx
2864	GRAMNEXUS0000002607	EIR-170022.docx
2865	GRAMNEXUS0000002608	EIR-170023.docx
2866	GRAMNEXUS0000002609	EIR-170024.docx
2867	GRAMNEXUS0000002610	EIR-170025.docx
2868	GRAMNEXUS0000002611	EIR-170026.docx
2869	GRAMNEXUS0000002612	EIR-170028.docx
2870	GRAMNEXUS0000002613	EIR-170031.docx
2871	GRAMNEXUS0000002614	EIR-170032.docx
2872	GRAMNEXUS0000002615	EIR-170034.docx
2873	GRAMNEXUS0000002616	EIR-170035.docx
2874	GRAMNEXUS0000002617	EIR-170036.docx
2875	GRAMNEXUS0000002618	EIR-170037.docx
2876	GRAMNEXUS0000002619	EIR-170038.docx
2877	GRAMNEXUS0000002620	EIR-170039.docx
2878	GRAMNEXUS0000002621	EIR-170040.docx

2879	GRAMNEXUS0000002622	EIR-170041.docx
2880	GRAMNEXUS0000002623	EIR-170042.docx
2881	GRAMNEXUS0000002624	EIR-170043.docx
2882	GRAMNEXUS0000002625	EIR-170045.docx
2883	GRAMNEXUS0000002626	EIR-170046 (1).docx
2884	GRAMNEXUS0000002627	EIR-170046.docx
2885	GRAMNEXUS0000002628	EIR-170048.docx
2886	GRAMNEXUS0000002629	EIR-170049.docx
2887	GRAMNEXUS0000002629.0001	Microsoft_Visio_Drawing1.vsdx
2888	GRAMNEXUS0000002630	EIR-170050.docx
2889	GRAMNEXUS0000002631	EIR-170051.docx
2890	GRAMNEXUS0000002631.0001	Microsoft_Visio_Drawing101010101011.vsdx
2891	GRAMNEXUS0000002632	EIR-170055.docx
2892	GRAMNEXUS0000002633	EIR-170056.docx
2893	GRAMNEXUS0000002634	EIR-170057.docx
2894	GRAMNEXUS0000002635	EIR-170060.docx
2895	GRAMNEXUS0000002636	EIR-170062.docx
2896	GRAMNEXUS0000002637	EIR-170063.docx
2897	GRAMNEXUS0000002637.0001	Microsoft_Visio_Drawing1.vsdx
2898	GRAMNEXUS0000002638	EIR-170066.docx
2899	GRAMNEXUS0000002639	EIR-170067.docx
2900	GRAMNEXUS0000002640	EIR-170070.docx
2901	GRAMNEXUS0000002640.0001	Microsoft_Visio_Drawing1.vsdx
2902	GRAMNEXUS0000002641	EIR-170071.docx
2903	GRAMNEXUS0000002642	EIR-170073.docx
2904	GRAMNEXUS0000002642.0001	Microsoft_Visio_Drawing1.vsdx
2905	GRAMNEXUS0000002643	TeamExport.pdf
2906	GRAMNEXUS0000002644	ATL-Our Values.pdf
2907	GRAMNEXUS0000002645	ATL New Hire Benefits Booklet 2020.pptx
2908	GRAMNEXUS0000002646	Wed_Night_Gravel_Ride.fit
2909	GRAMNEXUS0000002647	BTR_FIRST_QC_LYT_002-1326-1 (fix).pdf
2910	GRAMNEXUS0000002648	BTR_FIRST_QC_LYT_002-1340 (fix).pdf
2911	GRAMNEXUS0000002649	MicrosoftTeams-image.png
2912	GRAMNEXUS0000002650	WPT_Butterfly_Century.tcx
2913	GRAMNEXUS0000002651	Awesome_fun_route_but_4_flat_tires_messes_with_your_data_.gpx
2914	GRAMNEXUS0000002652	SOS Online-7516660-05042020-141111.PDF
2915	GRAMNEXUS0000002653	Under Counter Freezer RA (approved copy).pdf
2916	GRAMNEXUS0000002654	Refrigerator Double Door RA (approved copy).pdf
2917	GRAMNEXUS0000002655	Refrigerator Single Door RA (approved copy).pdf
2918	GRAMNEXUS0000002656	Single Door Full Size Incubator RA (approved copy).pdf
2919	GRAMNEXUS0000002657	BSC RA (approved copy).pdf
2920	GRAMNEXUS0000002658	NCR-0287.docx
2921	GRAMNEXUS0000002659	NCR-0286.docx
2922	GRAMNEXUS0000002660	unifying250.exe
2923	GRAMNEXUS0000002661	NCR-0229.docx
2924	GRAMNEXUS0000002661.0001	Microsoft_Visio_Drawing.vsdx
2925	GRAMNEXUS0000002662	TGA - Cleaning and Contamination Control - Regulatory Perspective.pdf
2926	GRAMNEXUS0000002663	20190606_PC_auto.pdf
2927	GRAMNEXUS0000002664	BX-GA-001.025-B - PMF version 3.pdf
2928	GRAMNEXUS0000002665	Engineering batch testing.pdf
2929	GRAMNEXUS0000002666	SVV-10P-PMF.pdf
2930	GRAMNEXUS0000002667	batch-analyses PSMA.pdf
2931	GRAMNEXUS0000002668	NCR-0088.docx
2932	GRAMNEXUS0000002669	NCR-0087.docx
2933	GRAMNEXUS0000002670	NCR-0072.docx
2934	GRAMNEXUS0000002670.0001	Microsoft_Visio_Drawing.vsdx
2935	GRAMNEXUS0000002671	NCR-0044.docx
2936	GRAMNEXUS0000002672	NCR-0042.docx
2937	GRAMNEXUS0000002673	STA-0005 Approval.pdf
2938	GRAMNEXUS0000002674	QC Lab Supervisor.pdf
2939	GRAMNEXUS0000002675	SV-GA-001.025-PMF.pdf
2940	GRAMNEXUS0000002676	EIR-180098.docx
2941	GRAMNEXUS0000002677	EIR-180070.docx
2942	GRAMNEXUS0000002677.0001	Microsoft_Visio_Drawing.vsdx

2943	GRAMNEXUS0000002678	EIR-180069.docx
2944	GRAMNEXUS0000002678.0001	Microsoft_Visio_Drawing.vsdx
2945	GRAMNEXUS0000002679	EIR-180068.docx
2946	GRAMNEXUS0000002680	EIR-180066.docx
2947	GRAMNEXUS0000002681	EIR-180065.docx
2948	GRAMNEXUS0000002681.0001	Microsoft_Visio_Drawing.vsdx
2949	GRAMNEXUS0000002682	EIR-180064.docx
2950	GRAMNEXUS0000002683	EIR-180062.docx
2951	GRAMNEXUS0000002684	EIR-180061.docx
2952	GRAMNEXUS0000002684.0001	Microsoft_Visio_Drawing.vsdx
2953	GRAMNEXUS0000002685	iTunes64Setup.exe
2954	GRAMNEXUS0000002686	VAL-1343 WFI System URS (CAM).docx
2955	GRAMNEXUS0000002687	VAL-1315 EMS URS r0.1.docm
2956	GRAMNEXUS0000002688	Scott.2018-07-27.pdf
2957	GRAMNEXUS0000002689	EIR-180058.docx
2958	GRAMNEXUS0000002690	EIR-180057.docx
2959	GRAMNEXUS0000002691	EIR-180055.docx
2960	GRAMNEXUS0000002692	EIR-180053.docx
2961	GRAMNEXUS0000002693	EIR-180052.docx
2962	GRAMNEXUS0000002694	Scott.2018-07-13.pdf
2963	GRAMNEXUS0000002695	EIR-180049.docx
2964	GRAMNEXUS0000002696	EIR-180041.docx
2965	GRAMNEXUS0000002696.0001	Microsoft_Visio_Drawing.vsdx
2966	GRAMNEXUS0000002697	EIR-180036.docx
2967	GRAMNEXUS0000002698	EIR-180034.docx
2968	GRAMNEXUS0000002698.0001	Microsoft_Visio_Drawing.vsdx
2969	GRAMNEXUS0000002699	EIR-180033.docx
2970	GRAMNEXUS0000002699.0001	Microsoft_Visio_Drawing1.vsdx
2971	GRAMNEXUS0000002700	EIR-180032.docx
2972	GRAMNEXUS0000002700.0001	Microsoft_Visio_Drawing1.vsdx
2973	GRAMNEXUS0000002701	EIR-180038.docx
2974	GRAMNEXUS0000002701.0001	Microsoft_Visio_Drawing1.vsdx
2975	GRAMNEXUS0000002702	EIR-180031.docx
2976	GRAMNEXUS0000002702.0001	Microsoft_Visio_Drawing1.vsdx
2977	GRAMNEXUS0000002703	EIR-180030.docx
2978	GRAMNEXUS0000002703.0001	Microsoft_Visio_Drawing1.vsdx
2979	GRAMNEXUS0000002704	EIR-180027.docx
2980	GRAMNEXUS0000002705	LIR-160038.pdf
2981	GRAMNEXUS0000002706	LIR-160049.pdf
2982	GRAMNEXUS0000002707	EIR-180028.docx
2983	GRAMNEXUS0000002708	LOG Template.docm
2984	GRAMNEXUS0000002709	EIR-180026.docx
2985	GRAMNEXUS0000002709.0001	Microsoft_Visio_Drawing1.vsdx
2986	GRAMNEXUS0000002710	EIR-180023.docx
2987	GRAMNEXUS0000002710.0001	Microsoft_Visio_Drawing1.vsdx
2988	GRAMNEXUS0000002711	EIR-180025.docx
2989	GRAMNEXUS0000002712	EIR-180029.docx
2990	GRAMNEXUS0000002713	EIR-180022.docx
2991	GRAMNEXUS0000002713.0001	Microsoft_Visio_Drawing.vsdx
2992	GRAMNEXUS0000002714	EIR-180021.docx
2993	GRAMNEXUS0000002715	EIR-180020.docx
2994	GRAMNEXUS0000002716	EIR-180015 (1).docx
2995	GRAMNEXUS0000002716.0001	Microsoft_Visio_Drawing1.vsdx
2996	GRAMNEXUS0000002717	EIR-180018.docx
2997	GRAMNEXUS0000002718	EIR-180017.docx
2998	GRAMNEXUS0000002719	GRAM Logo.jpg
2999	GRAMNEXUS0000002720	EIR-180015.docx
3000	GRAMNEXUS0000002720.0001	Microsoft_Visio_Drawing1.vsdx
3001	GRAMNEXUS0000002721	EIR-180014.docx
3002	GRAMNEXUS0000002721.0001	Microsoft_Visio_Drawing1111111111111111111.vsdx
3003	GRAMNEXUS0000002722	EIR-180008.docx
3004	GRAMNEXUS0000002722.0001	Microsoft_Visio_Drawing3.vsdx
3005	GRAMNEXUS0000002722.0002	Microsoft_Visio_Drawing1.vsdx
3006	GRAMNEXUS0000002722.0003	Microsoft_Visio_Drawing2.vsdx

3007	GRAMNEXUS0000002723	EIR-180009.docx
3008	GRAMNEXUS0000002723.0001	Microsoft_Visio_Drawing1.vsdx
3009	GRAMNEXUS0000002724	EIR-180004.docx
3010	GRAMNEXUS0000002724.0001	Microsoft_Visio_Drawing1.vsdx
3011	GRAMNEXUS0000002725	EIR-170096.docx
3012	GRAMNEXUS0000002725.0001	Microsoft_Visio_Drawing1.vsdx
3013	GRAMNEXUS0000002726	EIR-170095.docx
3014	GRAMNEXUS0000002726.0001	Microsoft_Visio_Drawing1.vsdx
3015	GRAMNEXUS0000002727	EIR-180002.docx
3016	GRAMNEXUS0000002727.0001	Microsoft_Visio_Drawing1.vsdx
3017	GRAMNEXUS0000002728	GRAM Directions (2).pdf
3018	GRAMNEXUS0000002729	FW_ ISO 8573-1 2010_04_15_pdf.msg
3019	GRAMNEXUS0000002729.0001	ISO 8573-1 2010.04.15.pdf
3020	GRAMNEXUS0000002730	PQ Strategy Spreadsheet.msg
3021	GRAMNEXUS0000002730.0001	Butterworth PQ Sampling Plan.xlsx
3022	GRAMNEXUS0000002731	FW_ SKAN EM Qualification of Isolators - High Level Overview .msg
3023	GRAMNEXUS0000002731.0001	Definition of the CD MBQ points.pdf
3024	GRAMNEXUS0000002731.0002	Overview of Cycle Development and microbiological Qualification Offered by SKAN.pdf
3025	GRAMNEXUS0000002732	Process Gases - ISPE Good Practice Guidance.msg
3026	GRAMNEXUS0000002732.0001	ISPE Good Practices Guide_Process Gases.pdf
3027	GRAMNEXUS0000002733	Draft of Sterilizer SOP with updates.msg
3028	GRAMNEXUS0000002733.0001	Draft Sterilizer SOP 051220 dm.docx
3029	GRAMNEXUS0000002734	RE_ VITEK Training.msg
3030	GRAMNEXUS0000002734.0001	048640-02 Procedure_-_VITEK_2_Systems_-_Network_Configuration_Guide_-_Win10 MAR_4259.pdf
3031	GRAMNEXUS0000002735	Grand River Aseptic Grand Rapids Mu 527987.msg
3032	GRAMNEXUS0000002735.0001	SA-499556_V1.pdf
3033	GRAMNEXUS0000002735.0002	ATT00001.txt
3034	GRAMNEXUS0000002736	Re_ Contact List_ Vitek 2 Compact Installation Summary.msg
3035	GRAMNEXUS0000002736.0001	VITEK 2 Compact Traceabilty Matrix VAL-00271 (GrandRiver)_Corrected.pdf
3036	GRAMNEXUS0000002737	Performance Solutions_Grand River Vitek 2 Compact IOPQ - Travel Restrictions.msg
3037	GRAMNEXUS0000002738	Vitek SOPs and Forms.msg
3038	GRAMNEXUS0000002738.0001	CORP-0558 GRAM Operation and Maintenance of the Vitek 2 Compact System.docx
3039	GRAMNEXUS0000002738.0002	GRAM SOP Administration of the Vitek 2 Compact System.docx
3040	GRAMNEXUS0000002738.0003	GRAM Vitek 2 Compact QC Card Release Form.docx
3041	GRAMNEXUS0000002738.0004	GRAM Vitek 2 Compact Analyst Qualification Form (1).docx
3042	GRAMNEXUS0000002738.0005	GRAM Vitek 2 Compact Identification Result Form (1).docx
3043	GRAMNEXUS0000002739	Re_ Performance Solutions - Grand River.msg
3044	GRAMNEXUS0000002739.0001	VITEK 2 Client Survey.pdf
3045	GRAMNEXUS0000002740	RE_ Contact List_ Vitek 2 Compact Installation Summary (1).msg
3046	GRAMNEXUS0000002741	RE_ Contact List_ Vitek 2 Compact Installation Summary (2).msg
3047	GRAMNEXUS0000002741.0001	9315662-002-US-A WHITE PAPER VILINK - HD version US.pdf
3048	GRAMNEXUS0000002741.0002	SecureLink_WhitePaper_RemoteSupportNetwork.pdf
3049	GRAMNEXUS0000002741.0003	SL_WhitePaper_ComplianceAndRegulations.pdf
3050	GRAMNEXUS0000002742	Contact List_ Vitek 2 Compact Installation Summary.msg
3051	GRAMNEXUS0000002743	Updated Quote.msg
3052	GRAMNEXUS0000002743.0001	GRAMV2C30Quote.pdf
3053	GRAMNEXUS0000002743.0002	Vitek 2 Compact SLOER Rev 02.A.pdf
3054	GRAMNEXUS0000002744	CORP-SOP-0548.msg
3055	GRAMNEXUS0000002744.0001	CORP-SOP-0548 EM of Isolator at Butterworth Facility.docx
3056	GRAMNEXUS0000002745	RE_ Isolator EMPQ Facilitated Review.msg
3057	GRAMNEXUS0000002745.0001	VAL-1817 Butterworth Isolator EMPQ with comments dm.docx
3058	GRAMNEXUS0000002746	RE_ Quarter 1 report.msg
3059	GRAMNEXUS0000002746.0001	Q1 2020 EM.docx
3060	GRAMNEXUS0000002746.0001.0001	Microsoft_Excel_Worksheet.xlsx
3061	GRAMNEXUS0000002746.0001.0002	Microsoft_Excel_Worksheet1.xlsx
3062	GRAMNEXUS0000002746.0001.0003	Microsoft_Excel_Worksheet2.xlsx
3063	GRAMNEXUS0000002746.0001.0004	Microsoft_Excel_Worksheet3.xlsx
3064	GRAMNEXUS0000002747	pH SOP with conductivity added.msg
3065	GRAMNEXUS0000002747.0001	GRAM Operation and Maintenance of the SympHony pH Meter (with conductivity) 070620.docx
3066	GRAMNEXUS0000002748	VAL-1817 Butterworth Isolator EMPQ with comments_JR_12JUL2020.docx
3067	GRAMNEXUS0000002749	VAL-1817 Butterworth Isolator EMPQ with comments_JR_14JUL2020.docx

3068	GRAMNEXUS0000002750	BTR wfi pq deviation 1.docx
3069	GRAMNEXUS0000002751	WPSettings.dat
3070	GRAMNEXUS0000002752	IndexerVolumeGuid
3071	GRAMNEXUS0000002753	CORP-SOP-0071 7-02-18(SAS).docx

Action Tracking

InfoCard Number	Document Title	Revision	Last Action Date	Done By	Last Action	First Name	Last Name
CORP-SOP-0548	Environmental Monitoring of the Isolator Fill Line	03	06 Jan 2021 6:26:06 PM	JWEIDENFELLER	View File	Jerrod	Weidenfeller
CORP-SOP-0558	Operation and Maintenance of the BMT Laboratory Sterilizer	02	06 Jan 2021 4:54:08 PM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0071	Microbiology Control Culture Handling	11	05 Jan 2021 1:38:27 PM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0071	Microbiology Control Culture Handling	11	05 Jan 2021 11:12:37 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-FRM-0106	On-the-Job Training Form	02	05 Jan 2021 11:00:39 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-FRM-0106	On-the-Job Training Form	02	05 Jan 2021 11:00:34 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0031	Sodium Chloride Multi-Compendial	01	05 Jan 2021 10:13:55 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0031	Sodium Chloride Multi-Compendial	01	05 Jan 2021 10:13:55 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0007	Sodium Chloride, Granular USP	04	05 Jan 2021 10:13:37 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
VAL-1641	Butterworth Pure Steam System PQ	01	05 Jan 2021 10:01:56 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
VAL-1640	Butterworth WFI System (WFI-001) PQ	01	05 Jan 2021 10:00:17 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
VAL-1595	Butterworth WFI System (WFI-001) IOQ	01	05 Jan 2021 9:59:06 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
VAL-1595	Butterworth WFI System (WFI-001) IOQ	01	05 Jan 2021 9:59:06 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0568	O & M of the Mueller WFI Still (STIL-001) and Distribution System (WFI-001) Butterworth	01	05 Jan 2021 9:58:19 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0568	O & M of the Mueller WFI Still (STIL-001) and Distribution System (WFI-001) Butterworth	01	05 Jan 2021 9:58:19 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0027	Water and Pure Steam Sampling	21	05 Jan 2021 9:57:39 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0064	Sodium Chloride, USP/EP/JP	02	05 Jan 2021 9:39:49 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0064	Sodium Chloride, USP/EP/JP	02	05 Jan 2021 9:39:49 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0058	Sodium Chloride, Low Endotoxins, Multi-Compendial	01	05 Jan 2021 9:39:06 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0058	Sodium Chloride, Low Endotoxins, Multi-Compendial	01	05 Jan 2021 9:39:06 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0059	Sodium Hydroxide Pellets, NF/EP/JP	01	05 Jan 2021 9:35:31 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CHM-0059	Sodium Hydroxide Pellets, NF/EP/JP	01	05 Jan 2021 9:35:31 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0249	Annual Requalification of Clean Rooms (Environmental Monitoring)	04	05 Jan 2021 8:34:50 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0010	Microbiology Media Handling and Controls	10	04 Jan 2021 3:37:10 PM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0071	Microbiology Control Culture Handling	11	04 Jan 2021 3:35:53 PM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0010	Microbiology Media Handling and Controls	10	04 Jan 2021 3:30:34 PM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CAPA-0049	To address the need for sterile printer paper as well as creating a course for QC microbiology for importance of control and mitigation of potential contamination.	1	04 Jan 2021 10:24:14 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0045	Operation and Maintenance of the Met One Particle Counters and PortAll Software	10	04 Jan 2021 10:22:28 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0097	Non-Viable Air Particulate Sampling	10	04 Jan 2021 10:21:33 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0074	Environmental Monitoring Program	25	04 Jan 2021 10:20:37 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0555	Aseptic Fill Line (FIL-070) and Lyophilization (LYO-007) Environmental Monitoring	03	04 Jan 2021 10:19:17 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller

CORP-SOP-0074	Environmental Monitoring Program	25	04 Jan 2021 10:18:57 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0549	Classified Area Environmental Monitoring	03	04 Jan 2021 10:17:38 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0074	Environmental Monitoring Program	25	04 Jan 2021 10:16:22 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0045	Non-Viable Air Particulate Sampling	10	04 Jan 2021 10:14:33 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0097	Non-Viable Air Particulate Sampling	10	04 Jan 2021 10:13:10 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CAPA-0049	To address the need for sterile printer paper as well as creating a course for QC microbiology for importance of control and mitigation of potential contamination.	1	04 Jan 2021 9:29:53 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CAPA-0049	To address the need for sterile printer paper as well as creating a course for QC microbiology for importance of control and mitigation of potential contamination.	1	04 Jan 2021 9:25:03 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CAPA TASK-0142	Order sterile printer tape and author material specification.	1	04 Jan 2021 9:24:19 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CAPA TASK-0142	Order sterile printer tape and author material specification.	1	04 Jan 2021 9:24:19 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0067	Laboratory Chemical and Solution Inventory and Handling	06	04 Jan 2021 9:06:30 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0067	Laboratory Chemical and Solution Inventory and Handling	06	04 Jan 2021 9:06:30 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0051	Environmental Investigation Reports	11	04 Jan 2021 9:05:54 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0577	Filling Line #1 (Butterworth) Operations	02	04 Jan 2021 9:05:02 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0577	Filling Line #1 (Butterworth) Operations	02	04 Jan 2021 9:05:02 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0517	Operation of the FILL-001 Filling Machine	02	04 Jan 2021 9:04:18 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0517	Operation of the FILL-001 Filling Machine	02	04 Jan 2021 9:04:18 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0080	Receiving, Releasing, and Maintaining Incoming Materials	23	04 Jan 2021 9:03:27 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
CORP-SOP-0080	Receiving, Releasing, and Maintaining Incoming Materials	23	04 Jan 2021 9:03:27 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller
MDA20011	Millipore TSA w/ LTHTh - ICR 30 mL	01	04 Jan 2021 9:02:49 AM	JWEIDENFELLER	View PDF	Jerrod	Weidenfeller